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The liver is the largest organ in the human body. It weighs approximately 1-2.5 kg, depending 
on the individual body size1. The liver has a very rich blood supply which consists of a dual 
system: (1) the portal system, which carries blood from the spleen and intestines and accounts for 
approximately 80% of the livers blood supply and (2) the hepatic arterial system, which arises 
indirectly from the aorta and delivers the remaining 20%. Additionally, the biliary system runs 
through the liver with its numerous branches. The liver is involved in many metabolic, synthetic 
and detoxifying processes. Besides these vitally important functions, the liver is unique due to its 
remarkable capacity to regenerate after injury. This regenerative ability has already been described 
in the ancient Greek mythology. Prometheus reminds us that the liver is the only organ that can 
regenerate. According to Greek mythology, Zeus was furious with the titan Prometheus because 
he gave fire to the mortals. In return, Zeus chained Prometheus to a rock in the Caucasus and sent 
his giant eagle to eat his liver during the day, only to have it regenerate by night. Although this 
is an exaggeration, the principles are correct that after partial hepatectomy, the remnant liver will 
hypertrophy over weeks to months to regain most of its original volume. It is interesting to note 
that the ancient Greeks seem to have been aware of this fact, because the Greek word for liver, 
“hepar”, is derived from the verb “hepaomai”, which means to mend or to repair. Hence “hepar” 
can be roughly translated as repairable. The regenerative capacity of the liver is important in liver 
transplantation and after liver surgery
1.1 Liver Surgery.
1.1.1 Historical perspective.
Liver surgery has been traditionally difficult. Partial hepatectomy carries the risk of massive 
bleeding because of the rich blood supply of the liver. Sepsis is favoured by bile leak due to 
the extensive biliary system. Additionally, there is a risk of liver failure when the volume and/ 
or quality of the remaining parenchyma does not ensure sufficient metabolic, synthetic and 
detoxifying functions. There are scattered reports of liver surgery for battlefield injuries in the 
past, but the first recorded elective hepatic resection was performed in 1887 in Germany by 
Langenbuch2. Other reports of liver resection followed soon. The main problem in the early 
history of liver surgery was the potential for massive bleeding during liver surgery. Because of 
this, very little progress in surgical techniques was recorded for the next half-century2. Thereafter, 
major advances have been made in hepatic surgery, which have been greatly aided by improved 
understanding of the intrahepatic anatomy. Externally, the liver appears to consist of a large 
right lobe and a smaller left lobe, separated by the falciform ligament. However, this division 
does not correspond to external and internal vascular and biliary territories. It was not until the 
1950s that the anatomy of the liver was well described. In 1957, Claude Couinaud saw a regular 
segmentation pattern that was constant from one liver to another and recognized the surgical 
importance of these observations3. He showed that the distribution of the feeding arteries and 














































each can be subdivided into subunits or segments. There are eight segments in total. These 
segments are enumerated clockwise, starting with the caudate lobe as segment I. The right lobe 
of the liver consists of four segments (segments V-VIII). The left lobe of the liver comprises 
three segments (II-IV). Segment one, the caudate lobe, has a bilateral (both right-sided and 
left-sided) portal, arterial and biliary supply and is regarded as a separate structure (Figure 
1). When partial hepatectomy meets these anatomical areas - a so called anatomical resection 
- the remaining parenchyma is kept well vascularized and drained. Additionally, when these 
anatomical borders are respected, it will lead to a better removal of tumors and their vascular 
territories, which is very important in surgical oncology. Another widely used classification is the 
Bismuth classification, which is mostly used in the United States. The Bismuth classification was 
introduced in 1982 and resembles the Couinaud classification, except some small differences. It is 
debated which classification provides the most detailed description of hepatic anatomy. In parallel 
with understanding the anatomy, progress in liver surgery was advanced by medical and surgical 
technological developments for control of hemorrhage and bloodless dissection3.



















































1.1.2. Indications for liver surgery.
There are four main indications for partial hepatectomy: (1) neoplasms, (2) living donor liver 
transplants, (3) infections and (4) traumatic injuries to the liver. The majority of liver resections 
is performed for malignant tumors, most commonly liver metastases, with colorectal cancer as 
the primary source. Hepatocellular carcinoma and cholangiocarcinoma are primary liver tumors 
and encountered less frequently. Benign neoplasms, including hepatic adenomas, focal nodular 
hyperplasia and hemangiomas are discovered incidentally and do not require resection in the 
absence of symptoms. However, adenomas are associated with a risk of spontaneous bleeding, 
causing intra-abdominal hemorrhage. Additionally, there is a risk of malignant degeneration 
in large adenomas and in these cases resection is sometimes required. Living donor liver 
transplantation has evolved in response to the severe shortage of organ donors. Since the 1980s, 
donation of liver lobes from adults into pediatric recipients has been widely practiced. These 
procedures typically involve resection and transplantation of the left lateral segment. Adult-to-
adult liver transplantation is more challenging because of the requirement for a greater hepatic 
mass. Right-sided hepatectomy is usually necessary to provide sufficient volume. Infection is a 
rare indication for hepatic resection, but particular abscesses from bacterial or fungal origin and 
hydatid cysts can be best treated with partial hepatectomy. 
1.1.3. Morbidity, mortality and survival.
Nowadays, mortality after partial hepatectomy has decreased from nearly 100% in the first 
reports to 0-6.6% in the modern era4. Postoperative morbidity ranges between 22-45%5. The 
5-year survival rates for partial hepatectomy in patients with colorectal liver metastases, the most 
common indication for surgery, are 12-67%, depending on the patient selection criteria.
1.1.4. Malignant tumors of the liver.
Malignant hepatic tumors, especially colorectal liver metastases, are the main indication for partial 
hepatectomy. Surgical resection is the therapy of first choice in these patients. Unfortunately, 
only 10-20% of the patients are candidates for partial hepatectomy6-9. Contraindications for 
liver resections in oncological patients are a high number of tumors in the liver, bilobar liver 
tumors, unfavourable localization of the tumor(s) in the liver, patient comorbidity and the 
presence of extrahepatic metastases. Although the resectability criteria for patients with liver 
tumors are changing - mainly because of improvement in chemotherapy, surgical techniques and 
postoperative care - the majority of patients still remain ineligible for partial hepatectomy. For 
these patients, a series of minimally invasive tumor ablation techniques have been developed. 
These techniques kill the tumor in situ by localized injection of chemicals – for example ethanol 
and acetic acid – or by intratumoral delivery of lethal energies to freeze or heat the tumor, as 
















































Hippocrates: “Those diseases which medicines do not cure, iron cures; those which iron cannot 
cure, fire cures; and those which fire cannot cure, are to be reckoned wholly incurable.”
1.2.1 Principles.
Radiofrequency ablation (RFA) is a viable and effective therapeutic option in the treatment of 
solid tumors in the skeleton, liver, spleen, kidneys, adrenal glands and lungs. It can be performed 
either percutaneously or by an open approach (Figure 2). The basic concept of RFA is a localized 
and contained heat generation, which induces focal coagulative necrosis and cell death. An RF 
system consists of a very high frequency alternating current generator (200 to 1200 kHz), an RF 
needle, a grounding pad which serves as a large dispersive electrode and the patient. All must 
be connected in series. In this circuit, electric current enters through both the electrodes with 
the patient as resistor. As the electric current alternates in directions at high frequency, tissue 
ions that are attempting to follow the direction of the current get agitated. Due to natural high 
resistivity in the living tissue, ionic agitation produces frictional heat at the immediate vicinity 
of the electrodes. Because the grounding pad has a very large surface area, the electrical resistance 
is low. Hence, the production of frictional heat is concentrated at the needle electrode. Thus, 
deposition of the energy from the electric current produces thermal injury. The extent and nature 
of this injury are dependent on two important factors which are (1) the temperature and (2) the 
duration of the RF application. To produce irreversible cell damage, it takes several hours at 45 
C°, but it takes only 4-5 minutes at 50 to 55 C°. At temperatures between 60 and 100 C°, there 
is immediate tissue coagulation because of irreversible damage to mitochondrial and cytosolic 
enzymes by heat induced denaturation of proteins. Above 100 C°, tissue simply vaporizes. 
Therefore, temperatures between 50 and 100 C° are ideal for RFA to induce cytotoxicity11, 12.
1.2.2 Historical perspective.
The effect of radiofrequency waves was first reported by Jaques d’Arsonval in 189113. He discovered 
that RF waves could pass through living tissue without causing neuromuscular excitation, i.e. 
an electric shock. This led to the development of medical diathermy by the German physician 
Carl Franz Nagelschmidt in 1897 and surgical electrocautery in the early to mid 1900s. In the 
1990s, two independent groups of investigators used modified RF equipments for percutaneously 
created focal thermal injuries in the liver. The first needles used were simple in design and 
consisted of standard stock needles insulated to the distal tip. These needles created a well-defined 
concentric region of coagulation necrosis – the ablation zone - around the exposed needle tip. 
However, the size of the ablation zone was small due to superficial charring around the needle tip. 
Subsequent research revealed several factors which increase the volume of coagulated tissue, such 



















































50 C°, a slow increase in generator power, prolonged RF application and an increase in the exposed 
surface area of RF needle electrodes. RFA for the management of solid malignancies necessitates a 
more dispersed distribution of relatively mild RF energy to cause a more extensive sphere of tissue 
destruction. This has been realized thanks to advances in imaging diagnosis with ultrasound (US), 
computer tomography (CT) and magnetic resonance imaging (MRI) and improved guidance in 
monitoring of interventional procedures with implementation of dedicated imaging modalities 
and endoscopic equipment. The efficacy of RFA has been improved significantly by upgrading 
RF generators to yield more appropriate power (pulsed current depositions), controllable tip 
temperature, impedance adaptation, optimizing RFA electrode configuration to improve heat 
generation and distribution and by decreasing local heat loss through vascular occlusion and 
induced hypotension. This enables ablation of larger lesions in the order of several centimeters 
compared with only several millimeters previously. Thus, as an alternative to standard surgical 
resection for the treatment of malignant tumors, RFA has rapidly evolved into one of the most 
popular minimally invasive therapies12.














































1.2.3. Indications for RFA.
RFA has been used to treat tumors of the skin, liver, bladder, gastrointestinal tract, lungs and 
brain. Meanwhile, the “electric scalpel”, an RF-instrument, has widened the therapeutic scope of 
all surgical specialities by allowing the safe division of tissue and by coagulating bleeding vessels. 
In addition, RFA is used for the destruction of peripheral sensory nerves for control of constant 
pain and as transcatheter ablation for the treatment of cardiac arrhythmia caused by abnormal 
cardiac conducting pathways.
1.2.4. Morbidity, mortality and survival after RFA for colorectal liver metastases.
Since part one of the thesis focuses on RFA as a treatment for colorectal liver metastases, the 
following morbidity, mortality and survival rates concern on this issue. The overall complication 
rate of RFA is below 10% with a mortality of less than 1%. RFA-associated morbidity and 
mortality are related to the age of the patient, RFA technique (open versus percutaneous), 
number of RFA sessions, type and size of the treated lesions, the presence of liver disease and 
concomitant liver surgery. The 5-year survival rate after RFA ranges between 17-55% with a 
median survival of 24-52 months14. These rates appear to rival with the 5-year survival following 
partial hepatectomy, which ranges between 12-67%5. Unfortunately, long-term data are sparse 
and randomized controlled trials failed in recruitment, thus resection remains the therapy of first 
choice in patients with colorectal liver metastases.
1.2.5. Ablation site recurrences after RFA for colorectal liver metastases.
Ablation site recurrences, also known as “local recurrences” or “local tumor progression” are the 
key determinant of the technical success of RFA and result from incomplete ablation. We prefer 
the term “ablation site recurrence” over “local recurrence” because the term “local” generally 
reflects a recurrence at the site of the primary tumor, which may be in the pelvis in the case of a 
colorectal carcinoma. Several factors are associated with a lower risk of ablation site recurrences, 
such as a small index tumor size (< 3 cm), a low number of treated tumors, a safety margin of 
at least 10 mm coagulation necrosis around the tumor, open RFA approach versus percutaneous 
CT-targeted approach and tumor location away from large vessels and biliary structures (heat sink 
phenomenon)15, 167, 8, 17. Reported rates of ASR range between 2-55%7, 8, 10, 16, 18, 19, mainly due to 
different data collection times.
There are different other treatment modalities in thermal ablative procedures. The most 
commonly used techniques are microwave ablation (MWA), high-intensity focused ultrasound 




















































As with radiofrequency ablation, heat is used in MWA to destroy cells. In MWA, antennas are 
inserted in the tumor. These antennas create electromagnetic fields which cause ionic agitation 
to induce frictional heat that destroys tissue. An important difference with RFA is that these 
electromagnetic fields do not require an intact electrical circuit or physical contact (no grounding 
pads). This leads theoretically to a higher heating effectiveness in tissues with high impedance 
(lung and bone). Additionally, there is a fast heat generation over a larger volume of active heating. 
MWA can penetrate tissues which are localized deeper and it produces higher temperatures than 
RFA without needle charring. Finally, MWA is reported to be less sensitive to the heat sink effect, 
which allows the technique to be applied in tumors in the proximity of large vascular structures. 
Clinical applications of MWA are tumors of the liver, lung, kidney and bones. MWA is widely 
used in Asian countries, but is not widespread in Europe and the United States20, 21.
1.2.7. Cryoablation.
Cryoablation uses extremely cold temperatures to destroy tumor tissue. Freezing is achieved by 
circulating liquid nitrogen through the cryoprobe or by the rapid expansion of argon gas in the 
tip of the probe placed in the tumor. Cell death is induced by two mechanisms. The subzero 
temperatures cause both intracellular and extracellular ice crystal formation. Intracellular ice 
crystal formation damages the cell membrane, intracellular proteins and organelles. Extracellular 
ice crystals cause a transmembrane osmotic gradient, which draws water from the cells, thereby 
dehydrating them. This leads ultimately to cell death. Cryoablation has been used in the 
treatment of tumors in the liver, kidney, lung, prostate, breast and skin. A main advantage of 
cryoablation is that it is independent from electrical current application, as freezing purely is a 
thermal process. Thus, it can be used in tissues with high impedance, such as lung and bone. 
Furthermore, the iceball created with the procedure can be monitored intraprocedurally with 
US, CT and MRI, since cryoablation does not interfere with these imaging techniques as the 
other ablation techniques do. However, there are several disadvantages of cryoablation. The 
main problem is that excessive torque or displacement of the probes in the tissue can lead to 
organ fracture and significant bleeding since frozen tissues are more brittle than heated tissues. 
Additionally, the probe tract cannot be cauterized, theoretically leading to an increased risk of 
tumor seeding. Furthermore, procedure times are longer than with other ablative techniques and 
the costs of cryoablation are higher, mainly because purchase and storage of sufficient quantities 
of argon and nitrogen gas can be costly. These are the main reasons that RFA and increasingly 














































1.2.8. High-intensity Focused Ultrasound.
In HIFU, high-power, highly focused ultrasound beams are used, which are targeted to converge 
on a specific point within the body. These ultrasound beams cause tissue vibration, which creates 
the heat to destroy tissue. It can be compared to the focusing of sun rays through a magnifying 
glass to start a fire. The main indications for HIFU are malignant tumors of the prostate, breast, 
liver and benign tumors such as uterine fibroids20. HIFU is a new technique on which data are 
scarce and its long-term effectiveness is yet not well established.
1.3. Radiology: Imaging of the liver.
1.3.1 Historical perspective.
The history of radiology goes back to 1895 when the x-ray was discovered by Wilhelm Conrad 
Röntgen. The x-ray was a previously unknown, extremely penetrating form of radiation. Medicine 
was revolutionalized by his discovery. The new diagnostic tool allowed the human body to be 
opened without dissection, so that anatomy and physiology could be studied on living patients. 
The first X-ray techniques were used to examine fractures, foreign bodies and pathological skeletal 
conditions. The wider physiological application of the technology had to wait for the development 
of appropriate apparatus and methods. Improvements were made step by step. Greater radiation 
intensities were achieved while the exposure time to x-rays was reduced. The introduction of 
ultrasound in the 1960s, the advent of the digital computer – making the invention of computed 
tomography (CT) possible in 1972 by Godfrey Hounsfield in England - and the introduction of 
magnetic resonance imaging (MRI) (1978) – have combined to create an explosion of diagnostic 
imaging techniques in the past 30 years.
For several decades, imaging of the liver was limited to plain radiography of the abdomen on which 
the shadow of the liver was scanned for calcifications, intestinal air or air in the biliary tract. Oral 
and intravenous cholecystography was used for examination of the bile ducts. Angiography of the 
liver was used for the detection of (hypervascular) tumors. With the introduction of ultrasound in 
the 1960s and CT and MRI from the 1970s, hepatic imaging underwent a revolution23.
1.3.2. Ultrasonography.
Ultrasound as used in medicine is a noninvasive imaging technique to visualize internal organs 
and structures. This technique uses high-frequency sound waves greater than 2 megahertz. These 
ultrasound waves are emitted and then received by a transducer. The transducer is placed against 
the skin of the patient. A thin layer of coupling gel is applied to the skin of the patient to displace 
the air that would otherwise reflect virtually the entire ultrasound beam. As the ultrasound 
waves travel into the patient, wave fronts spread out and diminish the overall beam intensity. 
Partial tissue absorption with associated heat conversion also contributes to beam attenuation. 



















































- or echoes - travel back to the transducer and are converted into electric signals, which are 
subsequently amplified. The amplitude of the returning wave partially depends on the degree 
of beam absorption and a shade of gray is then assigned to each of these amplitudes. Strong 
echoes are being assigned a shade near the white end of the spectrum. Weak echoes are assigned 
a shade near the black end of the spectrum. Additionally, the depth of the reflecting tissue can 
be calculated from the known total beam travel time and the average sound velocity in human 
tissue, which is 1.54 m/s. Limitations of ultrasound are primarily operator-dependent in nature. 
An additional limitation is the variable visualization of midline abdominal organs (pancreas) and 
vasculature when these structures are obscured by overlying bowels or bone, since ultrasound 
waves are unable to penetrate gas or bone.
Applications of ultrasonography are imaging of the abdomen, pelvis, fetus, vascular system, 
testicles, breasts, pediatric brain and chest. Furthermore, ultrasound guided interventions are 
routinely used to facilitate biopsies, drainages and RFA.
Another application of ultrasound in medicine is the Doppler ultrasound. This ultrasound 
technique utilizes the Doppler effect, which occurs when a sound emitter or reflector is moving 
relative to the stationary receiver of sound. An object which moves toward the detector appears 
to have a higher frequency and shorter wavelength. In contrast, an object which moves away 
form the detector has a lower frequency and longer wavelength. If the ultrasound beam strikes 
a reflector (the object) which moves toward it, the reflected sound will have a higher frequency 
than the original beam. Alternatively, if the ultrasound beam strikes a reflector which moves away 
from it, the reflected sound will have a lower frequency than the original beam. The Doppler shift 
is the frequency difference between the original beam frequency and the reflected beam frequency. 
Frequency differences are used to calculate the corresponding flow frequencies from which a 
Doppler waveform or tracing can be generated. This tracing describes the relationship between 
velocity and time and is unique to the flow pattern within the vessel. Color flow Doppler assigns 
colors (blue and red) to structures according to their motion toward or away from transducers. 
This information can be superimposed on a gray-scale image.
1.3.3. Computed tomography.
Computed tomography is an imaging technique in which cross-sectional images are created with 
the use of x-rays and computerized image processing. A large series of two-dimensional x-ray 
images are taken perpendicularly to a single axis of rotation as the patient passes through a 
gantry. This gantry contains one or more x-ray tubes on one side and an array of detectors on the 
other side. As the gantry rotates around the patient, information obtained from the detectors is 
analyzed by a computer and displayed as an image. The image information can be manipulated 
by the computer to reflect a greater spectrum of densities than possible with conventional x-ray 
films. Images can be manipulated - “windowed” - to display various tissue densities based on 














































width determines the range of CT numbers that will be represented on a specific image. The 
computer assigns different shades of gray to CT numbers that fall within the selected range. CT 
numbers that are above the chosen range will appear white, and numbers below the chosen range 
will appear black. By increasing the window width, a greater range of CT numbers is assigned to 
a shade of gray. This technique is used when it is desirable to view a variety of tissues that vary 
greatly in density (e.g., lung). The disadvantage to wider windows (400 to 2000 HU) is that 
subtle differences in density will not be visualized. CT images were initially limited to the axial 
plane, but modern scanners allow reconstruction of the pictures into coronal and sagittal planes. 
Additionally, three-dimensional (3D) reconstructions of the structures can be created, which is a 
useful tool in volumetric measurements of organs and lesions.
Contrast agents are often used to improve the sensitivity and specificity of CT imaging. Contrast 
materials for abdominal CT examinations can be administered by mouth, intravenous or rectal 
routes. Oral contrast agents are used for many abdominal CT examinations in an attempt to 
improve contrast opacification and distention of the bowel. Iodine, which has an atomic weight 
of 127, is used as a radiopaque intravenous contrast agent for improved demarcation of vascular 
structures.
1.3.4. Radiation risks.
With the increase in the diagnostic capability of CT and its availability, CT has become an 
indispensable tool in the medical diagnostic armamentarium. However, the widespread use of 
CT has led to increasing concerns about radiation exposure. Additionally, the widespread use of 
MDCT has raised concern because the dose of radiation delivered by MDCT is 27% greater than 
for single-detector CT and the dose increases with decreasing slice thickness.
The radiation risk from CT is modified by patient factors – for example body habitus - but is also 
affected by numerous potentially controllable factors, such as the used scan protocol. 
1.3.5. Magnetic resonance imaging.
Felix Bloch and Edward Purcell were awarded the Nobel Prize in 1952 for their independent 
discovery of the phenomenon of magnetic resonance in 1946. Between 1950 and 1970, nuclear 
magnetic resonance (NMR) was developed and used for chemical and physical molecular analysis. 
Raymond Damadian demonstrated in 1971 the utility of NMR in the diagnosis of cancer. This 
was based on prolonged relaxation times in pathologic lesions compared to the relaxation times in 
normal tissue. The first 2D proton NMR image of a water sample was generated in 1972 by Paul 
Lauterbur who used a back-projection technique, similar to that used in CT. In 1975, Richard 
Ernst used phase and frequency encoding, as well as Fourier transform analysis, to form the basis 



















































1.3.6. Principles of MRI.
MRI is based on the principle of nuclear magnetic resonance, in which energy emissions from 
nuclei in the presence of an applied, external magnetic field are detected after the nuclei have 
been stimulated by radiofrequency pulses with the same, or resonant, frequency as the nuclei 
themselves. The key atom in MRI is hydrogen, which is abundant within the body with more 
than 1020 nuclei per cubic centimeter of tissue. Since hydrogen nuclei do not contain any neutrons, 
they are often referred to simply as protons. When placed in a strong magnetic field, nuclei such 
as hydrogen, resonate and emit radio signals when pulsed with radio waves. A defined sequence 
of magnetic pulses and interval pauses produces measured changes in the magnetic vectors of the 
tissue. This results in an MR image. Proton relaxation is characterized by two time parameters, 
T1 and T2. T1, or longitudinal relaxation time, is the measurement of magnetic vector changes 
in the z-axis during the relaxation pause. T2, or transverse relaxation time, is the magnetic vector 
change in the x-axis and the y-axis.
Each tissue, whether normal or pathologic, has its own unique T1 and T2 for a given MRI field 
strength. The inherent tissue differences between various T1 and T2 values lead to the visual 
contrast seen between tissues on the MR image. An image is T1-weighted if it depends on the 
differences in T1 measurements for visual contrast and T2-weighted if it depends on differences 
in T2 measurements. T1-weighted images are often thought of as “anatomy” scans because they 
clearly delineate the boundaries between different tissue planes. Fluid is very dark, solid organs 
and muscles are gray, and fat (including fatty bone marrow) is very bright. T1-weighting is also 
chosen for contrast-enhanced scans because gadolinium, the most common MRI contrast agent, 
appears bright, owing to its T1 shortening effect. On T2-weighted images, fluid is very bright, 
while most other tissues are gray or dark. Such images are often thought of as “pathology” scans 
because abnormal fluid collections and edematous tissue are bright against the darker background 
of normal tissue. With contrast-enhanced and T2-weighted sequences, abnormal tissue is made 
even more conspicuous by suppressing the background fat signal using either chemically selective 
fat saturation pulses or (in combination with T2-weighting) inversion recovery sequences. A 
recently developed sequence of interest is diffusion weighted imaging, which is thought to be 
capable of differentiation between benign and malignant tissue. Another emerging sequence 
is MR spectroscopy, which detects metabolic changes in tissues and tumors. MR images are 
obtained in the transverse, sagittal, oblique, and coronal views.
Gadolinium (gadopentetic dimeglumine) is an ionic contrast agent that acts as a paramagnetic 
agent and enhances vessels and lesions of abnormal vascularity.
A major advantage of MRI compared to CT is that no ionizing radiation is involved. Additionally, 
it provides a better display of vascular anatomy without contrast, linear structures (spine and 
spinal cord, aorta, vena cava), the posterior fossa and other difficult-to-see CT areas are better 














































A major drawback of MRI is the long scanning time. Additionally, MRI is more expensive 
compared to CT. Another disadvantage of MRI is the presence of claustrophobia. Open bore 
MRI systems may help, but these are often not readily available. Lastly, the presence of metallic 
foreign bodies such as pacemakers, vascular clips, metallic eye fragments, and cochlear implants 
are contraindications for undergoing MRI examination.
1.3.7. Integration of radiology and surgery.
There is no doubt that the improvement in the results of surgical endeavors in the treatment of 
liver disease has been in part related to the developments in imaging. Imaging leads to a better 
knowledge of the liver anatomy and the opportunity to make a well pre-operative planning. Intra-
operative use of ultrasound from the early 1980s changed the surgical effectiveness dramatically, 
since it leads to better identification of vessels, intrahepatic structures and their relationship 
with tumors. The role of diagnostic imaging in liver surgery has gained increasing importance 
over the past decades. Whereas 30 years ago the thorough history taking, clinical judgement 
and laboratory analyses were the most important and often only tools to establish a diagnosis, 
nowadays a multitude of imaging methods provide complementary information. Frequently, 
the surgical decision making regarding the indication for partial hepatectomy relies heavily 
on imaging methods. Ultrasound, computed tomography, magnetic resonance imaging and 
positron emission tomography are the most often used imaging modalities in hepatic imaging. 
Tumors of the liver – both benign and malignant - are the main indication for liver imaging. 
Surgical removal with resection of negative margins remains the optimal therapy for primary and 
secondary liver tumors. Therefore, pre-operative knowledge regarding the number and size of 
liver lesions as well as their location regarding major liver vessels and the biliary system is crucial 
for successful surgical removal. Unfortunately, many patients who undergo curative liver surgery 
for primary or secondary malignancies will relapse due to undiagnosed small malignant lesions. 
Therefore, the goal of imaging methods is not only the characterization of the liver lesions and 
their anatomical localizations, but also the detection of small tumor burden.
1.4. Aims and outline of the thesis.
1.4.1. Part one: Imaging after thermal ablation.
Colorectal cancer is the third most common malignancy after lung, prostate and breast cancer. It is 
the second most common cause of cancer related death. Approximately 50% of the patients with 
colorectal cancer will develop liver metastases, but unfortunately only 10-20% of the patients are 
eligible for partial hepatectomy. As mentioned in the introduction, radiofrequency ablation has 
emerged as a widely accepted alternative for these patients6-9.
Incomplete ablation is one of the major problems with RFA, leading to ablation site recurrences. 



















































histopathology does not play a role after RFA, the evaluation of the effectiveness of the RFA 
procedure fully relies on imaging. Additionally, post-RFA imaging is performed to detect 
ablation site recurrences as early as possible to have the opportunity for repeating the RFA 
procedure. Although it is still unclear which imaging modality is preferable for post-RFA follow-
up, most institutions use multiphase contrast-enhanced computed-tomography (CT) or magnetic 
resonance imaging (MRI) with or without fluoride-radiolabeled-deoxy-glucose positron emission 
tomography (FDG-PET)24, 25. Post-RFA evaluation can be performed by measuring ablative 
margins or by fusing the pre-RFA and post-RFA scans to see whether the ablative margin is 
overlapping the index tumour. A disadvantage of these techniques is the variation that can 
occur in the position of the liver between the pre-RFA scan and post-RFA scan, which results in 
inaccurate measurements of the ablative margin. This may give false reassurance to the adequacy 
of the treatment and thus increase the probability of an ASR, since insufficient ablative margins 
remain unnoticed. Another strategy for the evaluation of the RFA-procedure is to focus on the 
presence or absence of contrast-enhancement in the ablation zone. Successfully and insufficiently 
ablated metastases have specific characteristics on contrast-enhanced post-RFA CT-scans and 
MRI-scans. However, ASR of hypovascular metastases – for example colorectal liver metastases - 
may present atypically. Furthermore, a benign pattern of contrast-enhancement can be observed 
shortly after an RFA procedure, due to inflammatory changes around the ablation zone. Although 
this benign periablational enhancement can be distinguished from contrast-enhancement due to 
residual tumor origin, differentiation between these two entities may be difficult26, 27. In addition, 
detection of subtle changes in tumor shape and size can be challenging with two-dimensional 
cross-sectional-imaging28. Three-dimensional assessment, such as volumetric quantification of 
ablation zones could theoretically be more accurate than two-dimensional measurements. It has 
been reported previously that ablation zones gradually become smaller because of shrinkage of the 
metastases and resolution of post-RFA-inflammation. Theoretically, ablation zones with viable 
metastatic cells should have a smaller decrease in volume between two subsequent time points 
of measurement. Residual tumor cells will continue to multiply and inhibit or slow down the 
volume-decrease of the ablation zone. Therefore, the first aim of part one of the thesis was to assess 
the impact of the variation in the position of the liver between pre-RFA scan and post-RFA scan 
on the evaluation of the success of the RFA procedure. These results are presented in Chapter 
2. The second aim was to study the relationship between volume changes of ablation zones on 
successive post-RFA CT-scans and the development of ablation site recurrences. This is discussed 
in Chapter 3. Thirdly, we studied whether immediate post-procedural contrast enhanced 
scanning provides reliable quantitative assessment of the effectiveness of the ablational procedure 















































1.4.2. Part two: Liver regeneration after partial hepatectomy.
Among all organs, the liver has a remarkable capacity of regeneration after surgery. The liver 
can tolerate resections as much as 75-80% with the prerequisite that there is no underlying 
parenchymal disease29, 29-31. Microscopically, liver regeneration is the result of cell replication 
which leads to macroscopic liver regeneration, thus volume increase. This increase in volume 
can be assessed with post-processing software for CT and MRI-scans. Liver regeneration depends 
on different factors, such as the presence of an underlying liver diseases, age and sex. There is a 
relationship between the resected volume and the amount of liver tissue that needs to regenerate, 
which implies that the resected volume might also be a trigger in the regeneration process after 
surgery32-34. However, the relationship between resected volume and liver regeneration has been 
studied less well. Studies which have evaluated liver regeneration have mainly based their results 
on the type of partial hepatectomy rather than on the exact amount of resected volume. Reported 
rates of liver regeneration range between 28-64% with lower regeneration rates after smaller 
resections, for example a bisegmentectomy. However, regeneration rates between patients with 
the same type of partial hepatectomy vary also substantially. This discordance might be explained 
by the fact that there is considerable interpatient variability in the size of the different segments 
of the liver. This means that the resected volume after a particular type of partial hepatectomy 
may differ considerably between patients35. Thus, liver regeneration should be seen in perspective 
of the resected volume rather than the type of partial hepatectomy. 
Parenchymal diseases of the liver are well known factors which have negative influence on liver 
regeneration. The most well known disease of the liver parenchyma is hepatic cirrhosis and it 
has been shown that cirrhotic livers do not regenerate well31. Hepatic steatosis, characterized 
by lipid accumulation within hepatocytes is a far more commonly encountered condition of 
the liver parenchyma. It is estimated to affect up to 30% of the Western population36, 37. It is 
reasonable to assume that its prevalence will further increase due to the current obesity epidemic. 
Although formerly regarded as a benign condition, hepatic steatosis can lead to non-alcoholic 
steatohepatitis, cirrhosis and development of hepatocellular carcinoma. In addition, steatosis is 
thought to be a risk factor for post-operative complications, although reports are contradicting38, 
39. Clinically significant steatosis is defined as steatosis of 30% or more. The regenerative capacity 
of steatotic livers is less well established. Studies which have evaluated liver regeneration in the 
presence of steatosis report that regeneration is not impaired by the presence of steatosis38, 40. 
However, these studies concern only living donors and may therefore not be comparable with 
patients undergoing elective liver surgery, since steatosis is not a major exclusion criterion in the 
latter group as it is in living donors.
The main indications for partial hepatectomy are currently primary and secondary malignant 
liver tumours. Unfortunately, the majority of these patients are no candidates for liver resection 
because of relevant comorbidities and, even more important, unresectable disease. Chemotherapy 



















































disease41. A major side effect of chemotherapy are its considerable hepatotoxic effects31, 41. It has 
been reported that postoperative morbidity and mortality is increased in patients who received 
pre-operative chemotherapy31. Additionally, chemotherapeutic agents can induce different types 
of injury to liver cells, which theoretically may lead to impaired liver regeneration after partial 
hepatectomy31, 41, but the impact of pre-operative chemotherapy on liver regeneration remains 
unknown.
On the molecular level, hepatic regeneration is an orchestrated interplay of signaling events, 
consisting of growth factors, cytokines and transcription factors42. Platelets, which contain 
multiple growth factors, have recently gained interest in their possible role in liver regeneration. 
Platelets are thought to be directly involved in liver regeneration, as demonstrated in several 
studies in rodents43-45. Thrombocytopenia resulted in a markedly reduced proliferative activity 
in the liver. On the other hand, trombocytosis was associated with accelerated liver regeneration. 
In humans, it has been shown that a low postoperative platelet count (PC) was associated with 
delayed functional recovery of the liver and trombocytopenic patients have increased markers of 
liver injury, function and mortality46. It has been reported that PC decreases after PH and that 
this decrease is related to the extent of resection47, 48. This could be due to the suggested role of 
platelets in liver regeneration. However, the extent of decrease in PC has never been related to 
posthepatectomy liver regeneration.
Part two of this thesis focuses on liver regeneration. Firstly, we aimed to study the rate of liver 
regeneration in patients who underwent partial hepatectomy and whether the rate of liver 
regeneration is proportional to the amount of resected volume. This is discussed in Chapter 
5. Secondly, the impact of steatosis on the rate of liver regeneration was evaluated, which is 
evaluated in Chapter 6. Thirdly, since pre-operative and postoperative platelet counts were 
available in the patient database, the decrease in postoperative platelet count in relationship to 
the regeneration response was evaluated. These results are presented in Chapter 7. Fourthly, the 
impact of pre-operative chemotherapy on early liver regeneration in patients undergoing right 
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Variation in the position of the liver between pre-ablation and post-ablation CT-images hampers 
assessment of treatment of colorectal-liver-metastasis (CRLM). The aim of this study was to test 
the hypothesis that discordant pre-ablation and post-ablation imaging is associated with more 
ablation-site-recurrences (ASR).
Methods:
Patients with CRLM were included. Index-tumour-size, location, number, RFA-approach and 
ablative-margins were obtained on CT-scans. Pre-ablation and post-ablation CT-images were 
assigned a “Similarity-of-Position-Score” (SiPS). A suitable cut-off was determined. Images were 
classified as identical (SiPS-id) or non-identical (SiPS-diff). ASR was identified prospectively on 
follow-up-imaging.
Results:
Forty-seven patients with 97 tumours underwent 64 RFA-procedures (39 patients/63 tumours 
open-RFA, 25 patients/34 tumours CT-targeted-RFA, 12 patients underwent >1 RFA). Images 
of 52 (54%) ablation-sites were classified as SiPS-id, 45 (46%) as SiPS-diff. Index-tumour size, 
tumour location and number, concomitant partial hepatectomy and RFA-approach did not 
influence the SiPS. ASR developed in 11/47 (23%) patients and 20/97 (21%) tumours. ASR 
occurred less frequently after open-RFA than after CT-targeted-RFA (P<0.001). ASR was 
associated with larger index-tumour-size (18.9 versus 12.8mm, P=0.011). Cox-proportional-
hazards-model confirmed SiPS-diff, index-tumour-size >20mm and CT-targeted-RFA as 
independent risk-factors for ASR.
Conclusion:
Variation in anatomical concordance between pre-ablation and post-ablation-images, index-

































































Liver metastases develop in approximately 50% of patients with colorectal carcinoma. Partial 
hepatectomy is a potentially curative treatment, but only 10-20% of the patients are eligible 
for partial hepatectomy. Radiofrequency ablation (RFA) is an alternative for patients with 
unresectable tumours and is often used as an adjunct to partial heptaectomy[1-4]. By using an 
image-guided approach, electrodes are positioned in the tumour either percutaneously or by an 
open approach[5-8]. One of the major problems with RFA is incomplete ablation, leading to 
ablation site recurrences (ASR)[9]. Factors associated with low ASR rates are small index-tumour 
size[10], low number of treated tumours[11], at least 10 mm margins of coagulation around the 
tumour[1, 12], open surgical approach (versus percutaneous CT-targeted approach)[2, 3] and 
tumour location distant from large vessels[2, 3]. The purpose of post-RFA imaging is the early 
detection of ASR, providing the opportunity to repeat the RFA procedure. Strategies used for 
post-RFA evaluation include measuring ablative margins or focusing on contrast-enhancement 
in the ablation zone. A disadvantage of these techniques is the variation that can occur in the 
position of the liver between the pre-RFA scan and post-RFA scan, resulting in an inaccurate 
quantitative assessment of the ablative margin. This may give false reassurance to the adequacy of 
the treatment and might thus be an indirect risk factor for development of ASR. In this study, we 
test the hypothesis that variation in the position of the liver between pre-RFA scan and post-RFA 
scan makes the assessment of completeness of ablation of colorectal liver metastases difficult, and 





The study was approved by our institutional review board. Between July 2000 and July 2008, 
142 RFA procedures were performed for primary (benign and malignant) and secondary liver 
tumours in our center. Sixty-five percent of these procedures were done with an open approach, 
35% was performed percutaneously under CT-targeting. Open procedures were performed in 
patients who also underwent a partial hepatectomy or if the tumour could not be safely reached 
using the percutaneous route. Laparoscopic procedures were not performed. All procedures were 
performed by one of the authors, an experienced hepatobiliary surgeon in collaboration with 
dedicated radiologists. CT-targeted RFA was performed in collaboration with a radiologist. Fifty-
two patients (37%) underwent RFA for colorectal liver metastases. Five patients were excluded 
- missing pre-RFA images (n=2), multiple and widespread liver metastases shortly after RFA 
making assessment of ASR impossible (n=2) and lost to follow-up (n=1). Thus, 47 patients 














































hepatectomy was performed as described previously and is considered the gold standard[13]. It is 
standard praxis to fix the liver remnant after partial hepatectomy with the aim to keep the liver 
remnant in the same position in order to prevent rotation of the remaining liver lobe. Rotation 
can lead to torsion of the draining hepatic vein and congestion of the liver lobe. RFA was only 
performed if partial hepatectomy was not able to render the liver tumour-free. 
RFA procedure
RFA was performed by one staff HPB surgeon (KPdJ) in collaboration with a staff radiologist 
(EJvdJ) for the CT-guided procedures. Ablation procedures are performed in our hospital since 
1995 with about 20 procedures per year for colorectal liver metastases. We used the RF 3000 TM 
Radio Frequency Ablation System (Boston Scientific, Boston, MA, USA). A LeVeen-electrode 
of 2, 3.5, 4 or 5 cm diameter was used, depending on tumour diameter. The RFA-electrode 
was positioned using ultrasonography in open and CT-guided in CT-targeted RFA. RFA was 
applied according to the protocol of the manufacturer. RFA was continued until the generation 
of radiofrequency waves was blocked by the rise in tissue impedance. Large tumours were treated 
by several overlapping positions of the deployed RFA-electrode. Terminology used in this paper 
is in accordance to the guidelines by Goldberg et al[14].
CT-protocol
Patients underwent triphasic CT-scanning before the RFA procedure, one week after the RFA 
procedure, then at three-monthly intervals during the first two years and every six months 
thereafter. CT was performed on a 16- or 64-slice multidetector CT scanner (Somatom Sensation 
64, Siemens, Erlangen, Germany). Intravenous contrast was used, 120 ml iodixanol 320 mg 
I/ml (Visipaque 320, GE Healthcare, Chalfont St Giles, UK), with a flow rate of 4.0 ml/sec. 
All subjects were scanned in craniocaudal direction during inspiratory breath-hold. CT-images 
were acquired in a supine position using a 16 x 1.5 (16-slice) or 24 x 1.2 (64-slice) collimation, 
tube potential 120 kV, tube current time product 130 mAs, pitch 1, slice thickness of 2 mm, 
reconstruction Kernel B30f and reconstruction increment 1.5.
Follow- up
Follow-up of the ablated tumours consisted of CT-imaging or [F-18]-fluorodeoxyglucose-positron 
emission tomography (FDG-PET) when CT-imaging was inconclusive. Patients were considered 
to have recurrences when there was a typical pattern of contrast-enhancement on CT-imaging 
and/or pathological glucose uptake on PET-scanning. 
Post-RFA evaluation
Radiological evaluation of the tumours before and one week after the RFA procedure was 
































































Images in axial and reconstructed coronal planes were used for three-dimensional measurements 
and comparison of the pre-RFA scan and the post-RFA scan (explanation in Figure 1). This 
was done by two of the authors (PGK, EJvdJ). Reliable comparison was only possible when the 
position of the liver was identical or almost identical on the pre-RFA scan and post-RFA scan. 
Therefore, a dichotomous “Similarity of Positioning Score” (SiPS) was developed in which post-
RFA scans were compared to pre-RFA scans. Post-RFA scans were centrally and blindly classified 
as SiPS-identical (SiPS-id, i.e. comparable to the pre-RFA scans, Figure 2) or SiPS-different 
(SiPS-diff, i.e. not comparable to the pre-RFA scan, Figure 3). A post-RFA scan was considered 
SiPS-id when the vascular configuration (especially hepatic and portal veins) was identical or 
nearly identical to that on the pre-RFA scan. In addition, the projection of the abdominal organs, 
bony structures (vertebrae and ribs) and the position of previously placed surgical clips had to 
be identical or nearly identical. When these criteria were not met, a scan was regarded as SiPS-
diff. For validation of SiPS, one of the authors (PK) classified all tumours twice for intra-observer 
agreement. Another radiologist with two years CT-experience performed the same classifications 
to obtain the interobserver agreement. Ablative margins > 10 mm were considered sufficient. The 
smallest margin in one of the six directions was considered the most imperfect one. Therefore, 
tumours with an ablative margin <10 mm in only one of the six directions were regarded as 
having an insufficient ablative margin.
Figure 1. Explanation of the method of measurement
Schematic representation of the method of measurement of the ablation zone.
Figure 1 representing the axial and coronal view respectively of the tumour (black circle with white T) and 
the ablation zone (white circle with black A).
Ablative margins were calculated as follows. The distance from the edge of the tumour to the surface of the 
liver was measured in all six directions on the pre-RFA scan (continuous line). The same measurements were 
performed for the post-RFA scan from the edge of the ablation zone scan to the surface of the liver (dotted 
line). The ablative margins are the difference between both distances.
The tumour in the left liver lobe is considered to be incompletely ablated because in one of the six directions 














































Figure 2. Similarity of Positioning Score-identical (SiPS-id)
Example of identical (concordant) pre-RFA CT-images and post-RFA CT-images, classified as Similarity of 
Positioning Score-identical (SiPS-id). The pre-RFA CT-scan (A axial, B coronal) and post-RFA CT-scan (C 
































































Figure 3. Similarity of Positioning Score-different (SiPS-diff)
Example of non-identical (discordant) pre-RFA CT-images and post-RFA CT-images, classified as Similarity 
of Positioning Score-different (SiPS-diff). The pre-RFA CT-scan (A axial, B coronal) and post-RFA CT-scan 
(C axial, D coronal) are not comparable.
Definition of ablation site recurrence
Progression at the site of a previously RFA-treated tumour was considered ASR when it met both 
of the following criteria: (1) growth of a contrast-enhancing lesion within or directly adjacent to 
the ablation zone and (2) the largest diameter of the lesion was in direct contact with the ablation 
zone. The latter prerequisite is to exclude outgrowth of satellite lesions in the vicinity of the 














































Figure 4. Definition of ablation site recurrence
Examples of ablation site recurrences (ASR). The largest diameter of both lesions on the right is in direct 
contact with the ablation zone. The lesion on the left is not an ASR, because the center of the line representing 
the largest diameter is not in direct contact with the ablation zone. It is more probably a satellite metastasis 
which was already present at the time of the ablation. Outgrowth of this lesion took place after the RFA 
procedure. This prerequisite is necessary to prevent erroneously identified outgrowing satellite lesions in 
close vicinity of the ablated tumour as ASR.
Statistical analysis
Chi-square and Fisher’s exact test were applied to assess the relationship between categorical 
variables SiPS (identical versus different), RFA approach (open versus CT-targeted), partial 
hepatectomy in the history (yes versus no), number of tumours ablated (<3 versus ≥3), localization 
of tumours (subcapsular, i.e. <10 mm under the liver capsule, versus central), ablative margins 
(>10 mm versus <10 mm and >5 mm versus <5 mm) and ASR (yes versus no). For comparing 
the continuous variable index-tumour size between tumours with and without ASR, Student’s 
t-test was used after correction for non-normal distribution (log-transformation). Survival was 
assessed with Kaplan-Meier analysis. Variables possibly contributing to ASR were analyzed by 
using log-rank test. Cox proportional hazard model was used to identify independent risk factors 
for ASR. Kappa statistics were calculated to test the intra-observer and interobserver agreement 
of SiPS. Agreement was rated as poor (kappa 0-0.2), fair (kappa 0.21-0.40), moderate (kappa 
0.41-0.60), substantial (kappa 0.61-0.80) or excellent (kappa 0.81-1.0)[15]. The significance 
level was set at a P < 0.05 for all tests. Statistical analysis was performed using SPSS (Statistical 
































































Table 1. Patient and tumour characteristics
Patients Tumours
Number 47 97
Sex ♂/♀ 30/17 (64 %/ 36 %) -
Age (mean, range) 61.8 years (39-81) -
Deceased 12/47 (26 %) -
Partial hepatectomy 34 (72 %) 73 (75 %)
- Before RFAa 5 (15 %) 20 (27 %)
- During RFA 25 (73 %) 43 (59 %)
- After RFA 4 (12 %) 10 (14 %)
Type of partial hepatectomy (n=34)
- Right-sided hemihepatectomy 12 (35 %) -
- Left-sided hemihepatectomy 8 (24 %) -
- Segment 2 & 3 resection 12 (35 %) -
- Other 2 (6 %) -
Synchronous/ metachronous disease 26/21 (55 %/ 45 %) 57/40 (59 %/ 41 %)
Indication RFA
- Bilobar disease 29 (62 %) -
- Recurrence after partial hepatectomy 8 (17 %) -
- Major comorbidity 7 (15 %) -
- Minimal residual disease 2 (4 %) -
- Severe steatosis 1 (2 %) -
RFA procedures
- 1 RFA 35 (75 %) -
- 2 RFAs 9 (19 %) -
- 3 RFAs 1 (2 %) -
- 4 RFAs 2 (4 %) -
RFA approach (64 procedures)
- Open 39 (61 %) 63 (65 %)
- CT-targetedb 25 (39 %) 34 (35 %)
No. of tumours ablated (64 procedures)
- 1 tumour 44 (69 %) -
- 2 tumours 13 (20 %) -
- ≥3 tumours 7 (11 %) -
Recurrence 33 (70 %) 74 (76 %)
ASRc 11 (23 %) 20 (21 %)
Repeat RFA for ASR
- Yes 5 (11 %) 10 (10 %)d
- No 42 (89 %) 87 (90 %)
Partial hepatectomy for ASR
- Yes 1 (2 %) 2 (2 %)
- No 46 (98 %) 95 (98 %)
aRFA: radiofrequency ablation.
bCT-targeted: computer tomography-targeted.
cASR: ablation site recurrence. 















































General characteristics and recurrence patterns
In 47 patients with 97 colorectal liver metastases, 64 RFA procedures were performed. An 
open approach was used in 39 patients with 63 metastases. Percutaneous CT-targeted RFA was 
performed in 25 patients with 34 metastases. There were 12 patients who underwent one or 
more further RFA procedures, of which 5 patients had repeat RFA for ASR. ASR was seen in 
11 patients (23%) with 20 metastases (21%). There were 2 patients (4%) with 3 metastases 
(3%) who showed ASR without recurrences elsewhere. Recurrent disease elsewhere occurred in 
33 patients (70%) with 74 ablated liver metastases (76%) and was concomitant with ASR in 
9 patients (19%) with 17 metastases (18%). Recurrence without ASR was seen in 24 patients 
(51%) with 57 tumours (59%) (Table 1). Mean index-tumour size before RFA was 13.9 mm (SD 
1.8, range 3.9-78.0 mm).
Similarity of Positioning Score (SiPS)
After CT-targeted RFA, 15 of the 34 tumours (44%) were classified as SiPS-id, the remaining 
56% as SiPS-diff. After open RFA, 37 of the 63 tumours (59%) were classified as SiPS-id, the 
remaining 41% as SiPS-diff. After open RFA with concomitant partial hepatectomy, 24 tumours 
were classified as SiPS-id (56%), the remaining 44% as SiPS-diff. Kappa statistics for intra-
observer agreement were excellent (kappa 0.834, p<0.001) and substantial for interobserver 
agreement (kappa 0.752, p<0.001). Index-tumour size, RFA approach, concomitant partial 
hepatectomy, number of ablated tumours and tumour localization were not different in the SiPS-
diff group versus the SiPS-id groups (Table 2).
Table 2. Effect of different factors on the Similarity of Positioning Score (SiPS)
SiPS-ida (n=52) SiPS-diffa (n=45) P value
Index-tumour size (mean ±SD)b 14.1 mm (1.9) 13.6 mm (1.8) 0.773
RFA approachc
- Open RFA (n=63) 37 (59 %) 26 (41 %) 0.203
- CT-targeted RFA (n=34) 15 (44 %) 19 (56 %)
Partial hepatectomy during RFAc
- Yes (n=43) 24 (56 %) 19 (44 %) 0.838
- No (n=54) 28 (52 %) 26 (48 %)
No. tumours ablatedc
- 1-2 (n=70) 40 (57 %) 30 (43 %) 0.364
- ≥ 3 (n=27) 12 (44 %) 15 (56 %)
Localizationc
- Subcapsular (n=76) 44 (58 %) 32 (42 %) 0.140
- Central (n=21)  8 (38 %) 13 (62 %)
aSiPS: Similarity of Positioning Score, identical (SiPS-id) or different (SiPS-diff).
bStudent’s t-test.

































































ASR occurred in 20 of 97 metastases (21%). Tumours with ASR were larger than tumours 
without ASR (18.9 mm versus 12.8 mm, P=0.011). ASR was seen in 17 (50%) tumours treated 
with CT-targeted RFA and 3 (5%) tumours with open RFA (P<0.001). ASR was seen in 6 (12%) 
tumours classified as SiPS-id and 14 (31%) tumours classified as SiPS-diff (P=0.017). ASR was 
not different in tumours with ablative margins <5 mm (P=0.464).
Univariate analysis showed more ASR in tumours treated with CT-targeted RFA (P<0.001), 
in tumours classified as SiPS-diff (P=0.023) and in tumours with an index-tumour size >20 
mm (P=0.009). Tumour localization (subcapsular versus central) and ablative margins were 
not associated with ASR (P=0.483 and P=0.576, respectively). Cox proportional hazard model 
identified RFA approach, SiPS and index-tumour size as independent predictors of ASR. CT-
targeted RFA was associated with the highest risk for developing ASR, followed by SiPS-diff and 
an index-tumour size >20 mm (Table 3). 
 
Table 3. Cox proportional hazard model showing the relative risk for development of ablation site recurrence 
compared to the reference standard (1.0).
Relative risk (95%-CI) P value
RFA approach
- Open RFA 1.0 0.001
- CT-targeted RFA 9.5 (2.6-34.0)
Similarity of Positioning Score (SiPS)
- SiPS-identical 1.0 0.019
- SiPS-different 3.9 (1.2-12.3)
Index-tumour size 
- < 20 mm 1.0 0.010
- ≥ 20 mm 3.6 (1.4-9.4)
Survival
Median time of follow-up was 36 months (interquartile range 25-49). Median overall survival in 
the open RFA group was 40.7 months (95%-CI 23.3 - 58.2) and was not statistically different 
for the CT-targeted RFA group (P=0.23). As the proportion of disease-free patients in the latter 
group was more than 50% at the end of the study, the median survival could not be estimated. 
After open RFA, median disease-free survival was 35.2 months (95%-CI 29.7 - 40.7) and 32.6 















































RFA is increasingly used in patients with malignant liver tumours in whom partial hepatectomy 
is not able to render the liver tumour-free. RFA seems to be a highly attractive treatment modality 
since it is associated with lower morbidity and mortality compared to partial hepatectomy. 
However, a major concern is the reported high incidence of ablation site recurrences (ASR). 
Early evaluation of the completeness of RFA - followed by immediate repeat RFA in case of 
an incomplete procedure – is essential to reduce the high incidence of ASR. A prerequisite for 
evaluation of the completeness of RFA is the anatomical concordance or comparability of the pre-
RFA scan with the post-RFA scan. In the present study, we hypothesized that incomparability 
of the pre-RFA scan and post-RFA scan may result in an increased number of future ASR, since 
completeness of ablation cannot be evaluated reliably. Indeed we found that this incomparability 
is a risk factor associated with ASR. Other risk factors were CT-targeted RFA approach (as 
opposed to open RFA) and an index-tumour size >20mm.
The reason for using Similarity of Positioning Score (SiPS) in this study was to evaluate the 
problem and consequences of incomparable pre-RFA imaging and post-RFA imaging. Fifty-
four percent of the post-RFA scans were classified as anatomically concordant or SiPS-identical 
(SiPS-id), the remaining 46% as anatomically discordant or SiPS-different (SiPS-diff). Open 
RFA and CT-targeted RFA were equally represented, suggesting that SiPS is not influenced by 
RFA approach and concomitant partial hepatectomy. Although intuitively it seems reasonable 
to expect that partial hepatectomy is associated with a change in position and configuration 
of the liver – and thus influences SiPS - we did not encounter this. A probable explanation is 
that the liver remnant is fixed in position at the end of the operation. This means that SiPS 
is determined by other factors, for example changes in the position of the liver as a result of 
longitudinal or rotational movements of the liver related to variations in diaphragm position. 
These factors could result in substantial organ position differences. These issues are well-known 
in the field of radiotherapy and nuclear medicine. In radiotherapy, this problem is improved 
by using implanted markers which optimize accurate tumour targeting and advanced scanning 
techniques such as four-dimensional CT-planning[16, 17]. In nuclear medicine, movements 
– particularly respiratory movements - can result in mismatch between PET and CT-images. 
Respiratory-motion tracking systems, mathematical correction models or scanning correction 
models and post-processional motion-correction methods are used to minimize this problem[18, 
19]. These techniques could be useful in reducing organ position differences between subsequent 
scans in the post-RFA follow-up.
Radiological evaluation of RFA procedures can be performed by different strategies. Firstly, 
ablative margins can be estimated by fusing pre-RFA images and post-RFA images. Unfortunately, 
this method is often hindered by incomparable pre-RFA images and post-RFA images. Secondly, 
































































often not reliable because of geometrical constraints or incomplete overlap of the index-tumour 
and ablation zone[7, 20]. Thirdly, evaluation can be performed by focusing on post-RFA contrast-
enhancement, which might be misleading because of contrast-enhancement associated with post-
RFA inflammation and contrast-enhancement due to residual tumour origin. Differentiation 
between these entities can be performed by their different morphological characteristics and 
contrast-enhancement patterns on multiphase-CT-scanning[[21, 22], but remains difficult.
A possible solution to detect residual tumour after RFA without being hindered by incomparable 
pre-RFA images and post-RFA images is to perform PET-CT. PET is reported to have a high 
diagnostic accuracy in detecting residual tumour after RFA compared to contrast-enhanced CT 
and even MRI, modalities which are more readily available[21, 23]. Until now, only few studies 
with small patient groups assessed the usefulness of PET-CT after RFA. Based on our study 
it might be that PET-CT is the preferred imaging modality to detect incomplete ablations in 
patients with discordant pre-RFA scans and post-RFA scans. A potential limitation might be 
a false-positive result because of glucose uptake associated with post-RFA inflammation in the 
early post-RFA period[24]. Another possibility to evaluate completeness of the ablation is to 
monitor ablation zone volume on consecutive CT-scans, since an ongoing decline in ablation zone 
volume on consecutive scans is highly predictive of complete ablation and because an increase 
in volume is associated with ASR[25]. However, this is only noticed later in the follow-up and 
not on the first post-procedural scan. Therefore, we recommend that in case of SiPS-id, patients 
undergo regular follow-up with multiphase CT-scanning every three months in the first two years 
after the RFA-procedure and biannually thereafter. Patients with SiPS-diff should be followed 
in similar fashion, but it might be advisablein these patients to perform additional PET-CT-
scanning three to six months after the RFA-procedure, when the post-RFA inflammation has 
subsided and eventual glucose uptake can be attributed to residual tumour.
We report an ASR rate of 23% per patient and 21% on a tumour basis. Previously reported ASR 
rates vary widely between 1.8-55%[2, 3, 11, 26-28]. We found more ASR in tumours with SiPS-
diff classified scans, CT-targeted RFA treated tumours and tumours with a diameter of >20 mm. 
Although some studies have shown a higher incidence of ASR with ablation margins <10mm 
[29-31], our findings are in line with that of others who have reported that ASR is not related to 
ablative margins[31, 32]. Unfortunately, authors often do not mention their evaluation methods, 
which may lead to contradictory reports because of the use of different techniques.
It has been reported that CT-targeted RFA is associated with a higher risk of ASR[2, 3, 12, 
26, 28, 33-35], which is in accordance with our results. The most important explanation for 
the higher ASR rate in CT-targeted RFA is limited access to the tumour compared to open 
RFA, leading to inadequate ablation. Open RFA allows complete mobilization of the liver, 
better electrode accessibility, additional manoeuvres (Pringle) and tumour visibility (using intra-
operative ultrasound). Especially relevant is our finding that despite the higher incidence of ASR 














































likely be explained by thorough post-procedural follow-up. By carefully monitoring patients, 
early detection of ASR offers the possibility of timely interventions such as repeat RFA or partial 
hepatectomy.
This study has certain limitations. Firstly, the newly introduced SiPS-classification system is 
used in a small patient population. We are planning to validate the SiPS-classification in a larger 
patient cohort. Secondly, we did not perform biopsies to confirm the diagnosis of ASR. However, 
the reason not to do so is well-founded - biopsies can be associated with tumour seeding. This 
risk outweighs the benefit of the procedure[36, 37]. Although SiPS was described in a relative 
small population encompassing 97 tumours, it is highly reproducible as reflected by the excellent 
intra-observer and substantial interobserver agreement.
In conclusion, lack of anatomical concordance between pre-RFA images and post-RFA images, 
CT-targeted RFA and index-tumour size >20 mm are independent risk factors associated with 
future ablation site recurrences. Anatomical concordance of pre-RFA images and post-RFA 
images, expressed in the Similarity of Positioning Score, is important in evaluating the RFA 
procedure. In discordant scans, no reliable judgement can be made about the completeness of 
ablation and thus whether an additional RFA is necessary. Therefore, it is associated with an 
indirect increased risk of future ablation site recurrences.
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Radiofrequency ablation (RFA) is a well-established locally directed therapy which considerably 
improves survival of patients with unresectable liver metastases(1-6). Intensive post-procedural-
follow-up is necessary since one of the yet unresolved limitations of RFA is the high incidence of 
ablation site recurrences (ASR). Reported rates of ASR vary widely between 2-60%(4,7). Early 
detection of ASR as well as other intrahepatic or extrahepatic recurrences is indicated to offer 
patients secondary interventions if possible. Although it is still unclear which imaging modality is 
preferable for post-RFA-follow-up, most institutions use multiphase contrast-enhanced computed-
tomography (CT) or magnetic resonance imaging (MRI) with or without fluoride-radiolabeled-
deoxy-glucose positron emission tomography (FDG-PET)(8,9). Successfully and insufficiently 
ablated metastases and intrahepatic recurrences have their own specific characteristics on post-
RFA-CT-scans and MRI-scans. However, ASR of hypovascular metastases may have atypical 
appearances(10,11). In addition, detection of subtle changes in tumor-shape and tumor-size can 
be challenging with two-dimensional cross-sectional-imaging(12,13). Volumetric quantification 
of ablation zones (AZ) could theoretically lead to a more accurate assessment compared to two-
dimensional measurements. Therefore, the aims of this study were (1) to test the hypothesis 
that volume-changes of AZs on successive post-RFA CT-scans of colorectal liver metastases are 
predictive of ASR and (2) to analyze the course of the AZ-volumes on successive CT-scans in the 
post-RFA-follow-up in relation to the development of ASR.
Material and Methods
Patients
The study was approved by our institutional review board. Consecutive patients who underwent 
open-RFA or percutaneous CT-targeted-RFA for colorectal liver metastases (CRLM) in the period 
from July 2000 until August 2009 were retrieved from a prospective database. One week after 
the RFA-procedure, a baseline control CT-scan was performed. Follow-up consisted of physical 
and biochemical examination (including carcino-embryonic antigen, CEA, as tumor marker) and 
CT-scanning every three months during the first two years and biannually thereafter. Patients 
were included when the pre-RFA-scan, post-RFA-scan and at least another scan afterwards was 
available. Patients were excluded if adequate scans for comparison were missing.
RFA details
RFA was performed by using a RF 3000 TM Radio Frequency Ablation System (Boston Scientific, 
Boston, MA, USA). A LeVeen-electrode of 2, 3.5, 4 or 5 cm in diameter was used, depending on 
index-metastasis diameter. The RFA-electrode was positioned under ultrasonography in open RFA 














































the manufacturer. RFA was continued until the generation of radiofrequency waves was blocked 
by the rise in tissue impedance. Large metastases were treated by several overlapping positions of 
the deployed RFA-electrode. RFA was performed under general anaesthesia. Terminology used in 
this paper is in accordance to the guidelines by Goldberg et al(14).
Standard of reference
The standard of reference was defined by combining clinical, biochemical (CEA) and imaging data 
(CT and PET-CT) during follow-up. Biopsies for histological confirmation were not routinely 
performed. When RFA was performed concomitantly with resection, histology was obtained of 
the resected part of the liver. ASR was identified if the recurrence fulfilled the following criteria: 
(1) growth of a contrast-enhancing lesion within or in the border of the AZ and (2) the largest 
diameter of the lesion was in direct contact with the AZ. The latter prerequisite is to exclude 
outgrowth of pre-existing micrometastases in the close vicinity but not the border of the AZ. 
We prefer the term “ASR” over “local recurrence” or “local tumor progression” because the latter 
terms are confusing with respect to recurrence at the primary tumor-site, for instance pelvic 
recurrence in patients with rectal cancer.
Imaging details
Multiphase intravenous contrast enhanced CT scans were obtained using either a 16-slice or 
64-slice multidetector-CT-scanner (Somatom Sensation 64, Siemens, Erlangen, Germany). One 
hundred and twenty cc of iodixanol 320mg I/ml (Visipaque 320, GE Healthcare, Chalfont 
St Giles, UK) was injected at a flow-rate of 4.0cc/sec. Images were obtained during arterial, 
portal-venous and delayed phases. FDG-PET-CT imaging was obtained when CT-imaging was 
inconclusive. All subjects were scanned in craniocaudal direction during inspiratory breath-hold. 
CT-images were acquired in a supine position using a 16x1.5 (16-slice) or 24x1.2 (64-slice) 
collimation, tube-potential 120kV, tube-current-time-product 130mAs, pitch 1, slice-thickness 
2mm, reconstruction Kernel B30f and reconstruction-increment 1.5.
Imaging follow-up consisted of multiphase CT-imaging that was obtained one week after RFA 
(t1), then every 3 months during the first 2 years and every 6 months thereafter (t2-t5). Multiphase 
CT-imaging consisted of a series without contrast and series in the arterial, portal-venous and late 
phase. FDG-PET-CT was performed when CT-imaging was inconclusive.
Volumetry
One of the authors (2 years abdominal CT-experience) performed all measurements retrospectively 
and was unaware of the follow-up results. After transferring imaging-data, volumetry was performed 
on a Siemens Syngo workstation (version CT2007A) with the “Volume calculation” application. 
Volumes of interest (VOIs) were manually drawn around the contours of the metastasis and the 

































































every other slice to minimize partial volume effects. The programme automatically interpolated 
between VOIs. Each interpolation was revised and corrected manually if necessary. Evaluation 
was started after finishing the definition of each individual VOI. Approximate volumes were 
calculated with automatic multiplication of the circumscribed areas by the CT-section-thickness. 
Volume-results were expressed in cubic centimetres (cm3). Minimum and maximum density 
values, expressed in Hounsfield units (HU), were set between -50 to 200 for metastasis-volumes 
and -50 to 50 for AZ-volumes, according to the minimum and maximum HUs measured in each 
individual metastasis and AZ which were automatically calculated by the application. This was 
done for all measurements. Measurements were performed on the pre-RFA-scan, the first post-
RFA-scan (t1) and available subsequent scans thereafter (t2-t5).
Intraobserver-varibility and interobserver-variability
To determine intra-observer and interobserver-variability, two radiologists performed all 
volumetry in triplo on a subset of 25 randomly selected pre-RFA and post-RFA scans from the 
patient database, with repetitive measurements at least two weeks apart.
 
Calculations with volumes





-ratio, in which V
metastasis
 is the index-metastasis-volume and V
t1
 is the volume of the AZ at 
t1. Volumes of AZs at the subsequent time points t2-t5 were represented as percentages compared 
to V
t1
, which was set at 100%. The proportional (volume) change of AZs between subsequent 
scans was the difference in volume-percentages between two successive time points. Negative 
values represented a decrease in volume, positive values represented an increase in volume.
Statistical analysis
Categorical variables were presented as numbers and percentages. Groups were compared using 
Chi-square-test or Fisher’s exact test and included the following variables: growth (yes versus 
no); CT-scan-results (positive versus negative versus doubt) and PET-scan-results (positive versus 
negative). Continuous variables were expressed as median and interquartile range (IQR). Groups 
were compared by using Mann-Whitney-U-test. Receiver-operating-characteristic (ROC) curves 





and proportional change at t1-t2, t2-t3 and t3-t4 are predictive of ASR. Sensitivity, specificity, 
positive predictive value, negative predictive value and accuracy were calculated for CT alone 
and CT-volumetry. Intraobserver-variability and interobserver-variability on volumetry were 
evaluated by using intraclass correlation coefficients (ICC). P-values <0.05 were considered 
statistically significant. Statistical analysis was performed by using the statistical software 















































General characteristics and recurrence patterns
Table 1 summarizes general patient and metastasis characteristics. A total of 58 patients were 
included. There were 37 males and 21 females. Median age at the time of the RFA-procedure was 
59 years (IQR 15.5). Fifty-eight patients with 117 metastases underwent 81 RFA-procedures. 
Twenty-four patients had  more than one metastasis ablated during an RFA-procedure (range 
2-7). Eighteen patients with 52 metastases had more than one RFA. Forty RFA-procedures were 
performed by laparotomy, 41 percutaneously under CT-targeting.
Recurrences, either intrahepatic, extrahepatic or both were seen in 50 patients (86%). ASR 
occurred in 17 patients (29%) and 27 AZs (23%). Intrahepatic and/or extrahepatic recurrence 
without ASR was seen in 35 patients (60%) with 78 AZs (67%). ASR without recurrence 
elsewhere was seen in 2 patients (4%) with 4 AZs (3%). Six patients (10%) with 12 AZs (10%) 
had neither recurrence nor ASR. Median time to ASR was 8 months (IQR 9). Median total 
follow-up time was 26 months (IQR 25). Median volumetric follow-up time was 9 months (IQR 
8.5). The difference between total and volumetric follow-up is due to loss of AZs (see below in 
section “Follow-up of AZs).
Metastases
Of the 117 metastases, 66 were treated by open-RFA (56%) and 51 by CT-targeted-RFA (44%). 
Median diameter of the index-metastases was 1.99 cm (IQR 1.62) and median index-metastasis-
volume was 4.2cm3 (IQR 12.5). Index-metastases of AZs with ASR were larger (2.45 cm) in 
diameter than those without ASR (1.85 cm, p=0.015). The volume of index-metastases of AZs 
with ASR was also larger (7.7cm3) than the volume of those without ASR (3.3cm3, p=0.014).
Follow-up of AZs
Imaging was performed in all 117 AZs at t1 and t2. There were 95 AZs left at t3. Twenty-two 
AZs were lost between t2-t3 because of recurrent disease (n=16, these underwent either repeat-
RFA, surgical resection or were referred for palliative chemotherapy), ASR (n=4, these were 
treated with either repeat-RFA, surgical resection or were referred for palliative chemotherapy in 
case of coexisting intrahepatic or extrahepatic recurrence) or other reasons (n=2). There remained 
60 AZs at t4. Thirty-five AZs were lost between t3-t4 because of recurrent disease (n=19), ASR 
(n=11), other reasons (n=3) or because there were no subsequent scans (n=2). A total of 40 AZs 
remained at t5. Twenty AZs were lost between t4-t5 because of recurrent disease (n=8), ASR 


































































Table 1. Patient and metastasis characteristics.
Patients Metastases
Number 58 117
Age, years: median (interquartile range) 59 (15.5) -








One RFA-procedure 40 (69 %)  -
More than one RFA-procedure** 18 (31 %)  -
Recurrence 50 (86 %) -
Intrahepatic recurrence 14 (28 %) -
Extrahepatic recurrence   7 (14 %) -
Intra- and extrahepatic recurrence 29 (58 %) -
Recurrence without ASR*** 35 (60 %) -
Intrahepatic recurrence   8 (23 %) -
Extrahepatic recurrence   7 (20 %) -
Intra- and extrahepatic recurrence 20 (57 %) -
ASR 17 (29 %) 27 (23 %)
ASR and site of additional recurrence 15 (26 %) 23 (20 %)
Intrahepatic recurrence   6 (40 %)   9 (39 %)
Extrahepatic recurrence   0   (0 %)   0   (0 %)
Both intra- and extrahepatic recurrence   9 (60 %) 14 (51 %)
ASR without recurrence elsewhere   2   (3 %)   4   (3 %)
*RFA: radiofrequency ablation.
**More than one RFA was performed for the following reasons: ablation site recurrences (6 patients with 10 
metastases) or intrahepatic recurrences other than ablation site recurrence (12 patients with 20 metastases).
***ASR: ablation site recurrence.
Course of AZ-volumes
Figure 1 represents the volumes of AZs without ASR as percentage of the first post-RFA volume 
one week after RFA (t1), which was set at 100%. Figure 2 shows the same for AZs with ASR. 
An increase in volume was seen in 26 (96%) of the 27 AZs with ASR. However, one AZ (4%) 
with ASR at t2 showed no increase in volume, but ASR was “proven” by a hotspot on FDG-PET-
imaging. Of note, none of the AZs without ASR increased in volume.





-ratio was smaller in AZs with ASR (5.6) than in AZs without ASR 




-ratio for occurrence of ASR showed 














































Figure 1.Volume percentages in ablation zones (AZ) without ablation site recurrences (ASR).
AZs without ablation site recurrences did not show growth. Some AZs became so small that volumetry was 
impossible to perform. The horizontal axis represents the different time points of measurement t1-t5, in 
which t1 is performed on the first post-RFA-scan (1 week post-RFA) and t2-t5 on the subsequent scans, 
performed at intervals of three months. The vertical axis represents the volume percentage in which the 
volume at t1 is set at 100%.
The proportional changes in AZs with ASR were all positive from t2-t3 and on and differed 
significantly from the proportional changes of AZs without ASR, which were all negative (all 
p<0.001) (Table 2). The ROC-curve of the proportional change at t1-t2 for occurrence of ASR 
showed an AUC of 0.54 (p=0.583, 95%-CI 0.42-0.66). For the proportional change at t2-t3 
for the occurrence of ASR, the AUC was 0.85 (p<0.001, 95%-CI 0.74-0.97). The AUC for the 

































































Figure 2. Volume percentages in ablation zones (AZs) with ablation site recurrences (ASR).
All AZs, except for one, showed an increase in volume percentage when there was an ablation site recurrence. 
An initial decrease was seen in AZs which developed ablation site recurrences later. The horizontal axis 
represents the different time points of measurement t1-t5, in which t1 is performed on the first post-RFA-
scan (1 week post-RFA) and t2-t5 on the subsequent scans, performed at intervals of three months. The 























































-ratio was smaller in AZs with ASR (p=0.010). Note: the scale on the y-axis is a 
logarithmic scale. 
Detection of ASR with conventional CT
Of the 27 AZs with ASR, 17 (63%) were identified correctly on follow-up-CT-scans, 7 (26%) 
were missed and 3 AZs (11%) were classified as doubtful. Additional PET-CT-scanning in these 
doubted AZs was positive, suggestive of an ASR. A total of 23 AZs with ASR (85%) underwent 
PET-CT-scanning, which was positive in all. PET-CT was not performed in 4 (15%) AZs with 


































































Table 2. Absolute volumes and proportional volume changes in AZs with and without ASR.
Volumes (cm3) ASR, median (IQR) No ASR, median (IQR) p





5.6 (20.1) 16.8 (23.5) 0.010
Volume t1 44.4 (56.8) 62.0 (82.5) 0.928
Volume t2 20.2 (31.2) 22.4 (41.9) 0.962
Volume t3 28.6 (43.4) 13.2 (22.9) 0.006
Volume t4 18.4 (42.1) 12.4 (20.7) 0.143
Volume t5 14.2 (32.7) 6.1 (18.5) 0.277
Volume change Δ
%
* ASR, median (IQR) No ASR, median (IQR) p
Δ
%
 t1-t2 -52.2 (41.5) -51.1 (35.8) 0.785
Δ
%
 t2-t3 +2.5 (17.4) -14.2 (16.4) < 0.001
Δ
%
 t3-t4 +5.8 (14.7) -5.0 (8.4) < 0.001
Δ
%
 t4-t5 +4.4 (9.7) -2.6 (5.2) < 0.001
In this analysis, all AZs with ASR are included in the ASR-group, irrespective whether ASR is already 
present at the time point of measurement or will develop in the future (future-ASR).




The ICC for intraobserver-variability for the first post-RFA-scan was 0.998 (95%-CI 0.996-
0.999, p<0.001) and 0.987 for the subsequent scans (95%-CI 0.975-0.994, p<0.001). The ICC 
for interobserver-variability was 0.993 (95 %-CI 0.987-0.996, p<0.001). 
Table 3. Diagnostic performance of conventional contrast-enhanced CT alone and CT-volumetry in the 
detection of ASR.
Sensitivity (95%-CI*) Specificity (95%-CI) PPV** (95%-CI) NPV*** (95%-CI) Accuracy
CT**** 74 % (52-88) 100 % (53-100) 100 % (80-100) 63 % (39-83) 94 %
CT-volumetry 96 % (79-100) 100 % (70-100) 100 % (84-100) 92 % (62-100) 99 %
*95%-CI: 95%-confidence interval.
**PPV: positive predictive value.
***NPV: negative predictive value.
****CT: computer tomography.
Discussion
Baseline control imaging and follow-up is mandatory to detect ASR in metastases treated with 
RFA. However, detection of ASR is not always straight-forward with CT and MRI. Three-
dimensional assessment of AZs, for instance by volumetry, could help in detecting ASR. In 
the present study, we hypothesized that proportional (volume) changes of AZs within the first 
three months after RFA (t1-t2) are predictive of ASR. Proportional changes at t1-t2 were not 














































indeed predictive of ASR. ASR is the result of new tumor growth in the border of an AZ or 
an insufficiently treated AZ in which viable metastasis is left. Theoretically, AZs with viable 
metastatic cells should have a smaller decrease in volume between two subsequent time points 
of measurement. Residual metastatic cells will continue to multiply and inhibit or slow down 
the volume-decrease of the AZ. An explanation that the proportional changes at t1-t2 were not 
predictive for ASR could be that the initial decrease in volume in this period, mainly due post-
RFA effects, exceeds the volume-increase caused by growth of viable metastatic cells. After three 
months, AZs with ASR did increase in volume, probably because the volume-increase caused by 
the growth of ASR is larger than the volume decrease caused by the shrinkage of the AZ. Another 
explanation could be the relatively small number of ASR in this study.
It has been reported previously that AZs gradually become smaller because of shrinkage of 
the metastases and resolution of post-RFA-inflammation(10,11,15). In the present study, AZs 
without ASR invariably decreased in volume. Volumes of AZs with ASR increased in volume 
and the proportional changes from t2-t3 and on were predictive of ASR. One AZ with ASR did 
not increase in volume. This AZ was situated in segment 8 of the liver in a patient with previous 
right portal vein embolisation in who an extended right-sided hepatectomy was planned at a 
later moment. The coils from the embolisation-procedure produced scattering artefacts. This 
disturbed volumetry, since the contours of the AZ were badly visible and difficult to define. 
Currently, there are no coils available which do not produce artefacts on imaging. Volumetry 
should be used with caution in patients with possible artefact-causing procedures.
There are several strategies to detect ASR in the follow-up after RFA, but detection of ASR can 
be very difficult. Firstly, ASR can be detected by focusing on contrast-enhancement on imaging. 
Most institutions perform multiphase contrast-enhanced CT. MRI has also proved to be useful, 
especially when used with liver-specific contrast media, but is used less commonly(16,17). ASR 
may appear as a focal enhancing lesion within or around the AZ. However, contrast-enhancement 
may also be due to inflammation in the first months after RFA. Post-RFA inflammation presents 
as a hyperattenuating, smooth thin rim around the AZ. ASR appears as an irregular thick rim. 
Another distinguishing feature is the appearance of the rim on portal-venous images. Where 
ASR appears hypoattenuating, post-inflammational changes remain either hyperattenuating or 
iso-attenuating. Additionally, ASR can present as a nodular contrast-enhancing lesion at the 
periphery of the AZ or as an overall increase in size of the AZ, features which are not seen 
in post-RFA inflammation(11). Differentiation between these two entities is possible with 
these morphological characteristics on multiphase CT and MRI, but remains troublesome(11). 
Furthermore, detection of changes in shape and size of AZs requires a precise section-by-section 
comparison with previous scans, which can be difficult when organ positions and orientations 
differ between successive follow-up-scans, unfortunately a commonly encountered problem for 

































































FDG-PET, especially in combination with CT, is regarded the best follow-up imaging modality 
in the early detection of ASR(8). Several studies demonstrated the superiority of FDG-PET to 
CT and MRI in post-RFA-follow-up(19,20). PET is able to detect ASR earlier than conventional 
imaging, because metabolic alterations are thought to occur before morphologic changes(21). 
However, PET has several limitations, namely its costs, unreliable results caused by the effects 
of chemotherapy(19) and the uselessness in PET-negative tumors(19). Additionally, PET has 
limitations in the early period after the RFA-procedure, because FDG-uptake may be due to 
inflammation and it has poor resolution and lack of anatomical references unless PET-CT is 
performed(19,20).




-ratio was smaller in AZs with ASR. This has also been reported 
in a previous study in which this ratio was called necrosis-tumor-quotient and the conclusion 




-ratio could be used in the prediction of ASR(22). Although the AUC of 









-ratios deserve attention, since they may be associated with ASR.
Volumetry has been used in several studies in the evaluation of AZs(8,12,13,23-25). Since manual 
volumetric quantification is time-consuming, most studies used semi-automated analyses. 
Nevertheless, volumetry takes relatively short time since AZs are small. In addition, semi-
automated measurements are less reliable than hand-made measurements, as is the case with all 
automated evaluation methods in the field of radiology. However, the latter may be overcome in 
the future, since software is being continuously improved. Volumetry has important advantages 
over conventional post-RFA evaluation methods as provided by CT, MRI and PET. Firstly, where 
CT, MRI and PET are of limited value in the first months after RFA, volumetry could help to 
detect ASR, since ASR presented with an increase in volume of AZs even within this period. 
Secondly, volumetry provides three-dimensional information on AZs, whereas conventional 
modalities only reveal two-dimensional information. Thirdly, quantitative post-RFA evaluation 
methods are often hindered by differences in organ position between subsequent scans. This could 
result in unreliable measurements on AZs. Theoretically, volumetry is not influenced by organ 
position differences. The radiologist will be able to perform reliable volumetry on successive scans 
and interpret them correctly, even when the scans are incomparable. Fourthly, data derived from 





One of the limitations of this study is its retrospective design. Patients were retrieved from a 
prospective database, but volumetry of AZs were performed retrospectively. ASR was previously 
evaluated by measuring diameters of AZs and screening for contrast enhancement at the site of the 
ablated metastases on post-RFA CT-scans. As ASR was not detected with conventional evaluation 
methods of CT-scans as early as with volume volumetry, immediate treatment was not performed. 
Imaging was continued in these patients until ASR was detected with conventional CT-scans 
or FDG-PET/CT. Repeat-RFA or surgical resection was performed after confirmation of ASR 














































since it has been shown that the risk of tumor seeding outweighs the benefit of the procedure 
and diagnostic accuracy of radiological imaging is up to 90%, which is further increased by 
with serial CEA measurements(26,27), biopsies to confirm ASR are not performed routinely in 
our centre. Thirdly, very small volume-increases, for example less than 5%, could also be due 
to an individual measurement error. However, our finding that none of the AZs without ASR 
showed any increase in volume argues against this. Additionally, the high reproducibility of the 
measurements, as suggested by the intraclass correlation coefficients of the intra-observer and 
interobserver variability, shows that the margins of an individual measurement error are very 
narrow. A strong aspect of this study is the relative large number of AZ compared to previous 
studies concerning post-RFA-volumetry.
In conclusion, volumetry of AZs is useful because an increase in AZ volume during follow-up is 
highly suggestive of ASR. AZs without ASR decreased in volume without exception. AZs with 




-ratio is seen more often in AZs 
with ASR. The proportional  (volume) changes of AZs within the first three months after the 
RFA-procedure were not predictive of ASR, but thereafter there was a strong correlation between 
the proportional changes and ASR. Although manually performed volumetry is relatively time 
consuming, it should be performed in addition to conventional evaluation methods, since early 
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Immediate post-procedural measurements on ablation 
zones after microwave ablation: 
the sooner is not always the better


















































To determine whether immediate postprocedural contrast-enhanced CT-scanning is suitable in 
determining the effectiveness of microwave-ablation (MWA) in patients with liver tumours.
Methods:
Fifteen patients with 21 tumours underwent MWA. Assessment was performed on contrast-
enhanced CT-scans immediately after the MWA-procedure and one week post-procedurally and 
consisted of measurements of volumes, diameters and Hounsfield-Unit-values of index-tumours 
and ablation-zones.
Results:
Median index-tumour-volume was 9.2cm3 (IQR 3.8-34.2), with a median diameter of 3cm (IQR 
1.6-5.5) and mean density of 57HU (SD 17). Mean immediate post-procedural-volume was 
89cm3 (SD 51) with a mean diameter of 6cm (SD 2.2) and mean density of 54HU (SD 11). Mean 
volume one week post-procedurally was 112cm3 (SD 64) with a mean diameter of 6.5cm (SD 
2.5) and mean density of 43HU (SD 11).Volumes and diameters of ablation-zones one week post-
procedurally were significantly larger than immediately post-MWA (both p<0.001). Densities of 
ablation-zones one week post-procedurally were significantly lower than immediate post-MWA 
densities (p=0.027). Eleven tumours appeared to be insufficiently ablated on immediate post-
procedural qualitative assessment, confirmed in 9 on the scan performed one week post-MWA, of 
which eight underwent repeat-MWA.
Conclusion:
Immediate post-ablational assessment is unreliable, since dimensions of ablation-zones are 





























































Local ablative techniques are increasingly used in patients with unresectable liver tumours 
(1, 2). Radiofrequency ablation is a well established locally directed therapy in these patients. 
Microwave ablation (MWA) is a more recently introduced thermo-ablative technique. MWA 
is not yet widely used in Europe and the United States, but has been used for several years 
in Asian countries(3)(4). In contrast to surgical resection, no tissue is obtained after thermal 
ablation for histopathological examination to assess whether all tumour tissue has been destroyed. 
Therefore, post-procedural evaluation fully relies on imaging, usually performed with contrast-
enhanced CT or MRI. Unfortunately, it is not known what the optimal time point is for the 
first post-procedural imaging. In the present author’s center, a non-contrast enhanced CT-scan is 
performed routinely immediately after percutaneous ablation on which the ablative procedure is 
initially assessed. One week after thermal ablation, a protocol multiphase contrast-enhanced CT-
scan is performed for assessment of the completeness of the ablative procedure. Immediate post-
procedural contrast-enhanced imaging could have several advantages: (1) increased visibility of 
the ablation zones (AZs), which could lead to better evaluation of the ablative procedure, making 
the scan performed one week after the ablative procedure unnecessary, (2) higher detection of 
insufficiently ablated tumours, reducing the need for the patient for being rescheduled and 
undergoing general anesthesia again, since ablation can be continued in insufficiently treated 
tumours in the same session and (3) reduction of the radiation dose, as it is not necessary for the 
patient to undergo an additional multiphase CT-scan one week after the ablative procedure. In 
the present study, we report our initial experiences on the value of an immediate post-procedural 
contrast-enhanced CT-scan in the assessment of thermal ablative procedures.
Material and Methods
Patients
The study was approved by our institutional review board. Data of consecutive patients who 
underwent percutaneous CT-targeted MWA for benign and malignant liver tumours in the 
period from October 2010 until December 2011 were retrieved from a prospective database. 
Non-contrast enhanced CT-scanning was performed for intraprocedural monitoring of the MWA-
procedure. Thereafter, a contrast-enhanced CT-scan (arterial or portal-venous phase, depending on 
the characteristics of the tumour) immediately at the end of the MWA-procedure was performed 
in all patients (t1). Multiphase CT-scanning – which consisted of a series without contrast and 
series in the arterial, portal-venous and late phase - was performed routinely one week after the 
MWA-procedure (t2). Follow-up of the patients consists of multiphase CT-scanning every three 
months during the first two years after the MWA-procedure and every six months thereafter, in 
















































MWA was performed percutaneously under CT-targeting using the Acculis microwave tissue 
ablation (MTA) system and the Accu2i pMTA applicator (Microsulis Medical Ltd. Denmead, 
UK). Ablation was performed with the intention to create ablation zones which at least cover the 
tumour and a safety margin of 1 cm around the tumour in all planes. Terminology used in this 
paper is in accordance to the guidelines as proposed by Goldberg et al(5).
Imaging details
CT-scanning was performed on a 16-slice multidetector CT-scanner for the immediate post-
MWA-scan. At the end of the MWA-procedure, a contrast-enhanced CT-scan was performed 
in the arterial phase in the case of hypervascular tumours and the portal venous phase in case of 
hypovascular tumours. A 64-slice multidetector-CT-scanner (Somatom Sensation 64, Siemens, 
Erlangen, Germany) was used for the protocol CT-scan one week after the MWA-procedure. 
Intravenous contrast was used, 120cc iodixanol 320mg I/ml (Visipaque 320, GE Healthcare, 
Chalfont St Giles, UK) with a flow-rate of 4.0cc/sec. All subjects were scanned in craniocaudal 
direction during inspiratory breath-hold. CT-images were acquired in a supine position using 
a 16x1.5 (16-slice) or 24x1.2 (64-slice) collimation, tube-potential 120kV, tube-current-time-
product 130mAs, pitch 1, slice-thickness 2mm, reconstruction Kernel B30f and reconstruction-
increment 1.5.
One of the authors (3 years liver CT-experience) performed all volume measurements manually 
on a Siemens Syngo workstation (version CT2007A) with the “Volume calculation” application. 
Volumes of interest (VOIs) were manually drawn around the contours of the index tumour and 
the AZs in the axial view on 2mm-thickness-slices. Volumetry on t2-scans was always performed 
in the portal-venous phase. Volume-results were expressed in cubic centimetres (cm3). The 
Hounsfield Unit values (HU) of the ablation zone at t1 and t2 were measured on the non-contrast 
enhanced series.
Statistical analysis
Categorical variables were presented as numbers and percentages. Continuous variables were 
expressed as mean and standard deviation (SD) when they were normally distributed. In the case 
of non-normal distribution, continuous variables were presented as median and interquartile 
range (IQR). Groups were compared by using Wilcoxon signed rank test. P-values <0.05 were 
considered statistically significant. Statistical analysis was performed by using the statistical 






























































Fifteen patients with 21 index tumours were included. Nine (60%) were male, 6 (40%) were 
female. Mean age at the time of MWA was 62 years (SD 13, range 37-82 years). A total of 
10 patients (66 %) with 15 index tumours (72%) underwent MWA because of colorectal liver 
metastases. Three patients (20%) with 3 index tumours (14%) had MWA for hepatocellular 
carcinoma. MWA was performed for liver metastases of a neuroendocrine tumour of the pancreas 
in one patient (7%) with 2 index tumours (9%). One patient (7%) underwent MWA for a benign 
adenoma (5%) (Table 1). Median time of follow-up was 9 months (IQR 7-16).
Volumetry
Figure 1 represents the course of the volumes of the index tumours and the AZs at t1 and t2, 
respectively. All AZs increased in volume between the two time points of measurement. Median 
index tumour volume was 9.2 cm3 (IQR 2.9-25.8), with a median diameter of 2.6 cm (IQR 1.5-
5.5). Median density of the index tumours was 60 HU (IQR 46-73) (Table 1). Median volume 
of the AZs at t1 was 71 cm3 (47-152) with a median diameter of 5.8 cm (IQR 4.6-7.5). Median 
density of the AZs immediately after the MWA-procedure was 54 HU (IQR 48-62). Median 
volume at t2 was 98cm3 (IQR 60-189) with a median diameter of 6.0 cm (IQR 4.8-8.4). Median 
density of the AZ one week after MWA was 46 HU (IQR 36-51). Median percentage of the 
volume of the AZ one week after the MWA compared to the immediate post-procedural volume 
was 124% (IQR 109-147). The volumes and diameters of the AZs at t2 were significantly larger 
than the t1-volumes and diameters (p=0.026 and p<0.001, respectively). Median densities (HU-
values) of the AZs at t2 were significantly lower than the t1-densities (p<0.001) (Table 2).
Table 1. Patient and index tumour characteristics.
Patients (n=15) Index tumours (n=21)
Male/female 9 / 6 (60 % / 40 %) -














Index tumour diameter in cm (median, IQRf) - 2.6 (1.5-5.5)
Index tumour volume in cm3 (median, IQR) - 9.2 (2.9-25.8)
HU-value (median, IQR) - 60 (46-73)
Abbreviations used: aSD: standard deviation; bMWA: microwave ablation; cCRCLM: colorectal liver 














































Figure 1. Volumes of the ondividual index tumours and the ablation zones at t1 and t2.
Volumes of the individual index tumours and the ablation zones at t1 and t2 in cm3. The volumes of the 
ablation zones at t2 were significantly larger than the volumes at t1 (p<0.001).
Table 2. Volumetry.
Ablation zone (n=21) t1a t2b p-value
Diameter in cm (median, IQRc) 5.8 (4.6-7.5) 6.0 (4.8-8.4) 0.026
Volume in cm3 (median, IQR) 71 (47-152) 98 (60-189) <0.001
Percentage of index tumour volume (median, IQR) 678 % (434-1791) 1093 % (470-3745) <0.001
Percentage volume of t1 (median, IQR) 100 % 124 % (109-147) -
Mean HU-valued (median, IQR) 54 (48-62) 46 (36-51) <0.001
Abbreviations used: at1: immediate post-procedural scan; bt2: scan one week after MWA; cIQR: interquartile 
range; dHU: Hounsfield Unit.
Discussion
The present study reports on the usefulness of an immediate post-procedural contrast-enhanced 
CT-scan in the assessment of the success of thermal ablation compared to the protocol multiphase 
CT-scan as performed one week post-procedurally. Volume and diameters of the AZs on the 
t2-scans were larger than volumes and diameters on the t1-scans. Additionally, the densities of 
the AZs on the t2-scans were lower compared to the t1-scans. These differences between the t1-





























































Imaging after thermal ablation is the cornerstone in the evaluation of the success of the procedure 
as well as in the follow-up. The recommended time point of the first post-ablation scan is not 
well determined and varies from immediately after ablation to one month post-procedurally(6). 
Unfortunately, there is no universally accepted optimal post-procedural imaging protocol. The 
first baseline control scan is important to assess whether there is a need of a re-intervention in 
the case of tumour residue. Ablation margins and volumes of the AZ are measured on the first 
post-procedural scan and compared to the dimensions or volumes of the index tumour. This 
is important to compare the size and/or volume of the AZ on subsequent scans. It has been 
shown that subtle changes - visually imperceptible but detectable with detailed measurements 
such as volumetry - could point toward ASR (7). Therefore, it is important to have quantitative 
information on AZs documented for comparing these values on subsequent scans. Based on the 
findings of this preliminary study, we recommend that measurements on AZs should only be 
obtained more delayed after ablation – for example one week after thermal ablation – because the 
size of AZs is changing after the first post-procedural week. The value of delayed post-procedural 
imaging has also been reported in the literature (8).
Tissue damage caused by thermal ablation involves a spectrum of processes. These include (1) 
dehydration of tissue; (2) enzyme deactivation; (3) rupture and aggregation of cell membranes 
and (4) vasoconstriction and intravascular coagulation. The response to thermal ablation varies 
per type of tissue, in which the heat effects on collagen and tissue architecture are determining 
factors (e.g. collapse around air filled spaces in the lung contrary to the solid tissue architecture 
of the liver)(9). Dehydration of tissue treated with thermal ablation is believed to cause tissue 
contraction. In the present study, AZs increased in volume on CT-scans performed one week post-
procedurally compared to the volumes on the immediate post-procedural scans. In the literature, 
an increase in the size of the AZ on imaging performed a few days after thermal ablation has 
been observed(6, 9, 10). Therefore, immediate post-procedural imaging may underestimate the 
original volume and diameter of treated tissue and measurements should not be performed on 
these scans. The delayed increase in the size of the AZ may be contributed to rehydration of the 
AZ or due to edema caused by inflammatory reactions. Another explanation might be delayed 
cell destruction in the border of the AZ. Since less heat is delivered in the periphery of the AZ, 
tissue destruction in the border may not be immediately realized but occur later, as these cells 
were also exposed to damaging temperatures. Unfortunately none of these hypotheses are neither 
confirmed nor reprobated.
A decrease in the density or Hounsfield Unit (HU) value of the AZs after thermal ablation 
compared to the HU-value of the index tumour has been described previously(11) and indicates 
the presence of necrosis. In contrast, prefunded tissue – as viable tumour cells – will not show a 
large decrease in HU-value. To our knowledge, it is not knowm whether CT-scanning generates 
different HU-values of AZs immediately after the procedure versus those obtained one week 














































progression of the ablation-induced necrosis or the resorption of coagulated blood within the 
AZs, which has a higher HU-value than the necrotic tissue within the AZ. 
In conclusion, quantitative assessment of AZs by measuring volumes and diameters should not 
be performed on immediate post-procedural images, since these parameters increase significantly 
in the first week post-procedurally. Therefore, quantitative assessment of thermal ablational 
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The liver is known to regenerate following partial hepatectomy (PH), but little is known about 
the timing and completeness of regeneration relative to the resected volume. This study examined 
whether liver volume regeneration following PH and its completeness 6 months after surgery is 
related to the resected volume.
Methods: 
A consecutive series of patients undergoing PH were included. All patients underwent 
preoperative computed tomography (CT) before and 7 days after surgery. Additional scans were 
performed 6 months after operation. Preoperative total liver volume (TLV), resected volume, 
future liver remnant (FLR) and liver remnant (LR) volumes were measured on CT images 
by freehand drawing of regions of interest in the portal venous phase on 2-mm thick slices. 
Regeneration indices were calculated at 7 days (RI
early
) and 6 months (RI
total
) using the formula 
100 × (LR volume – FLR volume)/FLR volume. Patients were classified into five groups based on 
resected volume as a percentage of TLV: 0–19, 20–39, 40–59, 60–69 and at least 70 per cent in 
groups 1–5 respectively.
Results: 
Ninety-one patients were enrolled. RI
early
 varied from 11 to 63 per cent in groups 1–5 (P < 
0.001). RI
early
 did not increase linearly with increasing resection volume and a plateau was seen 
from group 3 and above. In contrast, RI
total
 was related linearly to resected volume; values ranged 
from 21 to 233 per cent in groups 1–5 (P < 0.001). At 7 days, LR volume represented 97, 87, 
70, 58 and 41 per cent of TLV in groups 1–5. At 6 months, respective values were 102, 99, 87, 
82 and 91 per cent.
Conclusion: 
Early postoperative liver volume regeneration was not related linearly to resected volume. At 6 




























































The liver is unique in its remarkable capacity to regenerate after surgery. At a molecular level, 
liver regeneration begins almost immediately after partial hepatectomy (PH). It involves an 
orchestrated interplay of signalling events, including growth factors, cytokines and transcription 
factors1. Microscopically, liver regeneration consists of a time-dependent replication of different 
types of cell1 and ultimately results in macroscopic liver regeneration, with a volume increase 
after PH. 
The volume increase can be assessed by imaging techniques such as computed tomography (CT) 
or magnetic resonance imaging (MRI)2. CT is the most commonly used method, with well proven 
accuracy in the evaluation of liver volumes3. Studies using CT-based volumetry have shown that 
the liver regenerates rapidly and that regeneration is most pronounced in the first 7–10 days 
after surgery, with high regeneration indices (RIs)4,5. It is presently unclear when regeneration is 
complete. Some authors have suggested that regeneration is complete after 3 months, but others 
have proposed that it continues up to 1 year after surgery1,5–12. Furthermore, it has been shown 
that complete regeneration, to 100 per cent of the initial liver volume, is often not reached. 
The liver regenerates to only 80–85 per cent of the initial volume after large resections, such as 
(extended) right-sided hemihepatectomies5–12.
It is well known that liver regeneration depends on various factors, such as underlying parenchymal 
diseases, age and sex. Little is known about the process of liver regeneration after resection of 
different amounts of liver tissue. There is an obvious relationship between the resected liver 
volume and the amount of liver tissue that needs to regenerate, which implies that the resected 
volume may trigger the regeneration process after PH9–11. Studies evaluating liver regeneration 
have focused on right-sided hemihepatectomies or left lateral segmental resections. However, 
there is considerable interpatient variability in the size of the various liver segments. This means 
that the resected volume after a particular type of PH may differ substantially between patients13.
The aim of this study was to evaluate whether the amount of liver regeneration, expressed as 
the RI at 1 week and 6 months after surgery, is proportional to the resected volume after PH. In 
addition, the completeness of liver regeneration at 6 months after PH was studied.
Methods
Patients included in this study were all enrolled in a randomized controlled multicentre trial 
comparing the use of fibrin sealants versus no sealant on the liver resection surface after PH 
(registration number ISRCTN85205641; http://www.controlled-trials.com) between May 2006 
and June 2010. All patients underwent CT 1 week after surgery to objectively analyse resection 
surface-related fluid collections, in accordance with the protocol. Patients eligible for the present 














































anatomical liver resection in the present authors’ unit, had a preoperative CT scan available, 
and provided informed consent. Indications for liver resection were malignant or benign liver 
tumours or donor hemihepatectomies. Patients with pre-existing chronic liver disease and/or liver 
dysfunction were excluded. This study was conducted in compliance with national legislation as 
well as guidelines from the local medical ethics committee.
All patients underwent CT before and 1 week after surgery. Thereafter, CT was performed when 
indicated. Patients were classified into five groups according to the resected volume, calculated 
as a percentage of total non-tumorous liver volume: group 1, 0–19 per cent of total liver volume; 
group 2, 20–39 per cent; group 3, 40–59 per cent; group 4, 60–69 per cent, and group 5, at least 
70 per cent. 
Imaging and volumetry
Patients underwent multiphase CT before surgery (t0), 1 week after surgery (t1) and 6 months 
after operation (t2) when indicated. CT was performed using a multidetector scanner (Somatom 
Sensation 64; Siemens, Erlangen, Germany) with the use of intravenous contrast (120 ml iodixanol 
320 mg I/ml; Visipaque™ 320, GE Healthcare, Chalfont St Giles, UK). 
Volume measurements on CT images were performed by one investigator with 2 years’ experience 
in abdominal CT-volumetry, supervised by two other investigators (a radiologist with 25 years’ 
experience in abdominal radiology and an experienced hepatobiliary surgeon). After transferring 
imaging data, volumetry was performed on a workstation (Syngo version CT 2007A; Siemens). 
Regions of interest (ROIs) were drawn manually in the axial view on 2-mm thick slices in the 
portal venous phase. The volumes were calculated based on the surface of the ROIs multiplied 
by the slice thickness. The following contours were outlined: total liver, excluding vena cava and 
gallbladder; the part of the liver to be resected according to the Couinaud classification and on 
the basis of the hepatic (vascular) anatomy; tumour(s); and postoperative liver remnants on t1 and 
t2 scans. Approximate volumes were calculated by automatic multiplication of the circumscribed 
areas by the CT section thickness.
To determine intraobserver variability and interobserver variability, two investigators performed 
all volume measurements in triplicate on 25 presurgical and postsurgical scans, with repeat 
measurements at least 2 weeks apart. The weight of the resected part was measured at pathological 
anatomical examination and was considered the ‘gold standard’. Results of the CT-volumetry 
were then correlated with specimen weight.
Calculation of regeneration indices
After volumetry, tumour volume was subtracted from total preoperative liver volume and resected 
volume. All calculations involving total preoperative liver volumes and resected volumes were 
performed after subtraction of tumour volumes. The following variables were calculated: resected 
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LRt2
 is the liver remnant volume at t2. Complete regeneration was defined 
as a V
LRt2
 of at least 95 per cent of total preoperative liver volume, as there is a measuring error in 
CT-volumetry of 5–10 per cent.
Statistical analysis
Continuous variables are presented as median (interquartile range), unless stated otherwise. 
Comparisons of continuous variables between groups were performed with Kruskal–Wallis 
test. c2 test or Fisher’s exact test, as appropriate, was used for analysis of categorical variables. 
Associations between resected volumes and RIs were determined using Spearman’s rank 
correlation test. Intraobserver and interobserver variability were determined using the intraclass 
correlation coefficient. P < 0.050 was considered statistically significant. All statistical analyses 
were performed using SPSS® version 16.0 (SPSS, Chicago, Illinois, USA).
Results
A total of 91 patients undergoing PH were included in the study. Demographic and surgical 
characteristics are presented in Table 1. There were 50 men and 41 women. Median age at the 
time of PH was 62 (52–68) years and 75 patients (82 per cent) were older than 50 years.
Liver volume measurements and correlation with specimen weight
All patients had undergone CT at t1, a median of 7 (7–7) days after surgery. Sixty-four patients 
had a t2 scan, at a median of 6 (5–7) months after operation. Twenty-seven patients did not have 
a t2 scan for the following reasons: postoperative follow-up was performed with other imaging 
modalities (ultrasound or MRI, 18 patients), progressive metastatic disease (2), end of follow-
up of benign tumours (2), living donor (3) and death (2). There was no significant difference in 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2 shows the resected liver volumes in relation to types of PH and volume measurements are 
summarized in Table 3. Overall median preoperative total liver volume was 1529 (1328–1724) 
cm3, with no significant differences between groups (P = 0.481). Median tumour volume was 
43 (14–209) cm3 and was not significantly different among groups (P = 0.087). FLV differed 
according to the extent of resection (P < 0.001).
The intraclass correlation coefficient for intraobserver variability was 0.998 (95 per cent confidence 
interval 0.996 to 0.999) for the first postoperative scan (P < 0.001) and 0.987 (0.975 to 0.994) 
for the second scan (P < 0.001). The intraclass correlation coefficient for interobserver variability 
was 0.875 (0.354 to 0.981) (P = 0.005). There was a good correlation between measured volume 
and actual weight of the resected specimen (Spearman’s correlation coefficient 0.975, P < 0.001) 
(Fig. S1, supporting information).









































Bisegmentectomy 31 17 (55 ) 13(42 ) 1 (3 ) 0 (0) 0 (0)
Values in parentheses are percentages. Patients were grouped by resected liver volume, expressed as a 
percentage of preoperative total non-tumorous liver volume: group 1, 0–19 per cent; group 2, 20–39 per 
cent; group 3, 40–59 per cent; group 4, 60–69 per cent; and group 5, 70 per cent or more.
Regeneration indices and completeness of regeneration
Fig. 1 summarizes the RIs for each patient group. Median RI
early
 for all groups combined was 36 
(12–56) per cent. RI
early
 increased significantly as resections became larger (Spearman correlation 
coefficient 0.702, P < 0.001). A plateau was observed for group 3 and higher (more than 40 
per cent of total liver volume resected), indicating that RI
early
 did not correlate linearly with 
the amount of liver tissue resected. Median RI
total
 was 52 (24–107) per cent overall, and was 





correlated linearly with the amount of liver tissue resected (Spearman correlation coefficient 
0.705, P < 0.001).
For all groups combined, the median FLR was 61 (39–80) per cent of the total preoperative liver 
volume. The median liver remnant volume was 81 (61–93) per cent of total preoperative liver 
volume at t1 and 92 (82–102) per cent at t2. Thirty patients (47 per cent) reached their original 
preoperative liver volume by t2. The percentage of patients whose livers reached complete 
regeneration in the five groups was 85, 58, 29, 15 and 0 per cent respectively. Fig. 2 shows the 
















































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Box-and-whisker plots showing regeneration indices (RI
early
, regeneration in first week, between 
t0 and t1; RI
total
, regeneration in first 6 months, between t0 and t2) in relation to resected liver volume, 
expressed as a percentage of preoperative liver volume: group 1, 0–19 per cent; group 2, 20–39 per cent; 
group 3, 40–59 per cent; group 4, 60–69 per cent; and group 5, 70 per cent or more. Median values (line 
within box), interquartile range (box) and range (error bars) are shown. P < 0.001 (Kruskal–Wallis test). 
Figure 2. Box-and-whisker plots showing future liver remnant volumes at t0, and liver remnant volumes 
at t1 (1 week after surgery) and t2 (6 months after surgery) as a percentage of total preoperative liver 
volume. Patients were grouped by resected liver volume, expressed as a percentage of preoperative total 
non-tumorous liver volume: group 1, 0–19 per cent; group 2, 20–39 per cent; group 3, 40–59 per cent; 
group 4, 60–69 per cent; and group 5, 70 per cent or more. Median values (line within box), interquartile 
range (box) and range (error bars) are shown. The dotted line represents total preoperative liver percentile 















































In the present study, the RIs for liver volume regeneration were assessed at 1 week (RI
early
) and 6 
months (RI
total
) after PH in relation to the amount of resected liver tissue, and the completeness 
of liver regeneration was studied at 6 months. The two main findings were that RI
early
 was 
relatively low in patients who underwent a large liver resection (and thus had a relatively small 
liver remnant), and that liver regeneration was not (yet) complete by 6 months after surgery in 
patients who underwent a large liver resection, in contrast to patients who underwent a relatively 
small liver resection.
Previous studies have shown that liver regeneration occurs rapidly after PH, whether performed 
in living donors or for the resection of malignant liver tumours4,5,8–10,12,14. Many of these studies 
evaluated liver regeneration at a later time in the postoperative course, 1–6 months after PH5–12. 
Data on early liver regeneration (1 week after resection) are scarce. Reported early RIs range from 
28 to 64 per cent4,5,11. RIs in the later postoperative course are considerably lower, suggesting that 
the first week after operation is quantitatively important in the process of liver regeneration5,9,10,12. 
The discordance between reported RIs could be explained by different types of hepatectomy 
performed as well as by differences in amount of liver parenchyma resected. The pattern of 
liver regeneration observed after left-sided hepatectomy may not reflect what occurs after right-
sided hepatectomy. Besides anatomical differences in resections, the resected volume also varies 
according to type of PH. Equally, it has been shown that there is significant interpatient variation 
in liver volumes13. This implies that resected volumes in individual patients undergoing right-
sided hepatectomy may vary considerably. For example, a right-sided hepatectomy does not 
necessarily always involve 60 per cent of total preoperative liver volume, but may vary between 
20 per cent to more than 70 per cent. Thus, RIs may not be comparable purely according to 
type of PH, especially when tumour size is taken into account. The present study also showed 
considerable interpatient variability in resected volumes among those undergoing the same type 
of PH. This was why liver regeneration was studied based on resected volume rather than on type 
of PH. 
In the present study, RI
early
 was 11 per cent in the smallest resection group and 63–66 per cent in 
the groups with the largest resections, which were mainly right-sided hepatectomies. The latter 
is in line with findings from previous studies in which liver regeneration was studied after right-
sided hepatectomy4,5,12. Although the RI
early
 increased as resections became larger, a plateau was 
seen for patients who underwent resection of 40 per cent or more of total preoperative liver volume. 
An explanation for this could be that the regeneration process is of secondary importance to the 
metabolic demands of the patient. It is conceivable that a sufficient amount of liver parenchyma 
needs to remain active to preserve appropriate liver function. When the FLR is small, relatively 
more remnant liver cells are needed to support the metabolic needs. Cells that are undergoing 


























































cells that are fulfilling metabolic and detoxifying functions cannot enter the mitotic phase. If 
metabolic and detoxifying functions of the liver prevail over the process of liver regeneration 
– at least until there are enough hepatocytes to carry out both functions – regeneration will be 
relatively delayed after larger resections. The present data suggest that the early liver regeneration 
reaches a plateau phase when 40 per cent or more of the total liver volume is resected. In other 
words, early liver regeneration is less efficient when larger volumes are resected. Later on, however, 
there seemed to be a catch-up growth after larger resections.
Complete regeneration was found in only 47 per cent of the patients at 6 months after surgery. 
Complete liver regeneration at this time point occurred mainly in patients who had smaller 
resections. No patient who underwent resection of 70 per cent or more of total preoperative 
liver volume reached complete regeneration by 6 months after operation. It has been shown 
that the FLR regenerates up to 80–90 per cent of total preoperative liver volume for right-sided 
hepatectomies after 6 months and 92–97 per cent for left lateral segmental resections5,6,8–10. It is 
possible that not all patients reached complete regeneration by 6 months after surgery because 
complete regeneration take longer than this. Additionally, volume increase could continue 
beyond the time point chosen in the present study; this seems a topic worthy of future research.
The present study used CT for the evaluation of liver volumes. CT is a well established non-
invasive method for evaluating liver (vascular) anatomy and estimating segmental volumes2,3. 
Several types of error could affect liver volume measurements. However, the excellent correlation 
between estimated volume of resected liver and its actual weight in the present study suggests 
that the preoperative volumes were estimated accurately. The intraobserver and interobserver 
variability showed that volume measurements by CT are reliable and reproducible.
This study has certain limitations. First, several reported factors that could influence liver 
regeneration, such as steatosis, preservation of the middle hepatic vein, portal venous flow and 
spleen size, were not taken into account specifically because there was no significant difference in 
age, sex, body mass index, body surface area, preoperative chemotherapy and presence of steatosis 
between the five patient groups. Second, the increase in liver volume does not necessarily reflect 
liver regeneration. Parenchymal oedema, vascular engorgement and eventual inflammation, 
which are seen in the first phase of the regeneration process, could have influenced the measured 
liver volume. Last but not least, volume regeneration does not necessarily reflect functional 
recovery of the liver.
Disclosure
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Experimental studies in animals have suggested that liver regeneration is impaired in steatotic 
livers. However, few studies have focused on the impact of steatosis in patients undergoing partial 
hepatectomy (PH). This study aims to determine the role of steatosis on liver regeneration in 
humans following PH.
Methods:
Eighty-eight patients undergoing PH were included in the study. All patients underwent CT-
scanning of the liver preoperatively and 7 days after surgery. Additional CT-scans were performed 
6 months postoperatively. Pre-operative and postoperative volumes of the total liver (TLV), future 
liver remnant (FLR) and liver remnant (LR) were measured on CT-scans. Regeneration-indices 
(RI) were calculated at 7 days and 6 months using the formula: (Volume LR- Volume FLR) / 
Volume FLR*100%. Based on histological examination of the resected part of the liver, patients 
were classified into 3 groups: (1) no steatosis, (2) mild steatosis (1-29%) and (3) moderate-to-
severe steatosis (≥30%).
Results:
The early RI (at day 7) was 40%, 24%, and 20% for patients in group 1, 2 and 3, respectively. 
Late RI (at 6 months) was 81% for group 1, 44% for group 2, and 22% for group 3 (p=0.019). 
At 7 days, the LR represented 79%, 80% and 79% of the TLV for groups 1-3. At 6 months, this 
was 93%, 92% and 79%, respectively.
Conclusion:
Although early RI after PH did not differ in patients with or without steatosis, the late RI in 
patients with moderate-to-severe-steatosis was lower, suggesting that late liver regeneration is 
impaired in these patients.
Introduction
Hepatic steatosis is characterized by lipid accumulation within hepatocytes. It is a common 
finding in human biopsy specimens and is estimated to affect up to 30% of the Western 
population(1,2). It is reasonable to assume that its prevalence will further increase due to the 
current obesity epidemic. Hepatic steatosis can lead to non-alcoholic steatohepatitis, cirrhosis 
and development of hepatocellular carcinoma. In addition, it is reported to be a risk factor for 
postoperative complications, although reports are contradicting(3,4). The regenerative capacity 
of steatotic livers is less well established. Studies on liver regeneration and steatosis which have 
been performed in animal models have suggested that steatosis impairs liver regeneration(5), (6). 
In humans, these studies are scarce. Most of the few existing reports have focused on regeneration 
in living donors for liver transplantation, but again, the results are contradictory(3,7-11). 
Although most of these studies have suggested that regeneration is not impaired by steatosis, 
it should be noted that moderate-to-severe steatosis is generally a contraindication for living 
donation in relative contrast to partial hepatectomy for liver tumors. Therefore, living donors 
are not an ideal population to study the impact of steatosis on liver regeneration(3,12). To the 
best knowledge, there is no study which assesses the impact of steatosis on liver regeneration 
in patients undergoing elective partial hepatectomy for liver tumors. Therefore, the aim of this 
study was to determinate whether liver regeneration in patients after partial hepatectomy for liver 
tumors is associated with the degree of hepatic steatosis.
Material and Methods
Patients
All patients included in this study were identified retrospectively from the prospective database 
of the FRESCO-trial (Efficacy of fibrin sealant in reducing resection surface related complications 
after partial liver resections, registration number ISRCTN85205641). The FRESCO-trial was 
a multicentre randomized controlled trial on the efficacy of fibrin sealant in reducing resection 
surface related complications after partial liver resections(13). All patients underwent protocolized 
CT-scan one week after surgery in order to objectively analyze resection surface related fluid 
collections. Thereafter, CT-imaging was performed when clinically indicated. Patients included 
in the present study on liver regeneration met the following criteria: (1) an anatomical liver 
resection was performed in our center, (2) at least two CT-scans were available (preoperatively 
and at 7 days after surgery). Indications for liver resection were malignant or benign liver tumors. 
Liver function tests were assessed before surgery and daily thereafter until discharge. Parameters 
for liver injury used for the analyses in this study were alanine aminotransferase (ALT, normal 
range <45 U/L) and aspartate aminotransferase (AST, normal range <40 U/L). Liver function 
parameters used for the analyses in this study were total bilirubin (TB, normal range ≤17 
μmol/L) and prothrombin time (PT, normal range 9-12 seconds). Patients were classified in three 
groups based on the degree of steatosis assessed by histological examination of the resected liver 
specimen. Group 1 consisted of patients without steatosis, in group 2 were patients with mild 
steatosis (1-29%), and group 3 consisted of patients with moderate-to-severe steatosis (≥30%). 
All histological examination were performed by one experienced hepatopathologist (ASHG), who 
was unaware of the regeneration data. The FRESCO study protocol was approved by the medical 
ethical committee of our hospital and all patients gave their written informed consent. The study 
was conducted in compliance with national legislation as well as guidelines from our medical 
ethical committee.
Imaging Details and Volumetry.
Patients underwent multiphase CT-scanning before surgery, one week and 6 months after 
surgery. CT-scanning was performed on a multidetector CT-scanner (Somatom Sensation 64, 
Siemens, Erlangen, Germany) with the use of intravenous contrast (120ml iodixanol 320mg I/
ml, Visipaque 320, GE Healthcare, Chalfont St Giles, UK). 
Volumetry on CT-images was performed by one investigator (PK) with 2 years experience in 
abdominal CT-imaging, supervised by two other investigators (EJJ, a radiologist with 25 years 
experience in abdominal radiology and MTB, an experienced hepatobiliary surgeon). After 
transferring imaging data, measurements were performed on a workstation (Siemens Syngo version 
CT 2007A). Volumes of interest were manually drawn in the axial view on 2-mm-thickness slices 
in the portal-venous phase around the following contours: (1) the total liver with exclusion of the 
vena cava and the gallbladder, (2) the intended part of the liver to be resected according to the 
Couinaud-classification and on the basis of the hepatic (vascular) anatomy, (3) the tumor(s) and (4) 
the postoperative liver remnants at one week and 6 months after surgery. Approximate volumes 
were calculated with automatic multiplication of the circumscribed areas by the CT-section-
thickness. Results were presented in cubic centimetres (cm3) in a table. To determine intra- and 
interobserver-variability, two investigators performed all volume measurements in triplicate on 
25 pre-surgical and post-surgical scans, with repetitive measurements at least 2 weeks apart.
Calculations of Regeneration Indices.
After volumetry, the tumor volume was subtracted from the total pre-operative liver volume 
and the resected volume. All calculations with total pre-operative liver volumes and resected 
volumes were performed without tumor volumes. The following variables were calculated: 
(1) the percentage of the resected liver volume without tumor volume, calculated as V
resection
/ 
TLV*100% in which V
resection
 is the volume of the resected part and TLV is the total pre-operative 
liver volume; (2) the volume of the future liver remnant (V
FLR
), calculated as (TLV – V
resection
); (3) 
the percentage of the FLR, calculated as V
FLR
 / TLV*100%; (4) the regeneration index between 







*100% in which V
LRt1
 is the volume of the liver remnant at one week postoperatively 
and V
FLR
 is the volume of the future liver remnant; (5) the regeneration index between the pre-







*100% in which V
LRt2
 is the volume of the liver remnant at six months postoperatively; 
(6) the early regeneration, which is the volume of the liver remnant at one week postoperatively 




*100% and (7) the 
late regeneration, which is the volume of the liver remnant at six months postoperatively as 





Histopathological assessment of hepatic steatosis.
All resected specimens were subjected to pathological-anatomical examination. Speciments were 
weighted. The degree of steatosis was quantified as the percentage of hepatocytes containing fat 
droplets on conventional haematoxylin and eosin-stained slides and defined as none (0%), mild 
(1-29%%) and moderate-to-severe (≥30%) by a pathologist specialized in liver pathology. This 
was performed in sections of the liver distant from tumors.
Statistical analysis.
Categorical variables were presented as numbers and percentages, continuous variables were 
presented as median and interquartile range. Continuous variables were analyzed with Kruskal-
Wallis test. Categorical variables were compared by using Chi-square test or Fisher’s exact test, 
as appropriate. Intra- and interobserver-variability on volume-measurements were evaluated by 
using intraclass-correlation-coefficients (ICC). A p-value less than 0.05 was considered statistically 




A total of 88 patients who underwent partial hepatectomy were included in the study. There were 
49 males (56%) and 29 females (44%). Demographic and surgical characteristics of the patients 
are presented in Table 1. Median age at the time of surgery was 62 years (IQR 53-68 years). 
There were 13 patients (15%) younger than 50 years, 75 patients (85%) were older. According to 
the histological assessment of hepatic steatosis, 35 patients (40%) were classified in group 1, 47 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Intra-observer and Interobserver Variability.
The intraclass-correlation-coefficient for intraobserver-variability was 0.998 for the first 
postoperative scan (95%-CI 0.996-0.999, p<0.001) and 0.987 for the second scan (95%-CI 
0.975-0.994, p<0.001). The intraclass-correlation-coefficient for interobserver-variability was 
0.875 (95%-CI 0.354-0.981, p=0.005).
Regeneration Indices and Degree of Hepatic Steatosis.
All patients underwent protocol CT-scanning after a median of 7 days after surgery (IQR 7-7 
days). Sixty-four patients (70%) had a scan six months postoperatively, performed after a median 
of 6 months after surgery (IQR 5-7 months). Twenty-four patients did not have a scan at 6 
months for the following reasons: post-operative follow-up was performed with other imaging 
modalities than CT-scanning (i.e. ultrasound or magnetic resonance imaging, n=18); progressive 
metastatic disease (n=2); end of follow-up in the case of a benign tumor (n=2) and patient death 
(n=2). There was no significant difference in timing of the CT-scan at 6 months between the three 
patient groups. Liver volume measurements are presented in Table 2. Before surgery, the total 
liver volume was significantly different between the groups (p<0.001). There were no significant 
differences between the volumes of the resected part, FLR and liver remnants at one week and 6 
months postoperatively (Table 2).
Early RI at one week was 40%, 24% and 20% for groups 1-3, respectively and was not significantly 
different. Late RI at 6 months was 81%, 44% and 22% for groups 1-3, respectively and did differ 
significantly (p=0.021) (Figure 1).
At one week after surgery, the liver remnant represented 79%, 80% and 79% of the preoperative 
total liver volume for groups 1-3, respectively without significant difference (early regeneration). 
At 6 months after surgery, liver volumes were 93%, 92% and 79% of the preoperative volume, 
respectively and did not differ significantly (late regeneration) (Figure 2).
Biochemical Profiles
Perioperative changes in serum total ALT, AST, bilirubin and prothrombin time in the three 
groups are depicted in Figure 3. There were no significant differences in these parameters of liver 
injury and liver function among the three groups.
Figure 1.
Box-and-whisker plots representing the early (one week) and late (6 months) regeneration indices for the 
patient groups based on the degree of hepatic steatosis. The lower quartile (25th percentile), median and the 
upper quartile (75th percentile) are represented by the bottom, the line and the top of the box. The smallest 
and largest observations are represented by the ends of the whiskers (5th percentile and 95th percentile, 
respectively). Regeneration indices are declining as the degree of steatosis increases. The early RI did not 
differ significantly (p=0.292). The late RI was significantly different between the groups (p=0.021).
Figure 2.
Box-and-whisker plots of the volumes of the future liver remnant (FLR) and liver remnants one week and six 
months postoperatively as percentage of the total pre-operative liver volume, representing the completeness 
of liver regeneration at the different time points. The lower quartile (25th percentile), median and the 
upper quartile (75th percentile) are represented by the bottom, the line and the top of the box. The smallest 
and largest observations are represented by the ends of the whiskers (5th percentile and 95th percentile, 
respectively).The total pre-operative liver volume was set at 100 %. There were no significant differences 
between the groups.
Figure 3. Serum levels of alanine aminotransferase, aspartate aminotransferase, total bilirubin and 
prothrombin time.
Median peri-operative changes in levels of alanine aminotransferase (ALT, panel A) in U/L, aspirate 
aminotransferase (ALT, panel B) in U/L, total bilirubin levels in μmol/L (panel C) and prothrombin time 
in seconds (panel D). The smallest and largest observations are represented by the ends of the error bars (5th 
percentile and 95th percentile, respectively). Levels at day 0 were assessed immediately after surgery. The 
horizontal dotted lines represent the normal values for each parameter. There was no significant difference 
in pre-operative and postoperative serum levels of ALT, AST, bilirubin and prothrombin times in between 
the groups.
Discussion
The present study assessed liver regeneration in patients with and without steatosis who underwent 
partial hepatectomy. We found no significant differences in the early regeneration index (early 
RI, one week postoperatively), although the early RI tended to be lower with increasing degrees 
of steatosis. However, the late regeneration index (late RI, 6 months postoperatively) did differ 
significantly between the three patient groups with lower late RIs in patients with moderate-
to-severe steatosis. This finding suggests that liver regeneration is impaired by the presence of 
steatosis > 30%. Liver injury markers and liver function parameters did not differ significantly 
between the patient groups, as reflected by the serum levels of AST, ALT, total bilirubin and 
prothrombin time, but patients with moderate-to-severe steatosis seemed to have worse 
postoperative biochemical profiles. Our results suggest that large resections should be performed 
cautiously in these patients, because their regeneration response is impaired by the presence of 
steatosis.
Hepatic steatosis is an increasingly common encountered condition. Experimental models which 
have assessed the impact of steatosis on liver regeneration have shown that the regenerative 
capacity of the liver is affected by the presence of steatosis(5,6). Severe steatosis is associated with 
an impaired regeneration response, mainly due to an excessive pro-inflammatory cytokine response 
and insufficient antioxidant response which predisposes the hepatocytes to extensive necrosis. This 
results in increased hepatocellular damage, which affects the regenerative capacity of the steatotic 
liver after hepatectomy(6). However, results from human studies, mostly performed in the setting 
of living donor liver transplantation, are contradicting(3,7-11). Reported RIs tended to be lower 
in mildly steatotic livers, especially in the first three months after surgery. However, most studies 
failed to reach statistical significance, probably because of the small sample size of the steatotic 
patient groups, as steatosis is generally an exclusion criterion for donor candidates. Additionally, 
the degree of steatosis in these studies did not exceed 30%. This could have influenced the 
results, since impairments in liver regeneration are expected to become more pronounced when 
there is clinically significant steatosis (generally regarded as ≥30%). Furthermore, differences in 
general health and age between living donors and patients with liver tumors makes it difficult to 
compare liver regeneration in these patients. Lastly, disparities in the definition of steatosis and 
different histologic techniques used in the assessment of steatosis can also contribute to these 
discrepancies. It is difficult to extrapolate regeneration data of healthy living donors to patients 
undergoing elective partial hepatectomy. Therefore, it remains unknown whether clinically 
significant steatosis has a negative influence on the regenerative capacity of the liver in the latter 
population. The present study, performed in patients who underwent elective hepatectomy, 
showed a tendency towards a lower early RI in patients with moderate-to-severe steatosis, but 
this was not significant. The late RI was significantly different between the patient groups with 
lower late RIs in patients with moderate-to-severe steatosis. We hypothesize that hypertrophy of 
cells together with the presence of postoperative vascular engorgement and tissue edema could 
have resulted in falsely larger volumes of the liver remnants one week after partial hepatectomy, 
leading to less pronounced differences in the early RI between the patient groups. This resolves 
within a few weeks postoperatively, thus the late RI is not affected by this phenomenon and is 
in fact more strictly related to true cellular multiplication-related volume growth. Our results 
suggest that large resections should be performed cautiously in these patients, because their 
regeneration response is impaired by the presence of steatosis.
An increasing number of oncological patients undergo chemotherapy prior to resection in 
order to downgrade the stage of their (metastatic) disease. Certain types of agents used for 
chemotherapy – for example such irinotecan, oxaliplatin and 5-fluorouracil - are well-known risk-
factors for chemotherapy-induced hepatic steatosis(14-16). The impact of chemotherapy on liver 
regeneration is still unclear, but it is assumable that any type of injury induced by pre-operative 
chemotherapy negatively affects postoperative liver regeneration. Seven patients received pre-
operative chemotherapy in our study and none of them had moderate-to-severe steatosis. Thus, 
the presence of steatosis and the resulting impaired regeneration response in patients with 
moderate-to-severe steatosis cannot be explained by pre-operatively administered chemotherapy.
It has been described previously that patients with steatosis have worse postoperative biochemical 
markers for liver injury and liver function(4,12,17-20). In the present study, parameters of liver 
injury and liver function did not differ significantly between the patient groups. Although 
not statistically significant, there were higher peaks in serum ALT, AST, total bilirubin and 
prothrombin time in patients with moderate-to-severe steatosis. This suggests that the presence 
of steatosis has a negative influence on postoperative hepatic biochemistry. One explanation that 
the present study did not reach statistical significance on biochemical changes could be that the 
number of patients with moderate-to-severe steatosis was too low. Another explanation could be 
the wide distribution of the biochemical parameters at the time points of measurement (Figure 
3).
The present study has certain limitations. Firstly, specific factors which could influence liver 
regeneration such as preservation of the middle hepatic vein, the portal venous flow and spleen 
size were not taken specifically into account. Secondly, the increase in liver volume does not 
necessarily reflect liver regeneration. Parenchymal edema, vascular engorgement and eventual 
inflammation which are seen in the first phase of the regeneration process could have influenced 
the measured liver volume. Lastly, volume regeneration does not necessarily reflect functional 
recovery of the liver. 
In conclusion, hepatic steatosis impairs liver regeneration, as is reflected by the declining 
regeneration indices in patients with an increasing degree of steatosis. The clinical data of this 
study are in line with previous experimental animal data that hepatic steatosis is an important 
risk factor for impaired liver regeneration after partial hepatectomy.
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To study whether changes in postoperative platelet count is associated with liver regeneration in 
patients after partial hepatectomy (PH).
Methods:
Ninety-one patients undergoing PH were included in the study. All patients underwent pre-
operative CT-scanning and protocol CT-scanning 7 days postoperatively. Liver regeneration 
was assessed by volumetry of the pre-operative total liver volume (TLV) and postoperative liver 
remnants on CT-scans. After assessing the regeneration rate with respect to the amount of the 
resected liver volume, patients were classified in three groups according to their regeneration-
rate: (1) poor regeneration (regeneration rate≤25th percentile); (2) intermediate regeneration 
(regeneration rate between 25th-75th percentile) and (3) high regeneration (regeneration rate≥75th 
percentile). Platelet count was assessed pre-operatively and daily thereafter until discharge. The 
change in post-operative platelet count was defined as the difference between pre-operative and 
post-operative platelet counts. Platelet counts were presented as percentage of the pre-operative 
value.
Results:
Pre-operative platelet counts did not differ between the patient groups. Postoperative platelet 
counts decreased in all patients with a nadir at day 3 postoperatively and increased thereafter. 
At day 3 postoperatively, changes in platelet-count differed significantly between patient groups 
(p=0.049). Changes in platelet-count were significantly different at day 3 postoperatively in 
group 3 compared to group 1 (p=0.032) and group 2 (p=0.028).
 
Conclusion:
Platelet counts decrease in the first three days after PH and restore thereafter. Patients with high 
regeneration rates have stronger decreases in platelet counts compared to patients with poor 


























































Among all organs, the liver is unique due its remarkable capacity of regeneration after injury or 
partial resection. The liver can tolerate resections of as much as 75-80% of its volume with the 
prerequisite that there is no underlying parenchymal disease[1, 2]. Liver regeneration occurs 
rapidly after partial hepatectomy (PH) and is related to the amount of liver volume resected[3]. 
Hepatic regeneration is an orchestrated interplay of signaling events, consisting of growth 
factors, cytokines and transcription factors. Platelets, which contain multiple growth factors, 
are thought to be directly involved in liver regeneration. Several experimental studies in rodents 
have demonstrated a major role for platelets in liver regeneration[4-6]. It has been shown that 
platelets are recruited at the site of injury in direct contact to the hepatocytes to exert their 
positive effects in liver regeneration [7, 8]. Experimentally induced thrombocytopenia results 
in a markedly reduced proliferative activity in the liver. On the other hand, trombocytosis is 
associated with accelerated liver regeneration. It has been shown that platelets enter liver tissue 
quickly after a liver resection in mice. These platelets have been shown to enter the space of 
Disse which enables direct contact with the hepatocytes. This mechanism is likely required to 
stimulate liver regeneration by a mechanism involving release of various growth factors that are 
stored within platelet granules In humans, it has been shown that a low postoperative platelet 
count is associated with delayed functional recovery of the liver. Trombocytopenic patients have 
increased markers of liver injury, a higher degree of liver dysfunction and higher mortality[9]. 
It has been reported that platelet count decreases after PH and that this decrease is related to 
the extent of resection[10, 11]. A decrease in platelet count has also been described after liver 
transplantation[12]. Since both liver regeneration and the postoperative platelet count depend 
on the amount of the liver volume resected, we hypothesized that the decrease in postoperative 
platelet count is associated with the degree of liver regeneration. Specifically, we hypothesized 
that those patients with the largest drop in platelet count would have the highest regenerative 
response, since the drop in platelet count, at least partly, would reflect platelet accumulation and 
release of platelet-derived growth factors within the liver remnant. A direct relationship between 
postoperative platelet count and liver regeneration has never been studied or proven in humans. 
Therefore, the aim of this study was to evaluate whether the decrease in postoperative platelet 
count is related to liver regeneration in patients after PH.
Material and methods
Patients.
Patients included in this study were all enrolled in a randomized controlled multicenter trial 
comparing the use of fibrin sealants versus no sealants on the liver resection surface after PH 














































patients underwent per protocol CT-scanning one week postoperatively in order to objectively 
analyze resection surface related fluid collections. Patients eligible for the present study on 
liver regeneration participated in the randomized study and (1) underwent an anatomical liver 
resection in the present authors’ unit, (2) had an available pre-operative CT-scan and (3) provided 
informed consent. Indications for liver resection were malignant or benign liver tumours or 
donor hemihepatectomies. Patients with pre-existing liver cirrhosis were excluded. All patients 
underwent pre-operative and per protocol CT-imaging one week after surgery. Thereafter, CT-
imaging was performed when indicated. Platelet counts (normal range 150-350x109g/L) were 
assessed before surgery, immediately after surgery upon arrival at the intensive care unit (day 0), 
then at subsequent days until discharge. To evaluate the change in platelet count, pre-operative 
platelet count was set at 100% and postoperative platelet counts were calculated as percentage 
of the pre-operative platelet count. Hemoglobin (normal range 8.7-10.6 mmol/ L for men and 
7.5-9.9 mmol/L for women) and hematocrit (0.420-0.520 volume percentage for men and 
0.370-0.470 volume percentage for women) were assessed pre-operatively and then daily until 
discharge. Liver function tests were assessed before surgery and daily thereafter until discharge. 
Liver function parameters used for the analyses in this study were total bilirubin (TB, normal 
range ≤17 μmol/L) and prothrombin time (PT, normal range 9-12 seconds). Parameters for liver 
injury used for the analyses in this study were aspartate aminotransferase (AST, normal range <40 
U/L) and alanine aminotransferase (ALT, normal range <45 U/L). This study was conducted in 
compliance with national legislation as well as guidelines from our medical ethical committee.
Imaging Details and Volumetry.
Patients underwent multiphase CT-scanning before surgery and, one week postoperatively and 
thereafter when indicated. The second CT-scan used in this study was the CT-scan performed 6 
months postoperatively. CT was performed on a multidetector CT-scanner (Somatom Sensation 
64, Siemens, Erlangen, Germany) with the use of intravenous contrast (120ml iodixanol 320mg 
I/ml, Visipaque 320, GE Healthcare, Chalfont St Giles, UK). 
Volumetry on CT-images were performed by one investigator (PK) with 2 years experience 
in abdominal CT-imaging, supervised by two other investigators (EJJ, a radiologist with 25 
years experience in abdominal radiology and MTB, an experienced hepatobiliary surgeon). After 
transferring imaging data, measurements were performed on a workstation (Siemens Syngo 
version CT 2007A). Volumes of interest were manually drawn in the axial view on 2-mm-
thickness slices in the portal-venous phase around the following contours: (1) the total liver with 
exclusion of the vena cava and the gallbladder, (2) the intended part of the liver to be resected 
according to the Couinaud-classification and on the basis of the hepatic (vascular) anatomy, (3) 
the tumor(s) and (4) the postoperative liver remnants. Approximate volumes were calculated with 

























































Calculations of the Regeneration Index.
Pre-operative liver volumes and resected volumes were adjusted by subtracting tumour volumes. 





 in which V
resection
 is the resected volume and V
total
 is total pre-operative liver 
volume; (2) volume of future liver remnant (V
FLR
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 in which V
LR
 is the liver remnant volume one week postoperatively and 
V
FLR
 is the future liver remnant volume.
Since liver regeneration is dependent on the amount of resected liver tissue, regeneration indices 
need to be evaluated based on the volume of the resected part of the liver. A patient with a large 
resection will have a larger regeneration index than a patient with a small resection, which does 
not mean that the latter has poor regeneration. Therefore, patients were classified in 5 groups, 
according to the amount of resected liver tissue. Group 1 consisted of patients who underwent a 
resection of <20% of their total preoperative liver volume, group 2 were patients with a resection 
of 20-39%, group 3 consisted of patients with a resection of 40-59%, group 4 were patients with 
a resection of 60-69% and group 5 consisted of patients with a resection of ≥70% of their total 
pre-operative liver volume. Median regeneration indices were calculated for each patient group 
separately with interquartile ranges. Within each of these 5 groups, patients were categorized 
as having poor regeneration (regeneration index≤25th percentile), intermediate regeneration 
(regeneration index between the 25th and 75th percentile) and high regeneration (regeneration 
index≥75th percentile). Thereafter, all patients with poor, intermediate and high regeneration 
from the subgroups were rejoined in three large patient groups. Thus, there are three patient 
groups in total. Group 1 consisted of patients with poor regeneration (regeneration index≤25th 
percentile), in group 2 were patients with intermediate regeneration (regeneration index between 
the 25th and 75th percentile) and group 3 consisted of patients with high regeneration (regeneration 
index≥75th percentile). Changes in platelet count were analyzed in these three patient groups.
Statistical analysis.
Categorical variables were presented as numbers and percentages, continuous variables were 
presented as mean ± standard deviation (SD) or median and interquartile range (IQR). Continuous 
variables were analyzed with Student’s t-test (intergroup) or ANOVA (between-group) with 
Bonferroni post-hoc test in case of normal distribution. Mann-Whitney-U-test (intergroup) or 
Kruskal-Wallis test (between-group) were used for non-parametrically distributed variables. 
Categorical variables were compared by using Chi-square test or Fisher’s exact test, as appropriate. 
P-values <0.05 were considered statistically significant. All analyses were performed with the 
















































Ninety-one patients were included in this study. Demographic and surgical characteristics of 
these patients are presented in Table 1 and Table 2, respectively. Median intra-operative blood 
loss was 750 ml in the patient group with poor regeneration (IQR 375-1150), 600 ml in the 
patient group with intermediate regeneration (IQR 300-1050) and 400 ml in the patient group 
with high regeneration (IQR 250-825) (p=0.396). Intra-operative red blood cell transfusion was 
used in a total of 11 patients (12 %), of which 3 patients (15 %) with poor regeneration, 7 
patients (15 %) with intermediate regeneration and 1 patient (5 %) with high regeneration 
(p=0.684). There were no patients with intra-operative platelet transfusion. Postoperative red 
blood cell transfusion was used in a total of 2 patients, of which 1 patient with intermediate 
regeneration and 1 patient with high regeneration (p=0.713). A total of 44 patients (48 %) 
suffered from postoperative complications. Complications were seen in 11 patients (52 %) with 
poor regeneration, 24 patients (49 %) with intermediate regeneration and 9 patients (43 %) with 
high regeneration (p=0.886). Infectious complications occurred in 6 patients (29 %) with poor 
regeneration, 17 patients (35 %) with intermediate regeneration and 7 patients (33 %) with 
high regeneration (p=0.955). Bile leakage was seen in 3 patients (14 %) with poor regeneration, 
8 patients (16 %) with intermediate regeneration and 2 patients (10 %) with high regeneration 
(p=0.921). Liver failure occurred in 1 patient (5 %) with poor regeneration, 6 patients (12 %) 
with intermediate regeneration and no patient with high regeneration (p=0.258). Cardiovascular 
complications occurred in 1 patient (5 %) with poor regeneration and 1 patient (2 %) with 
intermediate regeneration. No patient with high regeneration suffered from cardiovascular 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Total serum bilirubin, prothrombin time, AST, ALT, haemoglobin and hematocrit not differ 
significantly between the groups before and after surgery (all p>0.05) (Figure 1).
The volume of the part to be resected, the future liver remnant and the liver volumes at one 
week and 6 months postoperatively did not differ significantly between the groups. Median 
regeneration index in the patient group with poor regeneration was 6.1 % (IQR 3.4-27), in the 
patient group with intermediate regeneration this was 25 % (IQR 12-51) and in the patient 
group with high regeneration, the median regeneration index was 57 % (IQR 35-90) (p<0.001).
Course of the postoperative platelet count.
Pre-operatively, there were no significant differences in platelet count among the regeneration 
index-based patient groups (p=0.504) (Table 1). Figure 2 shows the postoperative course of the 
platelet count as percentage of the pre-operative value. Platelet counts decreased postoperatively 
until day three postoperatively. Thereafter, platelet counts increased to above the pre-operative 
value and normalized at six months postoperatively. Platelet counts differed significantly between 
the groups at postoperative day 3 (p=0.049). On intergroup analysis, group 3 had significantly 
lower platelet counts at postoperative day 3 compared to group 1 (p=0.032) and group 2 (p=0.028). 
Immediately after surgery and on postoperative day 1 and 5, platelet counts were lower in group 
3 than in group 1, but these differences did not reach statistical significance (p=0.072, p=0.078 
and p=0.066, respectively). Figure 3 emphasizes the nadir of the platelet count at postoperative 















































Median peri-operative changes in levels of total bilirubin levels in μmol/L (panel A), prothrombin time in 
seconds (panel B), aspirate aminotransferase (AST, panel C) in U/L, alanine aminotransferase (ALT, panel 
D) in U/L, hemoglobin in mmol/L (panel E) and hematocrit in volume percentage (panel F). Patients were 
classified according to the regeneration index (group 1: poor regeneration index, continuous line, group 2: 
intermediate regeneration index, coarsely dotted line and group 3: high regeneration, finely dotted line). 
Pre-op: pre-operative platelet count, 0-7 immediate post-operatively-day 7 after surgery and at discharge 
is the platelet count at discharge. The smallest and largest observations are represented by the ends of 
the error bars (5th percentile and 95th percentile, respectively). Levels at day 0 were assessed immediately 
after surgery. The horizontal dotted lines represent the normal values for each parameter. There were no 
significant differences in pre-operative and postoperative serum levels of total bilirubin, prothrombin time, 


























































Postoperative course of the mean platelet count expressed as percentage of the pre-operative value. The 
smallest and largest observations are represented by the ends of the error bars (5th percentile and 95th 
percentile, respectively). Patients were classified according to the regeneration index (group 1: poor 
regeneration index, continuous line, group 2: intermediate regeneration index, coarsely dotted line and 
group 3: high regeneration, finely dotted line). Pre-op: pre-operative platelet count, 0-7 immediate post-
operatively-day 7 after surgery, at discharge is the platelet count at discharge and 6 months is 6 months 
postoperatively. A decrease was seen in all groups, but was most pronounced in the patient group with high 
regeneration. The decrease in platelet count was significant at postoperative day 3 (p=0.049) in all groups 
(marked with an asterisk). On intergroup analysis, group 3 had a greater decrease compared to group 1 and 















































Histogram of the mean platelet count (expressed as percentage of the pre-operative values) at postoperative 
day 3 in the three patient groups with poor, immediate and high regeneration. The smallest and largest 
observations are represented by the ends of the error bars (5th percentile and 95th percentile, respectively).
Discussion
The present study evaluated whether there is a relationship between the change in postoperative 
platelet count and liver regeneration in patients after partial hepatectomy (PH). We found an 
immediate decrease in platelet count after resection which continued until postoperative day 
3. From then on, platelet counts increased to above the pre-operative value and normalized six 
months postoperatively. Patients with high regeneration had a significantly larger decrease in 
their platelet count at postoperative day 3 compared to patients with poor and intermediate 
regeneration. This suggests that a larger decrease in postoperative platelet count is associated 
with better regeneration.
The liver responds to injury - for example PH - by regeneration of the lost volume. Liver 
regeneration is a complex process, which involves an orchestrated interplay of cytokines, growth 
factors and transcription factors. Liver regeneration starts within one day after resection in 
response to the loss of tissue[2]. Firstly, hepatocytes begin with replication. Thereafter other cell 

























































year after surgery when an appropriate amount of liver tissue is restored, approximating a normal 
liver/body mass ratio to enable proper organ function. There is a positive correlation between the 
amount of resected liver tissue and liver regeneration[4, 14, 15] Therefore, the magnitude of liver 
regeneration needs to be adjusted to the amount of resected liver[3]. 
Platelets have hemostatic, thrombotic, inflammatory and secretory functions, but their role in 
hepatic pathophysiology only gained interest in the past decade. Platelets contain numerous 
growth factors, such as serotonin, hepatocyte growth factor, platelet derived growth factor, 
vascular endothelial growth factor, epidermal growth factor, tissue growth factor and insulin-
like growth factor, which have been implicated in liver regeneration [5, 7, 8]. It has been shown 
in experimental models in rodents that platelets actively translocate into Disse’s spaces after 
partial hepatectomy. Platelets accumulate in the liver by migrating from sinusoidal spaces into 
Disse’s spaces through the fenestration of the sinusoidal cells[7]. Normally, flattened sinusoidal 
endothelial cells are fenestrated and the diameter of these pores is smaller than that of the 
platelets. The fenestrae become larger immediately after partial hepatectomy, allowing the active 
translocation of platelets into Disse’s spaces trough the fenestrae and thus direct contact between 
platelets and hepatocytes[7, 8]. In vitro, it has been demonstrated that this contact between 
hepatocytes and platelets is necessary for the release of the growth factors and cytokines from 
the platelets and their direct delivery to the hepatocytes to promote liver regeneration[7, 8, 16].
Thrombocytopenic rodents show an impaired regeneration response in experimental studies[17]. 
In contrast, thrombocytotic rodents show accelerated liver regeneration[18]. When platelets 
are massively recruited in the remnant liver, one expects a decrease in postoperative platelet 
count. Although never related to liver regeneration, a postoperative decrease in platelet count 
of 30-55% in human has been reported in the literature[6, 10, 11, 16]. The present study 
is the first in which the decrease in postoperative platelet count was shown to be related to 
the degree of liver regeneration. The results showed that patients with high regeneration had 
the largest decrease in postoperative platelet count. Therefore, these findings are in line with 
previous studies in experimental animal models which have shown that platelets have a pivotal 
role in liver regeneration by migrating into the remnant liver to exert their positive effects. 
Based on the literature discussed above, we thus hypothesize that the stimulating role of platelets 
in liver regeneration depends on intraparenchymal delivery of growth factors stored within 
platelet granules, although this mechanism has not yet been formally proven in vivo. Based on 
the findings described in the present study, we furthermore speculate that a greater reduction 
of platelet count is associated with an increased platelet influx into the remnant liver, with a 
consequently higher platelet-dependent proliferative response, but also this mechanism requires 
experimental verification. 
Platelet-derived serotonin is thought to be one of the candidate substances which are important 
in liver regeneration, since serotonin, or 5-hydroxytryptamine (5HT), is a potent mitogen which 














































serotonin transporters for internal storage[20]. About 95% of all serotonin found in blood is stored 
in platelets. In vivo, platelet-derived serotonin is responsible for postoperative liver regeneration 
by stimulating mitosis of hepatocytes via the 5-HT2A and 2B serotonin receptor subtypes which 
are present in hepatocytes [17]. Therefore, a close proximity between hepatocytes and platelets is 
likely needed[5]. Serotonin-antagonists or depletion both inhibit liver regeneration, suggesting 
that serotonin acts directly on the liver. However, more recently, the role of platelet-derived 
serotonin in liver regeneration has been challenged. Rodents deficient in the serotonin transporter 
SERT which have substantially decreased levels of serotonin in their platelets showed no 
difference in liver regeneration compared with controls, suggesting that serotonin is not relevant 
for liver regeneration [20]. Unfortunately, studies on the role of serotonin in liver regeneration are 
scarce and contradicting. Therefore, the precise mechanisms involved in platelet-mediated liver 
regeneration remain unknown.
It has been reported previously that a low post-operative platelet count measured just after the 
procedure was associated with delayed liver function recovery and with poor outcome after a liver 
resection[9]. These results are not necessarily in contrast with the results of the present study. The 
previous study suggested that a minimal platelet count is required for efficient platelet-mediated 
liver regeneration. In other words, in those patients with severe postoperative thrombocytopenia, 
there may be an insufficient translocation of platelets and platelet-associated growth factors into 
the liver remnant. In the present study, instead of examining the absolute platelet count, we 
have expressed the platelet count as percentage of preoperative platelet count, and found that a 
larger decrease in platelet count at day 3 was associated with a better outcome, which may be 
explained by a larger platelet influx with consequent release of platelet-derived growth factors in 
the liver remnant. This mechanism may be defective in those patients with a low platelet count 
immediately after surgery, but in the present study, none of the patients had an immediate post-
operative platelet count of <100.000/μl.
In conclusion, this study shows a decrease in platelet count during the first three days after partial 
hepatectomy, which resolves within one week after surgery. The decrease in platelet count is 
stronger in patients with a high regeneration index compared to patients with poor regeneration, 
suggesting that more platelets are consumed when there is a high regeneration index during the 
process of liver regeneration.
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An increasing number of patients undergo major liver resection following preoperative 
chemotherapy. Liver regeneration may be impaired in these patients, predisposing them to 
postoperative liver dysfunction. The aim of the present study was to evaluate the effects of 
preoperative chemotherapy on liver regeneration after partial liver resection.
Methods:
Patients planned for right hepatectomy either with (group B) or without (group A) prior 
chemotherapy were identified retrospectively from a prospective multi-institutional database 
created in the conduct of a national RCT investigating resection surface related complications. 
Prior chemotherapy was not an inclusion or exclusion criterion of the trial. Future remnant liver 
volume (FRLV) was calculated by measuring total functional liver volume (total liver volume – 
tumour volume) and resection specimen on preoperative CT-scans. Remnant liver volume after 7 
days (V
RLV7days
) was measured on scheduled postoperative CT scans. The early regeneration index 7 
days after surgery (RI
early
) was calculated as [(V
RLV7days
 - FRLV) / FRLV]* 100%. Data are expressed 
as median [interquartile range]. 
Results:
A total of 72 patients undergoing right hemihepatectomy were enrolled, 45 in group A and 27 
in group B. In the whole group the liver remnant showed a 58% [4-202] increase in volume of 
the FRLV at day 7 [2-13 days]. The RI
early
 was not significantly different between group A and B, 
60% [5-202%] and 50% [4-126%], respectively (p=0.47). However, patients who had received 
more than 6 cycles of chemotherapy had significantly less early liver regeneration than patients 
treated with 6 or less cycles of chemotherapy.
Conclusion:
Preoperative chemotherapy does not seem to have a negative impact on early liver regeneration 




























































Liver resection is the only potentially curative treatment for patients with colorectal rectal liver 
metastases (CRLM). Unfortunately, due to local irresectability, extra-hepatic disease and/or co-
morbidity only 15-20% of the patients with CRM are eligible for liver resection. In an attempt 
to increase resectability rates, a number of combined surgical and chemotherapy strategies are 
increasingly applied for patients with CRLM 1-3. Neo-adjuvant chemotherapy can change the 
surgical options and downstage patients who initially present with non-resectable disease 4. 
In patients with initially resectable disease secondary tumours can be downsized in order to 
achieve a radical margin with a smaller resection 5. The most commonly applied chemotherapy 
is oxaliplatin combined with capecitabine or folinic acid (leucovorin)/fluorouracil (5-FU) 6, 7. In 
some patients, targeted molecular therapy (bevacizumab or cetuximab) is added to this regimen 
to achieve higher clinical response rates 8, 9. 
Unfortunately, there is a clinical paradox, since preoperative chemotherapy may improve surgical 
options, but chemotherapy also has considerable hepatotoxic effects 10, 11. Oxaliplatin can cause 
vascular changes in the liver such as sinusoidal obstruction syndrome, which increases morbidity 
after liver resection 11, 12. 5-FU (insert ref Peppercorn Br J Cancer 1998;77:2008-11) and irinotecan 
(insert ref Parikh HH J Gastrointest Surg 2003; 7:1082-88) regimens can lead to steatosis of the 
liver and consequently increase the risk of impaired liver regeneration and postoperative liver 
failure. However, the exact effect of preoperative chemotherapy on liver regeneration after major 
liver resection in humans is unknown. The vast majority of liver regeneration occurs within 
the first week after major liver resections 13. The aim of the present study was to investigate 
whether preoperative chemotherapy impairs liver regeneration in patients undergoing major liver 
resection. To that purpose CT- based liver volumetry was used before and 7 days after straight 
forward anatomical right hemihepatectomy. 
Method
Patients
All patients undergoing anatomical right hemihepatectomy were identified retrospectively 
from the prospective database of the FRESCO-trial (title: “Efficacy of fibrin sealant in reducing 
resection surface related complications after partial liver resections”, registration number: 
ISRCTN85205641). The FRESCO-trial was a multi center randomized controlled trial on the 
efficacy of fibrin sealant in reducing resection surface-related complications after partial liver 
resections 14. In this trial, patients were intraoperatively randomized between application of fibrin 
sealant or no application of fibrin sealant. Primary endpoint of the study was the incidence of 
resection surface-related complications after partial liver resection. Part of the study was a CT 














































were eligible to participate in this trial irrespective of whether they had had preoperative 
chemotherapy, and this factor did not play a role in the randomization procedure. 
To investigate the effect of preoperative chemotherapy on liver regeneration in the present study, 
all patients who had undergone a right hepatectomy only, and had had pre- and postoperative 
scans as per protocol in the FRESCO-trial were divided into two groups: patients who were 
not treated with preoperative chemotherapy before undergoing liver resection (group A, no 
chemotherapy group) and patients who were treated with chemotherapy, either in an adjuvant 
or neoadjuvant setting, before undergoing liver resection (group B, chemotherapy group). The 
following information was recorded: type of chemotherapy regime, number of cycles and the date 
of last chemotherapy administration. The influence of chemotherapy-surgery interval and the 
number of chemotherapy cycles were analyzed in different subanalysis. 
Operative procedure. 
Liver resection was performed as detailed elsewhere 15. In short, laparotomy was performed 
by bilateral subcostal incision, followed by intraoperative ultrasonographic assessment of the 
liver. Once resectability had been confirmed, mobilization of the liver was performed to prepare 
for hepatic parenchymal transection. In all these right hepatectomies, transection followed 
Cantlie’s line from the top of the gallbladder, paralleling the middle hepatic vein straight to the 
suprahepatic inferior caval vein. In all patients the middle hepatic vein remained in situ with 
the liver remnant. There were subtle variations (e.g. type of incision) in the surgical procedures 
because these patients were operated by different surgeons in different centres, which is inevitable 
in a multicentre randomized controlled trial. 
CT imaging details. 
As part of the FRESCO-trial protocol, all patients had a contrast-enhanced triphasic CT-scan in 
their routine preoperative assessment and also a scheduled CT-scan 7 days after liver resection. 
All subjects were scanned in craniocaudal direction during inspiratory breath-hold. CT-images 
were acquired in a supine position. The CT-scanning protocol was predefined and agreed between 
centres in the context of the FRESCO-trial. 
Volume measurements. 
Two investigators (S.D.; P.K.) with considerable experience in abdominal CT-imaging volumetry 
performed all measurements. This was supervised by a specialist consultant abdominal radiologist 
(E.J.v.d.J.) and a hepatobiliary surgeon (M.d.B.). After transferring imaging data, volume 
measurements were performed on a Siemens Syngo workstation (version CT 2007A) with the 
“Volume calculation” application. Scans were retrieved from the individual patients in various 
centres, transferred and then all measured in the University Medical Centre of Groningen. 



























































venous phase. ROIs were drawn in every other slice to minimize partial volume effects. The 
volume programme automatically interpolated between two pending ROIs. Each interpolation 
was revised and corrected manually if necessary. After finishing the definition of each individual 
ROI, the evaluation procedure was started. Approximate volumes were calculated with automatic 
multiplication of the circumscribed areas by the CT slice thickness. The vena cava and the 
gallbladder were excluded from the ROIs. For definition of the anatomical segments Couinaud’s 
classification was used. 
On the preoperative scan, total liver volume (TLV), the volume of the resection specimen (V
resection
) 
and tumour volume (V
tumour
) were measured. V
resection
 was outlined according to Couinaud’s 
classification and on the basis of hepatic (vascular) anatomy. Remnant liver volume after 7 days 
(V
RLV7days
) was measured on the postoperative scan (figure 1). 
Calculations of volumes. 
Functional total liver volume (TLV
func
) was calculated as: TLV - V
tumour
. Future remnant liver 
volume (FRLV) was calculated as: TLV - V
resection. 
The early regeneration index 7 days after surgery 
(RI
early
) was calculated as: [(V
RLV7days
 - FRLV) / FRLV]* 100%. The functional resection percentage 
(Funct
Resection







Volumetric analysis Syngo®. 
For assessment of the accuracy of volumetric measurements of the liver with Syngo®, volumes of 
resection specimens were compared with actual weights of the resection specimens if these were 
available. The resection weights were measured in only two of the seven participating medical 
centres as this was not part of the FRESCO-trial protocol. This was done immediately after liver 
resection: weights of resection specimens were recorded in the operating theatre or at arrival on 
the pathology department. The actual weights of the resection specimens remained blinded to the 
investigators conducting CT-volumetry. 
Postoperative complications. 
Postoperative complications were registered according to the Clavien-Dindo score in the 
prospective database 16. 
Liver function and liver cell damage markers. 
Patients were admitted to the hospital one day preoperatively and routine blood tests were 
performed by the clinical chemistry department in the individual hospital. Routine blood tests 
for liver function and liver cell damage were performed on preoperative day 1, on postoperative 
day 0, 1, 3, 5, 7 and on the day of discharge. The levels of alanine-aminotransferase (ALT), 
aspartate-aminotransferase (AST), gamma-glutamyl transpeptidase (γGT), alkaline phosphatase 















































The study was approved by the medical ethical committee of the University Medical Center of 
Groningen and conducted according to the Declaration of Helsinki. All patients gave written 
informed consent. 
Statistics. 
All data are expressed as median (interquartile range). To compare different subgroups the 
nonparametric Mann-Whitney U-test was applied. Dichotomous data were compared using 
Fisher’s exact test. Multiple group comparisons for continuous data were done by Kruskal-Wallis 
test, with Dunn’s post hoc test. A p value <0.05 was considered to indicate statistical significance. 




Three hundred and ten patients were included in the FRESCO-trial of which 102 underwent 
a right hepatectomy. In 30 patients it was not possible to perform a complete CT-volumetric 
analysis (i.e. no adequate preoperative or postoperative CT-scan). This left 72 patients (35 male; 
37 female) undergoing right hepatectomy for benign (n=7) or malignant liver tumours (n=65) 
for the final analysis. Twenty seven out of 72 patients (37.5%) had been treated preoperatively 
with chemotherapy and 45 out of 72 patients (62.5%) did not receive preoperative chemotherapy 
(group A) (figure 1). 
There were no significant differences between groups in baseline characteristics (table 1). The 
vast majority of patients in group B (59.3%) received preoperative chemotherapy consisting of 
oxaliplatin, capecitabine and bevacizumab. The other patients in group B (40.7%) received a 
variety of other chemotherapy regimens (table 2). 18.5% of the patients in group B had adjuvant 
chemotherapy as part of treatment of the primary colorectal tumour and 81.5% of the patients 
in group B received neoadjuvant chemotherapy to treat the liver metastases. There was no 
significant difference in intraoperative blood loss between group A 750 mL [200-3,780 mL] and 
group B 800 mL [250-5,000 mL] (p=0.57). There was also no significant difference in operation 
































































Figure 1. Flowchart of the study. 
Table 1. Preoperative patient characteristics*
Group A  
No preoperative chemo 
Group B  
Preoperative chemo 
(n = 45) (n= 27) p-value
Age (years) 61 (33-78) 63 (40-79) 0.70
Sex 19 M, 26 F 16 M, 11 F 0.22
AST (IU/L) 28 (7-58) 26 (21-49) 0.60
ALT (IU/L) 26 (7-69) 28(13-71) 0.35
LDH (IU/L) 206 (142-519) 226 (154-663) 0.37
γGT (IU/L) 48 (10-431) 46 (17-204) 0.66
ALP (IU/L) 93 (42-323) 89 (57-365) 0.86
Bilirubin Total (μM) 9 (4-43) 12 (5-24) 0.22
C-Reactive Protein (mg/l) 4.4 (1.0-88.0) 4.0 (1.0-48.0) 0.57
Leucocytes (10Eg/L) 6.8 (4.0-11.0) 6.7 (3.0-10.0) 0.13
Albumin (g/L) 45 (16-97) 44 (38-46) 0.30
INR 1.0 (0.9-1.0) 1.0 (0.9-1.0) 0.80
PT (seconds) 10.6 (10.0-14.0) 10.7 (10.0 -13.0) 0.51
*) Data are presented as median (interquartile range)














































Table 2. Specification of the chemotherapeutic strategies 
Group B, n=27 Median (range) 
Number of cycles 6 (2-12)
Duration of chemotherapy 
(weeks)
15 (5-31)
Time between chemotherapy and surgery 
(months)
3 (1-24) 
Type of chemotherapy: Number (percentage of total) 
Oxaliplatin, Capecitabine, Bevacizumab 16 (59.3%)
Capecitabine 3 (11.1%)
Capecitabine, Bevacizumab 2 (7.4%)
5-FU, Leucovorin, Oxaliplatin, Bevacizumab 2 (7.4%)
5-FU, Leucovorin, Oxaliplatin 2 (7.4%)
5-FU, Leucovorin 1 (3.7%)
CT-measured liver volumes. 
The weight of the resection specimen as measured in 47 patients was 882 g [533-1760 g]. A strong 
significant correlation was found between the resection weight and resection volume measured 





 were 1591 mL [958-3002 mL]; 995 mL [541-1890 mL] and 
34 mL [1-1468 mL], respectively. The TLV
func
 and FRLV were 1527 mL [906-2378 mL] and 594 
mL [321-1470 mL],respectively. V
tumour
 was significantly larger in group A compared to group B: 
38 mL [1-1467 mL] vs. 19 mL [1-93 mL] (p<0.05) (table 3). 
 
















































































Table 3. CT-volumetry of livers and tumours*
N= 72 Group A  
No preoperative chemo  
(n=45)




TLV (mL) 1595 (1145-3002) 1550 (958-2266) 0.36
TLV
Func
1513 (968-2378) 1570 (906-2177) 0.57
V
tumour
 (mL) 38 (1-1467) 19 (1-93) 0.04
V
resection
 (mL) 1000 (682-1890) 967 (541-1473) 0.36
Funct
Resection
% 59 (23-80) 63 (42-77) 0.10
FRLV (mL) 613 (378-1470) 565 (321-975) 0.25
V
RLV7days
 (mL) 951 (574-1721) 895 (460-1281) 0.15
RI
early 
(%) 60 (5-202) 50 (4-126) 0.47
 
Data are presented as median (interquartile range)
Early liver regeneration. 
The RI
early 
at day 7 in the whole group of 72 patients was 58% [4-202%]. The RI
early
 was not 
significantly different between group A and B, (60 [5-202%] and 50 [4-126%] respectively; 
p=0.47) (table 3, figure 4A). In group B the time interval between chemotherapy and the 
liver resection was 3 months [1-24 months] (table 2). There was no significant difference in 
liver regeneration between patients who underwent liver resection within 3 months after 
chemotherapy (n=11) and patients who underwent liver resection after 3 or more months (n=16), 
61 [4-84%] and 49 [10-126%] respectively; p=0.57). There was also no significant difference 
in liver regeneration between patients who underwent liver resection within 3 months after 
chemotherapy (n=11) and patients who did not receive chemotherapy (n=45), 61 [4-84%] and 
60 [5-202%] respectively; p=0.x). 
It can be argued that if the time interval between the last cycle of preoperative chemotherapy 
and liver surgery is more than 6 months the chance is small that chemotherapy has still an effect 
on liver regeneration. To analyse this, a subanalysis was performed in which patients with a 
chemotherpay-surgery interval of more than six months (n=5) were included in the group of 
patients who did not receive chemotherapy (n=45) and this group was then compared to the 
group of patients who received surgery within 6 months after chemotherapy (n=22). Again there 
was no significant difference in liver regeneration between these two groups: 51 [4-126%] and 
59 [4-201%] respectively; p=0.71). 
The RI
early
 was significantly lower in patients who had had more than 6 cycles of chemotherapy 
(n=5) compared to patients who were treated with 6 or less cycles of chemotherapy (n=22) 
(37 [10-40%] and 62 [4-126%] respectively; p<0.05) (figure 4B). The time interval between 
chemotherapy and liver resection was not significantly different between patients who had 
received more than 6 cycles of chemotherapy compared to patients who were treated with 6 or 


















































Figure 3. An outline of the remnant liver volume after 7 days (V
RLV7days
) measured on the postoperative scan. 































































Figure 4. A RI
early
, as a marker of early regeneration in patients without preoperative chemotherapy (group 
































































Figure 4. B RI
early
, as a marker of early regeneration in patients who were treated with more than 6 cycles of 



























































Some patients did not have a postoperative CT-scan at day 7, but at an earlier or later time point. 
This deviation from the original protocol was usually related to early functional recovery of the 
patient and early discharge from the hospital. There was no significant difference between groups 
in the number of days between the operation and the first postoperative CT-scan (group A: 7 [2-
13 days] vs. group B: 7 [3-13 days], p=0.24). However, in order to exclude a potential difference 
in liver regeneration due to difference in time (surgery/CT-scan interval), the RI
early
 was also 
calculated and compared in patients who had a CT-scan exactly on postoperative day 7. In group 
A 26 patients and in group B 15 patients had a CT-scan exactly on postoperative day 7. In this 
sub-analysis the RI
early
 was also not significantly different between group A and B, (58 [4-202%] 
and 73 [22-126%] respectively; p=0.84). 
As mentioned RI
early
 in patients who had more than 6 cycles of chemotherapy was significantly 
lower compared with patients receiving 6 or less cycles and this remained different when only 
patients who had a CT-scan strictly on postoperative day 7 were analyzed, (37 [28-38%] and 78 
[22-126%] respectively; p<0.05). 
In order to investigate the potential negative impact of bevacizumab on liver regeneration, the 
RI
early
 in patients treated with preoperative bevacizumab was compared with patients who had 
not received bevacizumab. The RI
early
 was not significantly different between patients (n=20) 
that had received bevacizumab and patients (n=7) who had not (56 [4-126%] and 38 [9-85%] 
respectively; p=0.18).
Postoperative complications. 
There was no significant difference between groups in postoperative complications, length of 
hospital stay or 30-day mortality (table 4). 
Liver function and liver cell damage markers. In both groups ALT, AST, LDH, bilirubine 
and PT levels were postoperatively significantly increased compared to baseline (p<0.05). At the 
day of discharge ALT, AST, LDH, bilirubin and PT levels were normalized and comparable to 
baseline levels in both groups. Levels of γGT were significantly increased at postoperative day 7 
and on the day of discharge compared to baseline. There was also a significant increase of ALP on 
the day of discharge compared to baseline in both groups (figure 5 A-G). 
There were no significant differences in liver function and liver cell damage markers on the day 
before surgery between groups. Postoperatively, there were also no significant differences in liver 














































Table 4: Postoperative complications
Group A  
N=45 
No preoperative chemo





Total 17 9 0.80
Grade I 7 1 0.24
Grade II 10 8 0.58
Major Complications#
Total 10 7 0.78
Grade III a-b 7 3 0.73
Grade IV a-b 2 1 1.0
Grade V 1 3 0.15
Total 27 16 1.0
30-day mortality 1 (2.2%) 3 (6.7%) 0.11
Length of hospital stay 11 (4-83) 10 (5-55) 0.33
Length of intensive care stay 1 (0-51) 1 (0-21) 0.07















































































































































































































































































































































































Figure 5.A-D Postoperative plasma levels of ALAT, ASAT, γGT and ALP as markers of liver cell damage. 
Group A #p<0.05 compared to preoperative baseline level; group B *p<0.05 compared to preoperative 





































































































































































































































































































































Figure 6.A-C Postoperative plasma levels of PT and bilirubin, and LDH as markers of liver function and 
liver cell damage, respectively. Group A # p<0.05 compared to preoperative baseline level; group B *p<0.05 
compared to preoperative baseline level. No significant differences between groups. Data are medians and 
interquartile ranges.
Discussion 
This study aimed to investigate whether preoperative chemotherapy impairs liver regeneration 
in patients undergoing major liver resection. To that purpose CT-based liver volumetry was used 
before, and 7 days after right anatomical hepatectomy. This study indicates that chemotherapy 
prior to major liver resection has no negative impact on early liver regeneration. However, 
patients who had received more than 6 cycles of chemotherapy had significantly less early liver 
regeneration than patients treated with 6 or less cycles of chemotherapy. 
There are only few studies that have focused on early liver regeneration. Most of these studies 
measure the early liver regeneration index in living donor for liver transplantation and the results 
in these studies vary, presenting different regeneration indices after one week 13, 17, 18. The data 
of the present study showed that approximately 58% of liver regeneration takes place in the 
first week after resection of the right lobe. These results are in accordance with results from 














































right hepatectomy. Although several studies warn for the hepatotoxic effects of preoperative 
chemotherapy on liver regeneration in liver resection patients 10-12, 19, data on the exact effect of 
preoperative chemotherapy on liver regeneration in humans are scarce. To our knowledge the 
present study is the first study that analyses the effect of preoperative chemotherapy on liver 
regeneration in a large group of patients after major liver resection. All patients underwent 
an anatomical right hemihepatectomy and there were no major differences in mobilization 
and transection of the liver. Therefore these patients were comparable and the protocol of this 
randomized controlled trial provided the opportunity to investigate early liver regeneration 
in an adequate and valid human study model. Since there is no reliable marker to assess liver 
regeneration in humans, CT- volumetry is an attractive approach. The CT-volumetric method 
with Syngo®, a professional radiological software program used in the present study, was shown 
to be valid and reliable as evidenced by the excellent correlation between resected weight and 
volume. This method was comparable with other recently validated CT-volumetry methods 20, 21.
The type of chemotherapy and also the number of cycles of chemotherapy that are given to 
patients often varies. One would expect that patients have worse liver regeneration with an 
increasing number of cycles of chemotherapy because their liver is longer exposed to hepatotoxic 
compounds. This hypothesis was confirmed in the present study as a smaller RI
early 
was measured 
in patients who were treated with more than 6 cycles of chemotherapy compared with those 
who were treated with 6 or less cycles. Impaired early liver regeneration in these patients is 
probably also associated with an increased risk of complications after liver resection. In line with 
this Karoui et al. found that preoperative chemotherapy was an independent predictive factor of 
postoperative morbidity after liver surgery especially when an increasing number of cycles was 
given to patients 22. In order to reduce the risk of impaired liver regeneration and postoperative 
morbidity in patients who need preoperative chemotherapy, it would be better to minimize 
the number of cycles of chemotherapy if possible instead of completing the chemotherapeutic 
regimen. These data also provide evidence that treating patients with initially resectable disease 
with more than 6 cycles of chemotherapy is not advisable due to the increased risk of impaired 
early liver regeneration. 
Contradictive results have been reported by several researchers regarding the potentially negative 
impact of bevacizumab on liver regeneration. Aussilhou et al. 23 have shown that bevacizumab 
impairs liver regeneration after preoperative portal vein embolization. On the other hand 
Gruenberger et al. 24 showed that neoadjuvant bevacizumab does not affect liver regeneration 
3 months after resection. The same group of authors also showed in another study that when 
bevacizumab is combined with oxaliplatin, bevacizumab protects the liver against sinusoidal 
obstruction syndrome 25. Data of the present study showed that the preoperative administration 
of bevacizumab did not impair early liver regeneration after major liver resection. 
The present study has some limitations. It was assumed that percentage early liver volume 



























































part of the liver volume increase may be caused by edema or hepatic swelling due to high portal 
pressure induced by the concentrated flow of the entire stream of portal blood toward the small 
remnant liver 26. There were no significant differences between group A and B in traditional liver 
function and liver cell damage markers preoperatively and postoperatively in the first week. Yet, 
it has to be taken into account that these are relatively crude markers 27. In this context, it is 
worthwhile mentioning some recent reports using a combination of CT volumetric analysis and 
the LIMAx-function test 28, 29. Investigating recovery of liver function with LIMAx-test in the 
first week after liver resection in patients with or without preoperative chemotherapy in future 
studies may be an interesting future topic. 
In conclusion, this study shows that preoperative chemotherapy does not seem to have a negative 
impact on early liver regeneration after partial liver resection. However there was a significantly 
lower regeneration capacity in patients who were treated with more than 6 cycles of chemotherapy. 
This study shows that strategies combining preoperative chemotherapy with liver surgery are 
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Part one: Thermal ablation.
Although liver surgery is considered the gold standard in the treatment of malignant liver tumors, 
minimally invasive therapies have gained interest in the past decades. Local thermal ablative 
therapies offer an attractive treatment in patients who are not suitable for surgical resection. The 
main goal of these locally directed therapies is to achieve a survival rate similar to that of partial 
hepatectomy1-4. However, this is an issue which is still debated. Additionally, locally directed 
therapies are accompanied with less post-treatment morbidity. Thus, these offer great advantages 
over surgical resection.
The main problem with thermal ablation is the unacceptably high incidence of ablation site 
recurrence, which is the result of incomplete ablation. In the literature, ablation site recurrence rates 
vary widely, depending on the patient population and the definition of ablation site recurrences2, 
3, 5-8. Chapter 2 and 3 describe a series of patients who underwent radiofrequency ablation for 
colorectal liver metastases. The ablation site recurrence rates in both series approximate 20 % and 
are at the lower limit of what is reported in the literature. In line with previous studies, we found 
that the approach of the procedure – percutaneous versus open - and tumor size – tumors larger 
than 3 cm in diameter - are main risk factors associated with a higher ablation site recurrence 
rate. Interestingly, the ablation margin was not a risk factor for ablation site recurrence. However, 
it should be noted that ablation site recurrences did not occur with the ablation margins greater 
than 1 cm. This could point towards the importance of the size of the ablation margins.
In Chapter 2, the concept of a “Similarity Positioning Score” is introduced. This two-point 
scale, obtained by visual assessment, describes the comparability of the pre-operative scan and 
the first post-operative scan, which is the baseline control scan used in the further follow-up. 
Well-comparable scans were assigned the score “SiPS-identical”, whereas incomparable scan were 
classified as “SiPS-different”. When measuring ablation margins by comparing pre-treatment and 
post-treatment scans, it can be noticed sometimes that the liver (and other abdominal organs) 
has totally different positions on both scans. These are the SiPS-different scans. The dimensions 
of the tumor and the ablation zone may differ, so that measurements on such incomparable scans 
become highly unreliable. The distance in a certain direction from the border of the ablation 
zone to the border of the liver may be larger than the distance from the border of the tumor to 
the border of the liver. These “negative” margins are often encountered on SiPS-different scans, 
thereby hampering the radiologist to give a well-founded judgment on the success of the ablative 
procedure. The results in chapter two show that SiPS is an important risk factor for ablation site 
recurrences, not because incomparable scans are directly related to ablation site recurrences, but 
because of the lack of a reliable statement on the success of the ablative procedure. Unfortunately, 
it is impossible to obtain two exactly similar images even within one multiphase scan series, let 
alone after manipulation in the abdomen, as is the case after thermal ablation. Additionally, the 



























































contribute to these position differences. Motion tracking systems and mathematical models which 
correct for organ position differences may reduce the incomparability of two scans. However, they 
are not widely used in general radiology and until then, these patients should be followed up 
thoroughly.
Follow-up after thermal ablation is performed with clinical, biochemical and imaging procedures 
at regular intervals. Imaging consists of multiphase CT-scanning in order to detect ablation site 
recurrences as soon as possible. The interval at which imaging is performed, varies between centers. 
In the University Medical Center Groningen (UMCG), patients undergo CT-scanning every three 
months in the first two years after the procedure and thereafter biannually. Unfortunately, it may 
be very difficult to detect ablation site recurrences, especially in early phases when the ablation 
site recurrence is very small and eventual post-procedural inflammatory changes are present, 
which may be confused with ablation site recurrences9. Additionally, when subsequent scans 
are incomparable – SiPS may also apply to subsequent follow-up scans – it might be extremely 
difficult to compare these scans section-by-section. PET-CT is regarded the best follow-up 
modality in the detection of ablation site recurrences, but is not used routinely because of its 
drawbacks – mainly its costs1011, 12. A more simple method to detect early changes in the size of 
an ablation zone is by measuring its volumes on successive scans and compare the results of these 
measurements. The use of volumetry in the follow-up after radiofrequency ablation is studied 
in Chapter 3. Volumetry showed to be a valuable tool in the follow-up of after radiofrequency 
ablation with a detection rate of ablation site recurrences of 96 %. For comparison, conventional 
two-dimensional evaluation with CT showed a detection rate of 63 % and ablation site recurrence 
was doubted in 11 %. Thus, the detection rate of ablation site recurrences with conventional CT 
is at best 74 %. Volumetry provides highly detailed three-dimensional information on ablation 
zones, whereas all other imaging modalities, including PET-CT, only reveal two dimensional 
information. Additionally, it is not hindered by organ position differences. However, volumetry 
has two main drawbacks. Firstly, volumetry can be disturbed by artifacts, for example produced 
by the presence of coils after portal vein embolisation. This was the case in the only one ablation 
zone with ablation site recurrence which was not detected with volumetry in chapter 3. 
Therefore, volumetry should be used with caution in patients who underwent possible artifact-
causing procedures. Secondly, it is relatively time-consuming to perform. However, since ablation 
zones are relatively small, it is recommended to perform volume measurements in addition to 
conventional evaluation methods, since the earlier ablation site recurrences are detected, the 
sooner patients can be offered a secondary treatment.
As shown in Chapter 2 and 3, imaging is the cornerstone in the follow-up after thermal ablation. 
After thermal ablation, imaging is performed at regular intervals. A well-documented post-
procedural baseline scan is the starting point in the follow-up of patients who underwent thermal 



























































vigorously on this scan. It is not well known what the ideal time point is to perform the baseline 
scan. Centers have their own protocol on when to perform the first scan after ablation13. The 
timing of this baseline scan varies from immediately at the end of the procedure to up to a month 
post-procedurally13. In the UMCG, patients are scheduled for the baseline scan one week after 
thermal ablation. When thermal ablation is performed with laparotomy, ultrasound is performed 
after the procedure to assess the completeness of the ablational procedure. In case of percutaneous 
CT-guided ablation, a non-contrast enhanced CT-scan is performed immediately after the 
thermal ablative procedure for a rough first evaluation of the ablation. Extensive evaluation is 
only performed on the protocol scan one week post-procedurally. In our own experience, the 
success of radiofrequency ablation can be reasonably estimated on immediate post-procedural 
non-contrast enhanced scans. With the introduction of microwave ablation, the same assumption 
was made: immediate post-procedural non-contrast enhanced scans should also be suitable for 
gross evaluation of the completeness of the microwave ablative procedure. Unfortunately, it 
became clear that ablation zones created by MWA were more difficult to visualize than ablation 
zones created by RFA on immediate post-procedural non-contrast enhanced scans. This resulted 
in a higher incidence of incomplete ablations than we were used to with RFA. These incomplete 
ablations became only visible on the baseline scan performed one week post-procedurally. 
Therefore, the question rose whether an immediate post-procedural contrast enhanced scan is of 
additional value in the initial evaluation of the success of a microwave ablation procedure. The 
results are discussed in Chapter 4. Ablation zones were evaluated quantitatively. Quantitative 
assessment included measurements of ablation margins, volumes and Hounsfield units on 
the immediate post-procedural scan. The same was performed on the protocol scan one week 
post-procedurally. Quantitative assessments of both scans were then compared to see whether 
significant changes occur in the first post-procedural week. The protocol CT-scan performed 
one week post-procedurally was used as gold standard. Thus, the evaluation could only be 
performed retrospectively, since the protocol CT-scan one week post-procedurally had to become 
available. The results in Chapter 4 show that immediate postprocedurally performed quantitative 
measurements were highly unreliable because ablation zones increased in volume in the first 
week after the MWA-procedure. Ablation margins, volumes and diameters of the ablation zone 
changed significantly within this period. Therefore, quantitative assessment should not be 
performed immediately after thermal ablation. Thus, the baseline scan performed one week post-
procedurally is indispensable for the quantitative baseline control values, which should be used 
in the further follow-up. We recommend this time point of measurement, since the volumes of 
ablation zones are not stationary in time14. Ablation zones show an increase in volumes in the first 
post-procedural week to a maximum size and after three months, a decrease in volume is seen. 
Although the results in Chapter 4 are observations from microwave ablation procedures, there are 
no reasons to assume that there are differences for radiofrequency ablation, since tissue damage is 



























































In conclusion, imaging after thermal ablation is highly important for the post-procedural follow-
up. Incomparability between the pre-operative and baseline control scan hinders evaluation of the 
success of thermal ablative procedures, since ablation margins cannot be reliably assessed. Volume 
measurements should be performed at any time point in the follow-up, since subtle changes can 
be detected with volumetry which otherwise remain undetectable with the naked eye. After 
thermal ablation, quantitative assessment should only be done on scans performed one week 
post-procedurally, since shape and size of ablation zones change significantly within this period.
Part two: Liver regeneration.
Partial hepatectomy is increasingly performed in patients with liver tumors. With the availability 
of improved imaging techniques, it is now possible to carefully select patients with tumors 
restricted to the liver or with limited extrahepatic disease. Pre-operative chemotherapy may lead 
to downstaging of the tumor load in patients who would otherwise be unsuitable candidates 
for surgical resection, but is associated with hepatotoxicity15, 16. Improved intra-operative and 
postoperative management has improved the safety of hepatic surgery. These factors together 
have lead to expansion of the indications of partial hepatectomy. The main limitation of partial 
hepatectomy is that there needs to remain a sufficient amount of functional liver, since extensive 
resection may lead to liver failure and death within a few days after surgery. Several strategies 
which may increase liver volume and function of the future liver remnant before resection are 
developed with the intention to make hepatic surgery safer. The most commonly used technique 
is portal vein embolisation. There are several experimental pharmacologic approaches, of which 
the effectiveness has to be established yet15.
After partial hepatectomy, the liver regenerates in response to lost tissue. There are several studies 
on liver regeneration, but most have been conducted in living donors17, 181920, 2122, 23. Patients were 
selected based on the type of partial hepatectomy, instead of the amount of resected volume. Since 
there is a considerable interpatient variability in the size of the various segments, the amount 
of resected volume may differ between patients with the same type of partial hepatectomy24. 
Additionally, the regenerated volume is thought to be related to the amount of resected volume20, 
21, 25. Therefore, liver regeneration should be measured against the amount of liver tissue resected. 
This is studied in Chapter 5. The patients enrolled in the study on liver regeneration were patients 
included in the FRESCO-trial, a study on the benefits of fibrin sealant on the resection surface. 
A pre-operative CT-scan was available and all patients all underwent a protocol CT-scan exactly 
7 days after partial hepatectomy. The pre-operative total liver volume, the volume of the part to 
be resected and eventual tumor volumes were measured on the pre-operative CT-scan. With these 
data, the volume of the future liver remnant could be estimated. Tumor volumes were subtracted 
from the total pre-operative liver volume and the volume of the part to be resected, since the 



























































in 5 groups, based on the extent of the resection. Volumes of the liver remnant were measured 
on two time points: (1) exactly one week after partial hepatectomy and (2) 6 months after partial 
hepatectomy if there was a CT-scan available at this time point. Liver regeneration was expressed 
in two “regeneration indices”, namely an early regeneration index (one week postoperatively) and 
a total regeneration index (6 months postoperatively). These regeneration indices were calculated 
as the increase in liver volume, with respect to the volume of the future liver remnant as measured 
on the pre-operative scan. The results in Chapter 5 show that regeneration indices become higher 
as resections become larger. Interestingly, the early regeneration index shows a plateau in patients 
with a resection of 40 % or more of their total pre-operative liver volume. An explanation for this 
finding may be that the process of liver regeneration is of secondary importance to the metabolic 
demands of the patient. Patients with a resection of 40 % or more have a relatively small liver 
remnant. There remain less hepatocytes to preserve appropriate liver function. Cells which are 
actively replicating – undergoing mitosis – do not take part in hepatic metabolism. Vice versa, cells 
fulfilling metabolic and detoxifying functions cannot enter the mitotic phase. Thus, metabolic 
functions prevail over the process of liver regeneration until there are enough hepatocytes to carry 
out both functions properly and regeneration is delayed after larger resections. This hypothesis is 
supported by the total regeneration index. The finding that the total regeneration index increases 
steadily with larger resections points towards a catch-up growth in patients with major partial 
hepatectomies. Although liver regeneration seems to be highly efficient, the majority of patients 
did not reach their total pre-operative liver volume. This was especially the case in patients with 
large resections. It might be that the time point of six months post-surgically was chosen too 
soon and that volume increase continues beyond this time point. Since it is not known when liver 
regeneration is finished, it seems a topic worthy of future investigation to assess whether liver 
volume increases beyond the time point of six months after partial hepatectomy.
It is well known that liver regeneration depends on various factors. Age, sex and the presence of 
underlying parenchymal disease affect the process of liver regeneration. Cirrhosis is a well-known 
parenchymal disease which is a risk factor for impaired regeneration. A more common parenchymal 
condition is steatosis. The incidence of hepatic steatosis is thought to be increasing due to the 
current obesity epidemic. Hepatic steatosis is not as innocent as was previously assumed. It can 
lead to non-alcoholic steatohepatitis, cirrhosis and the development of hepatocellular carcinoma. 
Additionally, some studies have found increased post-operative complications in patients with 
steatosis2627-29. Most studies on liver regeneration are performed in animal models30, 31. Studies 
on the impact of steatosis on liver regeneration in humans are scarce and most studies concerned 
on living donors19, 20, 28, 32, 33. Most studies have suggested that regeneration is not impaired by 
the presence of steatosis. The main problem with these studies is that they were conducted in 
living donors. Clinically significant steatosis is generally a contraindication for living donation, 
in contrast to partial hepatectomy for liver tumors. Therefore, we aimed to determinate whether 



























































hepatectomy. The results are discussed in Chapter 6. The same patient data were used as in 
chapter 5, but now with the exclusion of the living donors. Patients were classified in 3 groups 
according to the degree of steatosis and regeneration indices were compared between the groups. 
There were no differences in the amount of resected volume and other factors that might have 
influence on liver regeneration between the patient groups. Of note, no patient with clinically 
significant steatosis had received chemotherapy prior to partial hepatectomy. This is an important 
issue, since chemotherapy is a well known risk factor for induction of hepatic steatosis34. The only 
significant difference was the BMI, which is known to be related to hepatic steatosis. The results 
in Chapter six show that although the early regeneration index is not significantly affected by 
hepatic steatosis, the total regeneration index was significantly lower in the presence of steatosis. 
This was most pronounced in patients with clinically significant steatosis. Animal models show 
that steatosis is associated with an excessive pro-inflammatory cytokine response and insufficient 
antioxidant response, which predispose hepatocytes to extensive necrosis. This leads to increased 
hepatocellular damage, which affects the regenerative capacity of steatotic livers after partial 
hepatectomy30, 31. It is assumable that this also applies to human livers. The study in Chapter 6 is 
the first which reports on liver regeneration and hepatic steatosis in patients with elective partial 
hepatectomy. Since steatosis was associated with a lower regeneration response, extensive liver 
resections should be performed with caution in patients with hepatic steatosis.
Following partial hepatectomy, liver regeneration is initiated by a complex series of growth factors 
and cytokines. Platelets have gained interest in their role in liver regeneration because they contain 
multiple growth factors35-37. Experimental models have shown that thrombocytopenia result in 
decreased proliferative activity in the liver35, 38, 39. Thrombocytosis is associated with accelerated 
liver regeneration. In humans, it has been showed that a low post-operative platelet count was an 
independent predictor for delayed recovery of liver function40. In Chapter 7, the decrease in post-
operative platelet counts was studied in association with the regeneration response. The same 
patient data was used as in Chapter 5. Firstly, patients were classified in five groups, according 
to the extent of the resection (see Chapter 5). Within each patient group, patients were assigned 
as having a poor, intermediate or high regeneration response. Thereafter, all patients were joined 
into three patient groups, according to their regeneration response: poor, intermediate or high. 
Platelet counts were assessed pre-operatively, upon arrival at the intensive care unit and then 
daily until discharge. The decrease in postoperative platelet count, expressed as percentage of 
the pre-operative platelet count, was compared in these three groups. In all groups, platelet 
count decreased in the first three postoperative days, but the decrease was most pronounced in 
the patient group with high regeneration. The question rises whether this finding means that 
platelets have a role in liver regeneration. It has been reported that there is a decrease in platelet 
count after partial hepatectomy39, 41-43. However, this has never been linked to liver regeneration. 



























































exert their regeneration-potentiating effect directly at the site they are needed. Large resection 
surfaces could theoretically lead to entrapment of more platelets than small resection surfaces. 
However, the results in Chapter 7 are corrected for this bias, because patients were classified in 
having poor, intermediate or high regeneration responses according to the amount of resected 
volume. A larger decrease in postoperative platelet counts in patients with a high regeneration 
response suggests a link between platelets and liver regeneration. The mechanism beyond this 
finding has to be clarified in future research.
Partial hepatectomy is nowadays mostly performed in patients with primary and secondary 
malignant liver tumours. Although only a minority of patients are candidates for surgery, criteria 
for respectability are changing, partly due to innovations of cytotoxic agents and improvements 
of chemotherapeutic regimens. A major side effect of chemotherapy is hepatotoxicity, resulting 
in increased postoperative morbidity and mortality15, 16. Injuries to the liver parenchyma induced 
by pre-operatively administered chemotherapy could theoretically have a negative effect on 
postoperative liver regeneration. However, the effect of pre-operative chemotherapy on liver 
regeneration has not been studied well in human. Chapter 8 studies the impact of pre-operative 
chemotherapy on early liver regeneration. Patients enrolled in the FRESCO-trial who underwent 
right hemihepatectomy were included. Volumetry and calculation of the early regeneration index 
were performed as described in Chapter 5. There was no difference between the regeneration 
index in patients with or without pre-operative chemotherapy. However, patients who received 
more than 6 cycles of chemotherapy had significantly smaller early regeneration indices than 
patients who received less than 6 cycles of chemotherapy. It has been reported that an increasing 
number of pre-operative chemotherapy increases the risk of postoperative morbidity and 
mortality44. Together with the results of Chapter 8, it is advisable to minimize the number of 
chemotherapeutic cycles prior to surgery to lower the risk of increased postoperative morbidity, 
mortality and impaired liver regeneration. This especially applies to patients undergoing large 
resections.
In conclusion, liver regeneration highly depends on the amount of resected liver volume. The 
early regeneration index increases as resections become larger. The early regeneration index – one 
week after partial hepatectomy – plateaus in patients with a resection of 40 % or more of their 
pre-operative total liver volume. However, the total liver regeneration index – 6 months after 
partial hepatectomy – shows a steady increase in regeneration indices with larger resections. 
This indicates that patients with larger resections show a catch-up growth after an initial delay 
in liver regeneration. Liver regeneration is affected by hepatic steatosis and large resections 
should be performed with caution in patients with this condition. The role of platelets in liver 
regeneration in humans has to be elucidated, but patients with a high regeneration response show 
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The aim of this thesis is twofold. Part one concerns on imaging after thermal ablation. Part two 
discusses liver regeneration after liver surgery.
General introduction.
Among all organs, the liver is a unique because of its ability to regenerate after injury, for example 
partial hepatectomy. This regenerative capacity was already recognized in ancient history and has 
been mentioned in Greek mythology. Liver surgery has traditionally been performed in battle 
field injuries. Because the liver is a highly perfunded organ, massive hemorrhage is the major risk 
in liver surgery. Therefore, patients often did not survive liver surgery. The first well-documented 
partial hepatectomy dates from 1887. Thereafter, larger studies followed soon. However, liver 
surgery remained risky with a high mortality. This changed with improvement of surgical 
techniques and postoperative care. A major breakthrough was the anatomical segmentation of 
the liver by the French surgeon Couinaud in 1957. He devided the liver into eight segments, 
each with a seperate blood and biliary supply. When these anatomical distributions are taken into 
account during partial hepatectomy, blood loss and bile leakage could be reduced significantly 
in liver surgery. Liver surgery is nowadays mostly performed in patients with malignant liver 
tumors and is regarded as the therapy of first choice. Benign liver tumors are less often treated 
surgically. Most malignant liver tumors are metastases from a primary tumor elsewhere in the 
body. Colorectal cancer is one of the most common types of cancer and metastasizes often to the 
liver. Unfortunately, the majority of patients (80-90 %) with colorectal liver metastases are no 
candidates for surgical treatment because of the extent of the disease. For these patients, other 
treatment options need to be sought. The aim of these secondary treatments is to destroy the 
tumors, but to spare liver tissue. Thermal ablation is one of the most widely used forms of this type 
of secondary therapies. A needle - the electrode – is inserted in the tumor under image guidance. 
Subsequently, the electrode is heated, for example by radiofrequency waves as in radiofrequency 
ablation or electromagnetic waves as in microwave ablation. Tissue in the vicinity of the electrode 
is destroyed by this heating. Radiofrequency ablation and more recently microwave ablation are 
the most common forms of thermal ablation. Thermal ablation can be performed by opening the 
abdomen (laparotomy), by keyhole surgery (laparoscopy) or through the skin (percutaneous). In 
thermal ablation by laparoscopy and laparotomy, localization of the tumor and placement of the 
electrodes is performed by using ultrasound. For percutaneous thermal ablation, ultrasound can 
be used, but the needles are usually placed under computed tomography guidance (CT). Imaging 
is also essential to monitor the progress of treatment. Additionally, imaging is used at the end 
of treatment to check whether the ablation zone overlaps the tumor. The major advantage of 
thermal ablation is that it is associated with less postoperative morbidity than liver surgery. The 
major drawback of thermal ablation is that the cure rate is significantly lower than after liver 














































are the feared ablation site recurrences. The incidence of ablation site recurrences varies widely 
in the literature from 2 % to 55 %. It is important that ablation site recurrences are detected at 
an early stage, because the sooner they are discovered, the better the chances are for successful 
additional treatment. After thermal ablation, patients will undergo intensive follow-up. This is 
performed by regular physical, biochemical and imaging studies. Imaging is mostly performed 
with multi-phase CT examination. This means that firstly a scan without contrast is obtained: the 
non-contrast scan. Thereafter, contrast is administered intravenously to the patient and scanning 
is performed on three time points after contrast administration, namely the arterial phase, the 
portal venous phase and the late phase. In some centers, magnetic resonance imaging (MRI) or 
positron emission tomography (PET), with or without with CT is performed.
Part 1: Imaging after thermal ablation.
 
In contrast to liver surgery, after thermal ablation no tissue is obtained for pathological-
anatomical examination. After partial hepatectomy, the pathologist investigates whether the 
resection margins are tumor-free. This is not possible after thermal ablation, since no tissue is 
removed. Destroyed tissue remains in situ. Postprocedural imaging is the only way to assess 
the completeness of thermal ablation. During percutaneous thermal ablation, multiple non-
contrast CT scans are performed to monitor the progress of the procedure. If the clinician is 
convinced that the procedure is completed, a last non-contrast CT scan is performed to see if the 
tumor overlaps the ablation zone completely. When this is the case, the ablation is finished. If it 
appears that the ablation zone does not fully enclose the tumor, the procedure is continued until 
the ablation zone is large enough. This last non-contrast scan is a rough first check. Thereafter, 
patients will be followed at regular intervals with imaging studies. Follow-up imaging is usually 
performed with multiphase CT scans, although in some centers MRI or PET are used instead. 
The first multiphase CT-scan is performed one week after thermal ablation. This baseline control 
scan is used to determine definitively whether the treatment has been successful or not. The 
radiologist looks for contrast enhancement which may indicate the presence of residual tumor in 
or around the ablation zone. In addition, the diameter of the ablation zone and ablation margins 
are measured, analogous to the size of the tumor-free resection margin after liver surgery. These 
dimensions are used as comparative material for subsequent scans which will be performed in the 
follow-up. To obtain these measurements, the preprocedural scan is compared with the baseline 
postprocedural control scan. The main issue is that a very precise, section-by-section comparison 
is required for the measurements. The liver must be situated in (nearly) the same position on 
both scans. Unfortunately, it appears quite often that this is not the case. Measurements of the 
ablation zone on such incomparable scans are unreliable, when the liver has different positions 
on both scans. These differences in position of the liver may be explained by the fact that the 














































differences of the liver. Although an abdominal CT scan is always performed in full inspiration, 
the depth of inspiration often differs between two scans. As a result, the liver may be positioned 
differently on both scans. Chapter two discusses that these positional differences have significant 
influence on the reliability of measurements and that they are a major risk factor for ablation site 
recurrences. In this chapter, a scoring system is introduced – the Similarity Postitioning Score 
(SIPS). This score classifies the preprocedural and postprocedural CT-scans as well comparable or 
badly comparable (SiPS-identical and SiPS-different). Measurements performed on SiPS-different 
scans will give unreliable results. SiPS is also a risk factor for ablation site recurrences. Of course, 
SIPS does not cause directly ablation site recurrences. If the preprocedural and postprocedural 
images are not well comparable, no reliable judgment can be given on the success of the ablation. 
Thus, only time will learn whether the procedure was actually successful: whether ablation site 
recurrences will appear in the months after the ablation or not. Unfortunately, this problem has to 
be overcome yet. A possible solution would be the use of specialized software that mathematically 
corrects for differences in the position of the liver on the preprocedural and postprocedural images. 
Such images are “converted” by recalculation in order to project the liver in an equal position on 
both scans. Another possible solution is the so-called “respiratory motion tracking system” where 
the depth of inspiration is monitored by sensors and an image is created at the appropriate depth. 
These methods are used mainly in the radiotherapy, but not for this purpose in radiology. Perhaps 
this is worthy for future investigation.
After this first postprocedural scan, imaging is performed regularly in the follow-up. Patient 
undergo multiphase CT-scanning every three months during the first two years after treatment 
and thereafter biannually. The radiologist evaluates the ablation zone and compares the images 
with previous scans. Normally, ablation zones become smaller with time. One of the signs of 
an ablation site recurrence is that the ablation zone increases in size. Ablation site recurrences 
will usually result in slow growth of the ablation zone, especially in its early stages. This 
growth is barely visible to the naked eye. Other features of ablation site recurrences are specific 
contrast-enhancement patters, but these can be easily missed when the ablation site recurrence 
is small. Early detection of ablation site recurrences is extremely important. Chapter three 
describes whether volume measurements of ablation zones can help in the early detection of 
ablation site recurrences. Volumetry provides three-dimensional information: length, width 
and height. Measurements of the diameter of the ablation zone provides only two-dimensional 
information: length and width. The results show that ablation site recurrences are better detected 
with volume measurements than with two-dimensional measurements on ablation zones or 
by focusing on contrast-enhancement patterns. All but one ablation zones with ablation site 
recurrences showed growth. With two-dimensional measurements, this growth was detected at 
a later stage or not at all. Ablation zones without ablation site recurrences became invariably 
smaller. Addtionally, volume measurements are not affected by position differences between 














































measurements on diameters of ablation zones in each patient who underwent thermal ablation. 
Recently, the principle of microwave ablation has been introduced. The procedure is performed 
percutaneously under CT-guidance. Postprocedurally, patients undergo the same follow-up as 
after radiofrequency ablation. Just like after percutaneous radiofrequency ablation, the protocol 
in the UMCG was to perform non-contrast CT scans during and at the end of the procedure. 
Unfortunately, it appeared that the ablation zone was very badly visible on the non-contrast scans 
with microwave ablation, in contrast to the ablation zones created with radiofrequency ablation. 
This is especially a main problem for the last scan performed immediately after the procedure, 
because it could hardly be determined whether the ablation zone enclosed the tumor or not. This 
resulted in more incomplete ablations than the specialists were used to. Chapter four investigates 
whether a contrast-enhanced CT-scan results in improved assessment of the ablation zones at 
the end of the microwave ablation procedure. The assessment of the immediate post-procedural 
contrast-enhanced scan was performed quantitatively by measuring diameters and volumes of 
ablation zones. These assessments were also done on the standard baseline multi-phase CT scan 
performed one week after the thermal ablation. The results of both scans were compared with 
each other. Quantitative assessment – measurements – should not be performed on the immediate 
contrast-enhances postprocedural images. Since the size of the ablation zone changes significantly 
within the first week after treatment, results of measurements on the immediate postprocedural 
scans are unreliable. The first measurements are very important for the further follow-up of the 
patient because they are compared with subsequent studies. For quantitative assessment, the 
scan one week after the procedure remains important. Based on the results of chapter four it is 
therefore recommended that quantitative assessment should not be performed on the immediate 
postprocedural scan. Instead, measurements should be performed on the scan which is made one 
week after the ablation, because the dimensions of the ablation zone are changing substantially 
during this period.
Part two: Liver regeneration after partial hepatectomy.
The liver is an unique organ due to its remarkable capacity to regenerate after partial hepatectomy. 
The process of liver regeneration has been studied extensively in experimental models. There are 
relatively few studies on liver regeneration in humans. Existing studies are performed in living 
donors, which are the ideal population to study liver regeneration on, since these individuals are 
young and in good health. After all, major comorbidities are contra-indications to participate as 
living donor. The majority of patients undergoing elective partial hepatectomy have liver tumors 
and many of them are oncological patients. These patients are older and the incidence of major 
comorbidities is higher in this patient group. Therefore, it is important to have knowledge on the 
process of liver regeneration in these patients, since they are the largest patient group undergoing 














































account. Liver regeneration was studied according to the type of partial hepatectomy, with the 
assumption that with each type of partial hepatectomy, approximately the same volume of tissue 
is removed. Since there is considerable interindividual variability in the size of the liver segments, 
volumes of the resected part of the liver may differ substantially between patients with the same 
type of partial hepatectomy.
Chapter five discusses liver regeneration in patients after partial hepatectomy. The amount 
of regenerated volume is expressed in an early and a late regeneration index, for which the 
measurements are obtained on CT-scans one week and six months after surgery. The results show 
that the amount of regenerated liver tissue is higher after larger resections. Although the early 
regeneration index is increasing with larger resections, a plateau phase is observed in patients with 
a resection of 40 % or more of their total pre-operative liver volume. Liver regeneration is not 
efficient after major resections in the early post-operative phase. However, the late regeneration 
index increases steadily with larger resections, which indicates that patients with large resections 
show a catch-up growth in the late post-operative phase. The liver will not regenerate to its 
original pre-operative total liver volume, especially not after major resections.
Liver regeneration is well known to depend on different factors, such as sex, age and the presence 
of major co-morbidities, especially diabetes, cardiovascular and pulmonary diseases. The liver 
can only regenerate sufficiently when the liver parenchyma is healthy. Liver cirrhosis is a well-
known condition of the liver parenchyma which negatively affects liver regeneration after partial 
hepatectomy. Another far more common parenchymal disease of the liver is the fatty liver – 
hepatic steatosis. Steatosis was previously regarded as relatively harmless. However, it has been 
recognized that hepatic steatosis may lead to non-alcoholic steatohepatitis, cirrhosis and even 
hepatocellular carcinoma. Steatosis is found to affect up to 30 % of the patients who underwent a 
liver biopsy for any reason. Since obesity is a major risk factor for steatosis, it is assumable that the 
incidence of steatosis will increase with the obesity epidemic. Steatosis can be classified roughly 
in three degrees: no steatosis (0 %), mild steatosis (1-29 %) and moderate-to-sever steatosis (30 
% or more). The percentages represent the percentage of hepatic cells with fat droplets. Clinically 
relevant steatosis is regarded as steatosis of 30 % or more. It has been reported from experimental 
models that steatosis has a negative influence on liver regeneration after partial hepatectomy, but 
the results are contradicting. Human studies on the influence of steatosis on liver regeneration do 
not show any negative influence of steatosis on liver regeneration. It should be noticed that these 
studies have been performed in living donors. Since steaosis is a relative contra-indication for 
being a living liver donor, individuals with clinically significant steatosis are generally excluded 
from living donation to warrant proper function of the graft in the recipient as much as possible. 
Therefore, the results from these studies may not be extrapolated gratuitously to the patient 
population with elective partial hepatectomy, since steatosis is not a general contra-indication 
for surgery in these patients. The influence of hepatic steatosis on liver regeneration is studied in 














































steatosis, mild steatosis and moderate-to-severe steatosis. Factors which could have influenced 
liver regeneration, especially the size of the resected part, did not differ between the patient 
groups. Interestingly, no patient with moderate-to-severe steatosis had received chemotherapy 
pre-operatively. This is important, because certain chemotherapy regimens are notorious as they 
can induce steatosis. The early regeneration index did not differ significantly between the groups, 
although it tended to be lower in patients with mild and moderate-to-severe steatosis. The total 
regeneration index was significantly lower in patients with any degree of steatosis. Thus, it can 
be concluded from these results that the presence of hepatic steatosis has a negative impact on 
liver regeneration after partial hepatectomy. Therefore, large resections should be performed with 
caution in these patients, since the regenerative capacity of the liver is impaired.
The process of liver regeneration is an orchestrated interplay of signaling events, cytokines 
and growth factors. Platelets are thought to play an important role in liver regeneration, since 
they contain multiple growth factors. Experimental studies showed that thrombocytopenia is 
associated with poor regeneration. On the other hand, thrombocytosis leads to a high regeneration 
response. In human studies, a low postoperative platelet count was associated with a delayed 
recovery of liver function and a higher postoperative mortality. The relationship between platelets 
and liver regeneration has not been studied in humans. Chapter seven discusses relationship 
between the course of the postoperative platelet count and liver regeneration. Patients were 
classified in three groups: (1) poor regeneration response, (2) intermediate regeneration response 
and (3) high regeneration response. The amount of resected volume is taken into account with 
this classification, as described in chapter 5. The results show a general decrease in postoperative 
platelet count with a nadir at day 3 postoperatively. However, patients with a high regeneration 
response have a stronger decrease in postoperative platelet count and show a significantly lower 
platelet count at day three postoperatively than patients with a poor or intermediate regeneration 
response. The question rises whether this finding shows a causal relationship between liver 
regeneration and platelets, which has been found in experimental studies. This is a topic worthy 
of future research.
Liver resection is mostly performed in oncological patients. The majority of the patients with 
liver tumours are no suitable candidates for surgery, mainly because irresectable disease. Advances 
in chemotherapeutic agents and regimens have changed the resectability criteria by downstaging 
the extent of the disease. Patients who were initially classified as non-resectable can undergo 
surgery as a result of a proper response to chemotherapy by shrinkage of the tumours. A major side 
effect of chemotherapy is its hepatotoxicity. Pre-operative chemotherapy has been associated with 
higher postoperative morbidity and mortality. Theoretically, chemotherapy could have influence 
on liver regeneration. The effect of chemotherapy on liver regeneration is studied in Chapter 
eight. The early regeneration index, as described in chapter 5, was calculated for patients who 














































chemotherapy and patients who did not. There was no difference between the early regeneration 
indices between these two patient groups. However, within the patient group with pre-operative 
chemotherapy, patients who received more than 6 cycles of chemotherapy had a smaller early 
regeneration index than patients who received less than 6 cycles of chemotherapy. It is advisable 
to minimize the number of chemotherapeutic cycles prior to surgery, since more cycles will lead 













































































































Het doel van het dit proefschrift is tweeledig. In het eerste deel wordt beeldvorming na thermale 
ablatie van levertumoren besproken. In het tweede deel wordt ingegaan op het proces van 
leverregeneratie na leverchirurgie. 
Algemene introductie.
De lever is een uniek orgaan vanwege zijn vermogen tot regeneratie na kwetsuren, bijvoorbeeld 
na leverchirurgie. Dit regenererende vermogen werd al in de oudheid onderkend en zelfs in de 
Griekse mythologie genoemd. Operaties aan de lever zijn al vroeg verricht, waarbij het meestal 
ging om verwondingen bij soldaten. Omdat de lever een zeer goed doorbloed orgaan is, is 
verbloeding het grote gevaar bij chirurgische ingrepen aan de lever. Om deze reden overleefde de 
patiënt de ingreep meestal niet. De eerste goed gedocumenteerde operatie aan de lever stamt uit 
1887. Enkele jaren later volgden de eerste studies met grotere aantallen patiënten. Leverchirurgie 
bleef echter een riskante onderneming met een hoge mortaliteit. Dit veranderde toen de operatieve 
technieken en postoperatieve zorg verbeterden. Een grote doorbraak was de anatomische indeling 
van de lever door Franse chirurg Couinaud in de jaren vijftig van de twintigste eeuw. Hij 
deelde de lever op in acht segmenten met elk zijn eigen bloed- en galvoorziening. Door bij 
leveroperaties rekening te houden met deze verdelingen, kon het bloedverlies en gallekkage flink 
teruggebracht worden. Leverchirurgie wordt tegenwoordig vooral uitgevoerd bij patiënten met 
maligne levertumoren. Benigne levertumoren worden veel minder vaak chirurgisch behandeld. 
De meeste maligne levertumoren zijn metastasen van een primaire tumor elders in het lichaam. 
Met name het colorectaal carcinoom, één van de meest frequent voorkomende soorten kanker, 
metastaseert naar de lever. Helaas is er bij het grootste deel van de patiënten met colorectale 
levermetastasen geen chirurgische behandeling mogelijk vanwege de uitgebreidheid van de 
metastasering. Hierbij moet gedacht worden aan 80-90 % van de patiënten die niet meer met 
een operatie geholpen kunnen worden. Om deze patiënten toch te kunnen helpen, is er naar 
andere behandelmogelijkheden gezocht. Hierbij is het doel de tumoren te vernietigen, maar 
zoveel mogelijk leverweefsel te sparen. Thermale ablatie is één van de meest toegepaste vormen 
van dit soort alternatieve therapieën. Hierbij worden de tumoren met een naald – de elektrode - 
aangeprikt. Vervolgens wordt de elektrode verhit. Weefsel in de buurt van de elektrode wordt door 
deze verhitting gedood. Radiofrequente ablatie en meer recent microwave ablatie zijn de meest 
toegepaste vormen van thermale ablatie. Bij thermale ablatie kunnen de elektroden middels door 
het openmaken van de buik (laparotomie), door een kijkoperatie (laparoscopie) of door de huid 
(percutaan) worden geplaatst. Bij thermale ablatie via laparotomie en een laparoscopie wordt de 
tumor met behulp van echografie gelokaliseerd en aangeprikt. Bij percutane thermale ablatie kan 
de tumor ook met echo worden gevonden en aangeprikt, maar meestal wordt hiervoor computer 
tomografie (CT) gebruikt. Beeldvorming dient er ook voor om de voortgang van de behandeling 






















































tumor overlapt. Het grote voordeel van thermale ablatie is dat er minder complicaties optreden 
dan na leverchirurgie. Het grote nadeel van thermale ablatie is dat de genezingskans een stuk 
lager is dan na leverchirurgie, vooral omdat de tumor maar al te vaak terug blijkt te komen 
in of om de ablatiezone. Dit zijn de beruchte lokaalrecidieven. Getallen over hoe vaak lokaal 
recidieven voorkomen, wisselen erg in de literatuur, namelijk van 2 % tot 55 %. Belangrijk is 
om deze lokaal recidieven in een vroeg stadium op te sporen, want hoe eerder ze ontdekt worden, 
des te groter de kans dat er aanvullende behandeling mogelijk is. Om dit te kunnen waarborgen, 
ondergaan patiënten na thermale ablatie intensieve follow-up. Dit gebeurt door regelmatige 
poliklinische bezoeken, waarbij lichamelijk, laboratorium- en beeldvormend onderzoek verricht 
worden. Beeldvorming vindt meestal plaats door middel van multifase CT-onderzoek. Dit houdt 
in dat er eerst een scan zonder contrast wordt gemaakt: de blanco scan. Daarna wordt er contrast 
toegediend aan de patiënt en op drie vaste tijdstippen na toediening gescand, namelijk de arteriële 
fase, de portaal veneuze fase en de late fase. in sommige gevallen magnetic resonance imaging 
(MRI) of positron emissie tomografie (PET), al dan niet gecombineerd met CT.
Deel 1: Beeldvorming na thermale ablatie.
Anders dan na leverchirurgie wordt bij thermale ablatie geen weefsel verkregen voor pathologisch-
anatomisch onderzoek. Na een leverresectie controleert de patholoog of de snijvlakken tumorvrij 
zijn. Bij thermale ablatie is dat niet mogelijk; er wordt immers geen weefsel weggehaald, maar 
weggebrand wat vervolgens in het lichaam van de patiënt achterblijft. Beeldvorming na thermale 
ablatie is dus het enige middel om te beoordelen of de behandeling succesvol is of niet. Bij 
percutane thermale ablatie wordt er gedurende de procedure regelmatig een blanco CT-scan 
gemaakt om de voortgang van de procedure te monitoren. Als de behandelaar meent dat de 
procedure klaar is, wordt er nog een laatste CT-scan gemaakt om te zien of de ablatiezone de 
tumor volledig overlapt. Is dit het geval, kan de ablatie gestaakt worden. Indien blijkt dat de 
ablatiezone de tumor niet volledig omvat, wordt de ablatie voortgezet net zolang tot de ablatiezone 
groot genoeg is. Deze laatste scan zonder contrast is voor een grove eerste controle. Hierna volgt 
de follow-up. Patiënten ondergaan na thermoablatie op regelmatige tijdstippen beeldvormend 
onderzoek. Beeldvorming wordt meestal verricht middels multifase CT-scans met contrast. In 
sommige centra wordt ook wel MRI verricht. De eerste CT-scan na de thermale ablatie wordt 
één week na de procedure verricht en is belangrijk om te bepalen of de behandeling succesvol 
is geweest of niet. Op de eerste postprocedurele scan wordt gekeken naar de aanwezigheid van 
contrastaankleuring wat kan wijzen op een tumorrest in de ablatiezone. Daarnaast worden de 
afmetingen van de ablatiezone en ablatiemarges gemeten, analoog aan de tumorvrije afstand tot 
het resectievlak bij leverchirurgie. Deze afmetingen worden gebruikt als vergelijkingsmateriaal 
met afmetingen van de ablatiezone op latere scans. Voor deze metingen wordt de preprocedurele 






















































precieze vergelijking nodig is van beide CT-scans. De lever moet in dezelfde positie liggen op 
beide scans. Helaas blijkt dat maar al te vaak niet het geval te zijn waardoor de metingen aan de 
ablatiezone niet betrouwbaar zijn. Hierdoor kan niet goed worden beoordeeld of de ablatiezone 
de tumor volledig overlapt of niet. Deze verschillen in positie van de lever zijn vaak toe te dichten 
aan het feit dat de lever zich vlak onder het diafragma bevindt. Ademhalingsbewegingen en de 
diepte van de ademhalingsbewegingen zorgen ervoor dat de lever meebeweegt, wat voornamelijk 
rotationele positieverschillen geeft. Hoewel een abdominale CT-scan altijd wordt gemaakt in 
inspiratiestand, kan niet altijd dezelfde diepte van inademing gegarandeerd worden. Hierdoor 
is het mogelijk dat lever op de ene scan net iets anders gedraaid ligt dan op de andere scan. Dat 
deze kleine verschillen in positie de metingen sterk beïnvloeden en een risicofactor vormen voor 
het optreden van lokaal recidieven, wordt in hoofdstuk 2 besproken. In dit hoofdstuk is een 
scoresysteem geïntroduceerd - de Similarity Positioning Score (SiPS) - dat de beelden van voor 
en na de ablatie indeelt in goed of slecht vergelijkbaar (SiPS-identical en SiPS-different). Het 
blijkt dat metingen bij patiënten met slecht vergelijkbare beelden onbetrouwbare resultaten 
opleveren. Daarnaast treedt er vaker een lokaal recidief op. Natuurlijk heeft de SiPS-score geen 
directe relatie met het al dan niet optreden van een lokaal recidief. Echter, als de beelden niet 
goed vergelijkbaar zijn, kan er geen betrouwbaar oordeel gegeven worden over het succes van de 
ablatie. Dan is het afwachten of de procedure daadwerkelijk geslaagd is of niet: of er wel of geen 
lokaal recidief optreedt in de maanden na de ablatie. Helaas kan er weinig gedaan worden aan dit 
probleem. Een mogelijke oplossing zou het gebruik van gespecialiseerde software kunnen zijn, 
dat corrigeert voor de positieverschillen van de lever: beelden worden zodanig “omgerekend” dat 
ze op gelijke positie geprojecteerd worden op het scherm van de radioloog. Een andere mogelijke 
oplossing is het zogenaamde “respiratory motion tracking systeem” waarbij de diepte van de 
ademhaling wordt gevolgd door sensoren en op het juiste moment een afbeelding wordt gemaakt. 
Deze methoden vinden hun toepassing voornamelijk in de radiotherapie, maar nog niet voor dit 
doeleinde in de radiologie. Wellicht is dit iets voor de toekomst.
Na deze “éénweeksscan” wordt er in de follow-up regelmatig beeldvorming verricht. De patiënt 
ondergaat elke drie maanden gedurende de eerste twee jaar na de behandeling een multifase 
CT-scan. Daarna wordt er daarna halfjaarlijks een multifase CT-scan verricht. De radioloog 
beoordeelt de ablatiezone en vergelijkt de beelden met voorgaande scans. Normaal gesproken 
worden ablatiezones met de tijd kleiner. Één van de tekenen van een lokaal recidief is dat de 
ablatiezone in omvang toeneemt. Meestal groeit een ablatiezone ten gevolge van een lokaal 
recidief zeer langzaam, met name in het beginstadium. Deze groei is voor het blote oog niet tot 
nauwelijks waarneembaar. Andere kenmerken van lokaal recidieven zoals contrastaankleuring, 
kunnen in dit vroege stadium ook gemakkelijk gemist worden. Het is juist erg belangrijk dat 
een lokaal recidief vroeg herkend wordt, want hoe eerder het ontdekt wordt, des te groter is 
de kans op behandelmogelijkheden. In hoofdstuk drie wordt beschreven of volumemetingen 






















































geven driedimensionale informatie: lengte, breedte en diepte. Tweedimensionale beelden geven 
alleen informatie over lengte en breedte. De resultaten tonen dat met het meten van volumes van 
de ablatiezones lokaal recidieven beter ontdekt worden dan bij tweedimensionale metingen aan 
ablatiezones of door op contrastaankleuring te letten. Vrijwel alle alblatiezones met een lokaal 
recidief vertoonden groei. Deze groei werd niet ontdekt met tweedimensionale metingen of pas 
in een later stadium. Ablatiezones zonder lokaal recidief werden zonder uitzondering kleiner. 
Daarnaast hebben positieverschillen van de lever tussen twee verschillende scans geen invloed op 
volumemetingen. Het is dan ook aan te raden om bij elke patiënt na thermale ablatie niet alleen 
tweedimensionaal, maar ook driedimensionaal – dus volumes - te meten.
Recent is het principe van microwave ablatie geïntroduceerd. De behandeling wordt percutaan, 
CT-geleid verricht en patiënten ondergaan na afloop dezelfde follow-up als na radiofrequente 
ablatie. Net als na percutane radiofrequente ablatie werd er in het UMCG in eerste instantie na 
de behandeling nog een blanco CT-scan gemaakt om te controleren of de ablatiezone de tumor 
overlapt. Helaas is gebleken dat op deze blanco scan de ablatiezone na microwave ablatie vaak heel 
slecht zichtbaar is, in tegenstelling tot de ablatiezones gecreëerd na radiofrequente ablatie. Dit 
vormde een groot probleem, omdat niet goed beoordeeld kon worden of de ablatie wel volledig 
is geweest en resulteerde in veel incomplete ablaties. In hoofdstuk vier wordt onderzocht of 
de ablatiezones beter te beoordelen zijn als er aan het einde van de microwave ablatieprocedure 
een scan met contrast wordt gemaakt. De beoordeling van deze direct postprocedurele scan 
met contrast geschiedde kwantitatief, dus door metingen van de diameters en volumes van 
de ablatiezones. Deze beoordelingen werden ook gedaan op de standaard multifase CT-scan 
één week na de thermale ablatie. Beide scans werden met elkaar vergeleken. Kwantitatieve 
beoordeling moet echter niet op de direct postprocedurele beelden verricht worden. De afmeting 
van de ablatiezone verandert dusdanig in de eerste week na de behandeling, dat metingen geen 
betrouwbare resultaten geven. Ablatiezones namen namelijk significant toe in grootte in de eerste 
week na de ablatie. De eerste metingen zijn juist van belang voor de verdere follow-up van de 
patiënt; de afmetingen van de ablatiezone moeten immers worden vergeleken met voorgaande 
onderzoeken. Hiervoor is de scan gemaakt één week na de procedure onmisbaar. Op basis van de 
resultaten van hoofdstuk vier wordt dan ook aangeraden om metingen van diameters en volumes 
niet op de direct postprocedurele scan te verrichten. Daarvoor moet men de scan gebruiken die 
één week na de ablatie is gemaakt, omdat de afmetingen van de ablatiezone sterk veranderen in 
deze periode.
Deel 2: Leverregeneratie na partiële hepatectomie.
De lever is een uniek orgaan vanwege zijn vermogen tot regeneratie na chirurgie. Het proces van 
leverregeneratie is uitgebreid bestudeerd in proefdieren. In de mens zijn er relatief weinig studies 






















































zich is dit een ideale populatie om leverregeneratie te bestuderen, omdat het gezonde, jonge 
mensen zijn. Immers, relevante comorbiditeiten vormen een contra-indicatie om als levende 
donor te kunnen fungeren. Electieve partiële hepatectomieën worden voornamelijk uitgevoerd 
bij mensen met levertumoren, waarvan oncologische patiënten de grootste groep vormen. Deze 
populatie is meestal een stuk ouder en relevante comorbiditeiten komen bij hen vaker voor. 
Kennis omtrent het proces van leverregeneratie bij deze mensen is dus van belang, omdat zij de 
grootste groep patiënten vormen die partiële hepatectomie ondergaan. Daarnaast is er in de tot 
nu toe gepubliceerde studies geen rekening gehouden met de grootte van het gereseceerde stuk 
lever. Leverregeneratie is bestudeerd naar soort partiële hepatectomie, waarbij er vanuit gegaan 
werd dat bij een bepaalde resectie steeds dezelfde hoeveelheid weefsel wordt weggehaald. Dit 
blijkt niet zo te zijn, daar er aanzienlijke interindividuele variatie bestaat in de grootte van de 
verschillende leversegmenten. Het volume van het gereseceerde stuk lever na een rechtszijdige 
partiële hepatectomie kan dus tussen patiënten onderling verschillen.
In hoofdstuk vijf is uiteengezet hoeveel de lever regenereert na partiële hepatectomie. Deze 
hoeveelheid is uitgedrukt in een vroege en een late regeneratie index, respectievelijk één week 
en zes maanden postoperatief. De resultaten tonen dat er meer weefsel regenereert naarmate er 
een groter volume wordt gereseceerd. Echter, de vroege regeneratie index toont een plateaufase 
bij resecties van 40 % of meer van het totale pre-operatieve levervolume. Regeneratie in de 
eerste week na de operatie stagneert dus bij grote leverresecties. De totale regeneratie index 
vertoont wel een stijgende lijn bij toenemende grootte van de partiële hepatectomie. Daaruit kan 
men concluderen dat patiënten met een grote leverresectie een inhaalgroei vertonen in de latere 
postoperatieve fase. De lever groeit in de meeste gevallen niet meer terug naar het originele pre-
operatieve totale levervolume, vooral niet na grote resecties.
Leverregeneratie hangt af van verschillende factoren, zoals geslacht, leeftijd en comorbiditeiten, 
met name diabetes, cardiovasculaire aandoeningen en pulmonale problemen. Een lever 
kan alleen goed regenereren als het leverweefsel gezond is. Levercirrose is een bekende en 
beruchte aandoening van het leverparenchym dat leidt tot verminderde regeneratie na partiële 
hepatectomie. Leververvetting of steatose is een andere, veel vaker voorkomende aandoening van 
het leverparenchym. Steatose werd voorheen gezien als een relatief onschuldige conditie van het 
leverweefsel, maar het blijkt dat een vette lever kan leiden tot niet-alcoholische steatohepatitis, 
cirrose en zelfs hepatocellulair carcinoom. Steatose wordt bij ongeveer 30 % van de patiënten 
gevonden waarbij om welke reden dan ook een leverbiopt wordt verricht. Aangezien obesitas een 
belangrijke risicofactor voor steatose vormt en het een toenemend maatschappelijk probleem is, is 
het aannemelijk dat de incidentie van steatose ook zal stijgen. De mate van steatose kan grofweg 
worden ingedeeld in drie groepen: (1) geen steatose (0%), milde steatose (1-29 %) en matig tot 
ernstige steatose (30 % of meer). De percentages slaan op het percentage cellen in een biopt of 
preparaat met vetdruppels. Klinisch relevante steatose wordt gezien als steatose van 30 % of 






















































na partiële hepatectomie, maar de resultaten van de verschillende studies zijn tegenstrijdig. 
Studies bij de mens naar de invloed van steatose op leverregeneratie tonen geen negatieve invloed 
van steatose op de leverregeneratie. Hierbij dient wel aangetekend te worden dat deze studies bij 
levende donoren zijn verricht. Omdat alleen mensen met gezond leverweefsel als donor mogen 
fungeren, worden levers van kandidaat-donoren die te steatosisch blijken te zijn, uitgesloten 
om een goede functie van het transplantaat in de ontvanger te waarborgen. Hierbij is teveel 
vet in de lever al snel teveel, ook als het klinisch voor de donor niet van belang is. Steatose dat 
echt van klinisch belang is komt dus in deze groep niet voor. De resultaten uit deze studies zijn 
niet te door te voeren op de algemene patiëntengroep die een electieve partiële hepatectomie 
ondergaat, omdat bij deze patiënten steatose geen contraindicatie is voor partiële hepatectomie. 
In hoofdstuk zes wordt de invloed van steatose op leverregeneratie besproken. Patiënten zijn 
ingedeeld in drie groepen, namelijk geen steatose, milde steatose en matig tot ernstige steatose. 
De regeneratie indices, zoals gebruikt in hoofdstuk 5, zijn vergeleken tussen de drie groepen. Er 
was geen verschil in grootte van de resectie en andere factoren die van invloed zouden kunnen 
zijn op de leverregeneratie binnen de drie groepen. Interessant is hierbij te vermelden dat geen 
van de patiënten met matig tot ernstige steatose pre-operatief chemotherapie heeft ontvangen, 
daar chemotherapie bekend om staat dat het steatose kan induceren. De vroege regeneratie index 
was niet significant verschillend tussen de groepen, hoewel er een neiging was naar een lagere 
regeneratie index bij patiënten met milde en matig tot ernstige steatose. De totale regeneratie 
index was echter wel significant lager bij patiënten met milde en matig tot ernstige steatose. Er 
kan dus worden geconcludeerd dat de aanwezigheid van steatose wel degelijk een negatief effect 
heeft op de leverregeneratie. Grote resecties moeten met voorzichtigheid worden uitgevoerd bij 
deze patiënten omdat de lever minder goed in staat is om te regenereren.
Het proces van leverregeneratie is een goed georganiseerd samenspel van verscheidene signalerende 
factoren, cytokines en groeifactoren. Binnen de leverregeneratie wordt een belangrijke rol 
toegedicht aan bloedplaatjes, omdat zij vele groeifactoren bevatten. Uit dierexperimenteel 
onderzoek is gebleken dat trombocytopenie tot een verminderde regeneratierespons leidt. 
Trombocytose zorgt juist voor een goede regeneratierespons. Uit humane studies is gebleken 
dat een laag bloedplaatjesaantal een vertraagd herstel van de leverfunctie geeft na de operatie en 
leidt tot hogere mortaliteit. De relatie tussen bloedplaatjes en leverregeneratie is tot op heden 
nog niet in de mens bestudeerd. In hoofdstuk zeven wordt uiteengezet hoe het postoperatieve 
verloop van het aantal bloedplaatjes is in relatie tot de leverregeneratie. Patiënten werden in drie 
groepen ingedeeld: (1) een slechte regeneratierespons, (2) een intermediaire regeneratierespons 
en (3) een goede regeneratierespons. Bij deze indeling is rekening gehouden met de grootte van 
de resectie, zoals beschreven in hoofdstuk 5. De resultaten tonen dat het plaatjesaantal in alle 
patiënten postoperatief daalt met een dieptepunt op de derde dag na de operatie. Daarna neemt 
het aantal bloedplaatjes weer toe. Echter, patiënten met een goede regeneratierespons vertonen 






















































grote vraag rijst nu natuurlijk of dit gegeven een causaal verband aantoont tussen leverregeneratie 
en bloedplaatjes, wat ook gevonden is in dierexperimenteel onderzoek, of dat dit op toeval berust. 
Dit is een interessant onderwerp voor toekomstig onderzoek.
Leverresectie wordt voornamelijk verricht bij oncologische patiënten. Slechts een klein deel van 
patiënten met levertumoren komt in aanmerking voor chirurgische behandeling, voornamelijk 
vanwege de uitgebreidheid van de tumoren. Ontwikkelingen op het gebied van chemotherapie 
hebben ervoor gezorgd dat het toedienden van chemotherapie het aantal tumoren kan reduceren, 
zodat patiënten die eerst als niet-resectabel werden beoordeeld, alsnog chirurgische behandeling 
kunnen ondergaan. Één van de bijwerkingen van chemotherapie is hepatotoxiciteit door schade 
van het cytostatisch middel aan de levercellen. Pre-operatieve chemotherapie is geassocieerd 
met hogere postoperatieve morbiditeit en mortaliteit. Theoretisch zou chemotherapie ook het 
proces van leverregeneratie kunnen beïnvloeden. Dit wordt onderzocht in hoofdstuk acht. De 
vroege regeneratie index, zoals beschreven in hoofdstuk 5, werd berekend bij patiënten met een 
rechtszijdige hemihepatectomie. Deze werd vergeleken tussen patiënten die pre-operatief wel 
of geen chemotherapie hebben ondergaan. Er was geen verschil in de vroege regeneratie indices 
bij deze twee groepen patiënten. Echter, binnen de groep patiënten die chemotherapie hebben 
ondergaan, hadden patiënten die meer dan 6 cycli chemotherapie hadden ontvangen een lagere 
regeneratie index dan patiënten die minder dan 6 cycli chemotherapie kregen. Het is dan ook 
aan te raden dat het aantal cycli pre-operatieve chemotherapie tot een minimum beperkt wordt 






























































































Hoewel promoveren soms een eenzame aangelegenheid kan zijn, komt een proefschrift niet tot 
stand zonder de hulp van anderen. Een aantal personen wil ik graag in het bijzonder bedanken.
Allereerst mijn eerste promotor, professor E. J. van der Jagt. Geachte professor Van der Jagt, u 
bent altijd beschikbaar geweest als ik met vragen zat en zeer goed benaderbaar. Ik wil u graag 
bedanken voor uw betrokkenheid bij de totstandkoming van dit proefschrift.
Mijn tweede promotor, professor R. J. Porte. Beste Robert, als begeleider van tig andere 
promovendi heb jij toch nog tijd gevonden om je over mij te ontfermen. Met name in het tweede 
deel van dit proefschrift heb je een grote rol gespeeld. Je was goed benaderbaar en had altijd 
klare antwoorden op mijn vragen. Ook buiten kantoortijden om. Ik wil je dan ook ontzettend 
bedanken voor de stimulerende feed-back die je mij hebt gegeven.
Behalve mijn promotoren is er nog een aantal mensen die direct betrokken zijn geweest bij de 
totstandkoming van mijn proefschrift.
Dr. K.P. de Jong, hepatobiliair chirurg. Geachte dr. De Jong, door uw “hobby”, het uitvoeren 
van radiofrequente ablatie van levertumoren, bent u onmisbaar geweest voor het eerste deel van 
dit proefschrift. Ik heb veel geleerd van de grondigheid waarmee u te werk gaat bij het schrijven 
van een artikel. Check, check en double check is uw motto en dat is niet voor niets. Ik wil u 
graag hartelijk bedanken voor de samenwerking voor de totstandkoming van het deel van dit 
proefschrift dat over thermale ablatie gaat.
Drs. M.T. de Boer, hepatobiliair chirurg. Beste Marieke, jij hebt de patiëntengegevens voor de 
studies naar leverregeneratie beschikbaar gesteld. De levervolumes heb ik zelf moeten meten, 
maar jij had de klinische gegevens netjes bij elkaar staan. Het scheelde een hoop zoekwerk dat ik 
die mocht gebruiken! Ook je inzet voor en commentaren op de stukken mogen niet ongenoemd 
blijven. Je bent altijd goed bereikbaar geweest en toonde veel interesse in de voorgang van de 
artikelen. Bedankt!
Professor J.A. Lisman, afdeling Experimentele Chirurgie. Beste Ton, als opperhoofd van het 
leverlaboratorium met fundamenteel onderzoek naar leverregeneratie ben jij nauw betrokken 
geweest bij de artikelen over leverregeneratie in dit proefschrift. Hoewel deze geen fundamenteel 
onderzoek betreffen, zoals jij en jouw onderzoeksgroep verrichten, hebben we toch grote 
raakvlakken. Jij stond altijd klaar met goede, heldere commentaren en snel ook! Vaak kreeg ik 
dezelfde dag nog de stukken terug met bruikbare commentaren. Dit is lovenswaardig en daarom 
wil ik je hartelijk bedanken voor jouw bijdrage voor dit proefschrift.















































Mijn lot- en kamergenoten Hendrik Freling en Martijn den Dekker wil ik graag bedanken 
voor de vele gezellige en nuttige momenten die we samen hebben doorgebracht. Soms was het 
volgens “gedeelde vreugd is dubbele vreugd”, andere keren volgens “gedeelde smart is halve 
smart”. Elkaars stukken lezen, overleg over statistische methoden en ook niet werkgerelateerde 
zaken maken het hebben van fijne directe collega’s een waardevol goed. Henkie en Dubbel D, 
bedankt!
Gonda de Jonge, oud-promotiecollegaatje en nu arts-assistent in opleiding tot radioloog. Jij 
bent veel meer dan een collega alleen. Toen ik begon met promoveren, was jij een oude rot in het 
vak, mijn handleiding “Promoveren voor dummies”. Ik heb jou meegesleurd naar de Prinsentuin 
ter ontspanning toen jij keihard werkte aan de laatste loodjes van je proefschrift. Omgekeerd heb 
jij dezelfde steun geboden met wandelingen op het platteland van Groningen. Bedankt voor de 
vele gezellige momenten!
Hildebrand Dijkstra, klinisch fysicus. Een onmisbare factor in mijn promotietraject. Ik heb je 
vaak lastig gevallen met scans uit de periferie die niet ingelezen konden worden op het werkstation. 
Jij hebt al die honderden CD’tjes omgezet. Dat was niet het minste werk en verdient een groot 
dank je wel! Uiteraard was je niet alleen goed voor het compatibel maken van patiëntendata, 
maar ook een gezelligheidsfactor op de afdeling.
Marcel Greuter, hoofd van de Klinische Fysica. Met jou heb ik vruchtbare werkoverleggen 
gevoerd. Samen hebben we gepoogd om het verloop van volumes van ablatiezones na radiofrequente 
ablatie te beschrijven. Helaas is daar niets uitgerold: die stomme volumes lieten zich niet in een 
formule beschrijven. Wat er wel uit is voortgekomen, is een waardevolle vriendschap. Dank je 
wel voor al je inzet voor mijn onderzoek.
Dr. E. J. K. Noach, researchcoördinator. Stella, jij bent een grote steun voor iedereen die 
onderzoek doet op de afdeling. Je biedt een luisterend oor, stuurt aan waar nodig is en geeft 
praktische tips. Dank je wel voor al je hulp.
Jolanda Sijtsma, directiesecretaresse. Jolanda, sinds jij op onze vleugel bent gekomen, is er een 
mooie vriendschap tussen ons opgebloeid waar we zuinig op moeten zijn.
Verder wil ik graag iedereen werkzaam op de researchafdeling en de afdeling radiologie 
bedanken voor de prettige sfeer en de samenwerking. Collega-onderzoekers en AIOS, Anne, 
Monique, Daniël, Joost, Bart en alle anderen, bedankt voor alles. Paul Sijens, dank je voor 
de samenwerking aan het artikel over “diffusion weighted imaging”. Peter Kappert, MRI-
systeemspecialist, dank je voor de samenwerking met betrekking tot het “diffusion weighted 
imaging” project. Wim Tukker, CT-systeemspecialist, bedankt voor alle nuttige tips en hulp op 
het gebied van CT. Irene Willeboordse en Annemarie van Tienhoven, beide gespecialiseerde 
MRI-laboranten, dank voor het scannen van de patiënten en de gezellige momenten. Martijn van 














































Alle laboranten die ik heb lastig gevallen tijdens mijn volumemetingen op het werkstation 
in de CT-ruimte, bedankt voor de nuttige tips en natuurlijk de gezelligheid. Regina Elzes en 
Ingrid Meijer, voormalige directiesecretaresses, dank jullie wel voor alle hulp en gezelligheid. 
De goede contacten die we hebben opgebouwd, mogen niet verwateren, ook al werken we niet 
meer binnen dezelfde instelling. Alle anderen die ik niet genoemd heb, maar wel op de één of 
andere manier betrokken zijn geweest bij dit proefschrift, dank jullie wel!
Omdat een steunend thuisfront minimaal zo onmisbaar is als goede promotoren en collega’s, 
wil ik ter afsluiting van dit dankwoord een ode brengen aan de belangrijkste mensen in mijn 
leven. Mijn lieve ouders die altijd klaarstaan voor mij, luisteren naar alle verhalen, blij zijn met 
elk behaald succes en troosten bij tegenslagen. Tünde en Cornel, mama en papa, ik weet niet 
wat ik zonder jullie zou moeten. Mijn kleine grote broer Christiaan, of Cruq voor ingewijden, 
ook besmet met het geneeskundevirus, maar van wie nog niet duidelijk is welke richting de 
“ziekte”zich gaat ontwikkelen – snijdend of beschouwend – bedank ik graag voor de lessen 
“accentloos Engels”. Daarnaast was je onmisbaar voor alle gein en ongein omtrent promoveren. 
Ik hoop dat ik jou later bij een eventuele promotie, of eigenlijk met wat dan ook net zo goed 
kan helpen als jij mij geholpen hebt. Mijn grootouders – gelukkig heb ik ze alle vier nog-, Tató, 
Mamó, Ági en Dani wil ik graag bedanken voor alle interesse die ze hebben getoond omtrent de 
voortgang van mijn proefschrift. Mijn goede vrienden en mascottes, Zdwellie, Loos, Bwie, Met, 
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Diffusion Weighted Imaging in The Liver.
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